¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/24 ¤W¤È 07:53:16
²Ä 2083 ½g¦^À³
|
¬Ý¤@¤U¥»¤ë³q¹L¤T´ÁÁ{§Éªºtralokinumab, ¤G´ÁÁ{§Éµ²ªG¡Cwww.ncbi.nlm.nih.gov/m/pubmed/29906525/
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. Randomized controlled trial
Wollenberg A, et al. J Allergy Clin Immunol. 2019. Show full citation
Treatment,2b, 300mg/2¶g¤@°w¡A12¶g n=51:51,Á{§É结ªG¡AIGA 26.7%¹êÅç组vs 11.8%¹ï·Ó组¡C
Abstract BACKGROUND: IL-13 has an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human mAb that potently and specifically neutralizes IL-13.
OBJECTIVE: We sought to evaluate the efficacy and safety of tralokinumab in adults with moderate-to-severe AD.
METHODS: In this phase 2b study (NCT02347176), 204 adults were randomized 1:1:1:1 to receive 45, 150, or 300 mg of subcutaneous tralokinumab, or placebo, every 2 weeks for 12 weeks with concomitant topical glucocorticoids. Coprimary end points were change from baseline in Eczema Area Severity Index score and percentage of participants with an Investigator¡¦s Global Assessment response (0/1 score and reduction of ≥2 grades from baseline) at week 12.
RESULTS: At week 12, 300 mg of tralokinumab significantly improved change from baseline in Eczema Area Severity Index score versus placebo (adjusted mean difference, -4.94; 95% CI, -8.76 to -1.13; P = .01), and a greater percentage of participants achieved an Investigator¡¦s Global Assessment response (26.7% vs 11.8%). Greater responses were found in participants with greater concentrations of biomarkers of increased IL-13 activity. Participants treated with 300 mg of tralokinumab demonstrated improvements in SCORAD, Dermatology Life Quality Index, and pruritus numeric rating scale (7-day mean) scores versus placebo. Upper respiratory tract infection was the most frequent treatment-emergent adverse event reported as related to study drug in the placebo (3.9%) and pooled tralokinumab (3.9%) groups.
CONCLUSIONS: Tralokinumab treatment was associated with early and sustained improvements in AD symptoms and an acceptable safety and tolerability profile, thereby providing evidence for targeting IL-13 in patients with AD.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/23 ¤U¤È 08:20:40
²Ä 2082 ½g¦^À³
|
1.Dupilumab ,°w¾¯¨C²~ 300mg , 1500¬ü¤¸.¡]¥«³õ»ù®æ¡^ 2.Xolair ,°w¾¯ ¨C²~ 150mg ,1186¬ü¤¸¡C
www.goodrx.com/xolair?label_override=Xolair&form=vial&dosage=150mg&quantity=2
Price History for 2 vials of Xolair 150mg ,¡]¨C²~150mg 2376/2=1186¬ü¤¸.¡^ GoodRx Fair Price $2376.16
¬ü°ê¤H¡Aªø´Á¥´°w¥ÎÃĪ̡A¤j¦h¥h¤j½æ³õ¶R¦^¦b®a¦Û¤v¥´°w.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/23 ¤U¤È 08:04:28
²Ä 2081 ½g¦^À³
|
×¥¿¤@:
¤¤¡B««×ADÀøµ{¦¨¥» 3ÃÄPK¼ÒÀÀ¡C¡]Àø®Ä½Õ¾ã/°w¶q½Õ¾ã)
ASLAN004 ¨C¤ë¤@°wªº«Â¤O¬Æ¤j¡A¦¨¥»³Ì§C¡AÄvª§¤O¶W¯Å±j¡C
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K 16¶gÁ`¥ÎÃĶq(mg)x³æ»ù(¬ü¤¸/mg)/Àø®Ä(³Ì¨Î¤ÏÀ³IGA=0/1)
¤T´ÁÁ{§Éªº¥Dn«ü¼ÐIGA =0/1 Proportion of patients with a Investigators Global Assessment (IGA) score of 0 or 1 and a reduction in this measure of at least 2 points at week 16. [ Time Frame: Week 16 ]
¬ü°ê¤½/¨p¥ß«OÀI¤½¥q¬O¨Ì¾ÚÀøµ{¦¨¥»¡A¨Ó®Ö·Ç¥ÎÃıƧǡC ¦¨¥»§CªºÀu¥ý¨Ï¥Î¡C
16¶gÀøµ{¦¨¥» 1.Dupliumab 9°wx1500¬ü¤¸(300mg)/0.35(IGAÀø®Ä0/1) =38,500¬ü¤¸
2.Bermekimab 9针x1650¬ü¤¸(400mg)/0.53(°²³]Dupilumab IGA0.35/0.66=0.53)=28,000¬ü¤¸
3.ASLAN004 4°wx1425¬ü¤¸(250mg)/0.4(°²³]È) =14¡A250¬ü¤¸
¥H¤W°²³] 1.¼Ð¹vÃĪ«¨C²~300mg °w剤ÃĪ«©MDupilumab ¦P»ù¡A1500¬ü¤¸¡C °²³]»s³y¦¨¥»30% 2.¼Ð¹vµ²¦X©óIL13Àø®ÄÀu©óIL4¡C°²³]ASLAN004 IGA0/1=0.4,Aslan004¨C¤ë¥´¤@°w¡C 3.Dupilumab IGA 0/1 ¥Ø«e约35%¡A³Ì¨Î¤ÏÀ³¡C ESAI°§C75% Duplimab 47%/Bermekimab71%=66% ±ÀºâBermekimab IGA 0/1=0.35/0.66=0.53 4.¬ü°ê¬Û¦üÃĪ«¤j¦h±Ä¥«³õq»ùªk¡C 5.¬ü°ê¤½¡B¨p¥ß«OÀI³W©w¡A¦¨¥»§CªºÃÄn¥ý¥Î¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/12/23 ¤U¤È 07:51:37
²Ä 2080 ½g¦^À³
|
¦b²§¦ì©Ê¥Ö½§ª¢¨Ó»¡,Y004¥i¦b4¶g(¥L®a8~16¶g)§Ö³t¨£®Ä,´N¬Oµ´¨ÎÀu¶Õ! §Ú¬O»´·L¯gª¬,¦ýª¬ªpµyÄY«®É±ß¤W¬Æ¦Ü·|Äo¨ì¿ô¨Ó,³o®É¶îÂIÃÄ»I1~2¤é´N¨£®Ä, §Ú¬Û«H¨º¨Ç¤¤«µ{«×ªÌªº¥Í¬¡«~½èµ´¹ï«ÜºG! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/12/23 ¤U¤È 07:25:20
²Ä 2079 ½g¦^À³
|
Average Cash Price$2834.11// GoodRx Fair Price$2376.16
±q³o2®a¯à°÷»ù®tUS$458,¨¬¥HÃÒ©úù¤ó/¿ÕµØ¦bXolairÁȽ¤F!!! ·P¨ì·N¥~ªº¬OTMB355ªº§Q¼í«ç·|¨º»ò§C? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/23 ¤U¤È 07:24:16
²Ä 2078 ½g¦^À³
|
libir.tmu.edu.tw/bitstream/987654321/34152/1/¥þ¤å¹q¤lÀÉ.pdf
¦U°êÃĪ«q»ù¬ã¨s¡A¦p¤W.
¥xÆW°·«O§½©e¥~¬ã¨s |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/12/23 ¤U¤È 07:19:12
²Ä 2077 ½g¦^À³
|
¥uª¾¹D¬ü°ê¦PÃĪ«,·|¦]¬°¤£¦P«OÀI¤½¥q¦Óµ¹¥I»ù¤£¤@¼Ë! ¥L̨º®M«Ü½ÆÂø«¥¦Û»{¤£À´. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/23 ¤U¤È 07:15:22
²Ä 2076 ½g¦^À³
|
www.goodrx.com/xolair?label_override=Xolair&form=vial&dosage=150mg&quantity=2
Price History for 2 vials of Xolair 150mg BACK TO PRICES Average Cash Price $2834.11 GoodRx Fair Price $2376.16
¬ü°ê¦b®a¦Û¤v¥´°wªº¬Ò¦Û¤j½æ³õ¡A¶R¦^¡A ¼Ð¹vÃĪ«°w¾¯¶q¡A¤£¦P³æ»ù¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/12/23 ¤U¤È 07:02:19
²Ä 2075 ½g¦^À³
|
Xolair®ð³Ý/ºC©ÊëC³Â¯lÃĪ«,±wªÌ¨ÌÅ髬I¥´¾¯¶q,¦³¨Ç±wªÌ¨C2¶g¦³¨Ç¨C4¶gª`®g¤@¦¸,¦~¦¬¶O¬Û¦P. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/23 ¤U¤È 06:53:37
²Ä 2074 ½g¦^À³
|
¼Ð¹vÃĪ«°w¾¯©M¤fªAÃĦ¨¥»¤£¦P¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/12/23 ¤U¤È 06:51:10
²Ä 2073 ½g¦^À³
|
§ó¥¿¤µ¦~¬ü°êjakafi¤w½Õº¦3% 5 mg Jakafi oral tablet from $14107.68 for 60 tablet 10 mg Jakafi oral tablet from $14107.68 for 60 tablet 15 mg Jakafi oral tablet from $14107.68 for 60 tablet 20 mg Jakafi oral tablet from $14107.68 for 60 tablet 25 mg jakafi oral tablet from $14107.68 for 60 tablet |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/12/23 ¤U¤È 06:44:55
²Ä 2072 ½g¦^À³
|
¦]¬°¥«³õÄvª§©Ê¡A¾Ç¦WÃÄ»P¥Íª«¬Û¦üÃĤñ¸û±j½Õ¦¨¥»Ävª§¡A ·sÃÄ(»s³y¦¨¥»´N¬O9¤û1¤ò)ªº«ÂIÁÙ¬OÀø®ÄÀu²§©Ê»P¦w¥þ©Ê¡C
1.¦N§Q¼wªñ¤T¦~¡G¸¨¹æªºC¨x¥«³õ kknews.cc/zh-tw/finance/epbpx9z.html Y004¯à¤Ö¥´´X°w»P[[¸û§Ö®É¶¡]]¨£Àø®Ä´N¬OÀu¶Õ¡A¥t¥~¥Ø«eC¨x¬Oªv¡¡A¦]¦¹±wªÌ¼Æ³vº¥´î¤Ö¡C ¦ÓÂi±´X®a®ð³Ý/ADÃĪ«¤£¬Oªv¡¡A±wªÌ¼Æ¨Ã¤£·|³vº¥´î¤Ö¡A¦ý¬O¥[¤JªÌº¥¼W´N§K¤£¤FÄvª§©Ê¡A ¤ÏÆ[COPD¥«³õ¥Ø«e¤´¬O¤@±æµL»ÚÂÅÂŪº¤j®ü!
2.³o¬OPV¤G½uÃÄJakafi¬ü°ê»ù®æ¡A¤@¦~Àøµ{®t5¿ªº¤£¦P¾¯¶q¤]¦¬¦P¼Ë»ù16~18¸U¬ü¤¸! drugs.com/price-guide/jakafi 5 mg Jakafi oral tablet from $13,697.38for 60 tablet 10 mg Jakafi oral tablet from $13,697.38for 60 tablet 15 mg Jakafi oral tablet from $13,697.38for 60 tablet 20 mg Jakafi oral tablet from $13,697.38for 60 tablet 25 mg jakafi oral tablet from $13,697.38for 60 tablet
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/23 ¤U¤È 06:15:36
²Ä 2071 ½g¦^À³
|
¤Ñ©R¤j ÁÂÁ¤À¨É, ¨«¤@¨Bºâ¤@¨B, ¹Ú·Qn¦b¼Æ¾Ú¤½§i«á³v¨B½Õ¾ã¤~¯à¿v¹Ú½ñ¹ê ¤Ñ©R¤j©Ò¤À¨Éªº : ¤½¨p¥ß«OÀI¤½¥q³W©w¡A¦¨¥»§CªºÃĪ«¥ý¥Î ªº½T¹ï¨È·à±dASLAN004 «Ü¦³§Q ¦pªGÀø®Ä»P¥Ø«e¤w¤W¥«©Î¥¼¨Ó·|¤W¥«ªºÃĪ«±µªñ©Î§ó¦n¥[¤W¨ä
1§C°Æ§@¥Î°ª¦w¥þ©Ê ( ¥Ø«e¬°¤î¥¼µo¥Íµ²½¤ª¢ ª`®g³¡¦ì¨´¤µµL©úÅã¤ÏÀ³ ) Dupliumab (µo¥Íµ²½¤ª¢²v25%-50% ª`®g³¡¦ì¤ÏÀ³±`¨£²{¶H )
2¬I¥´¤è«KÀW²v§C (¹w´Áµê4¶gµ¹¤@¦¸ÃÄ ) Dupliumab (2¶gµ¹¤@¦¸ÃÄ)
3·Å«×Àx¦s¼u©Ê¤j (Äá¤ó25⁰C¥H¤U¥i¦s©ñ9Ó¤ë¥H¤W Àx¦s¤Î¹B°e±ø¥ó¼u©Ê¸û¤j) Dupliumab (µLªkÀx¦s25«×¥H¤W)
4¤£»Ý°_©lt²ü¾¯¶q ( Dupliumab »Ýn2¦¸ 600mg °_©lt²ü¾¯¶qª`®g)
¨È·à±dASLAN004²§¦ì©Ê¥Ö½§ª¢ ¨äµo®i¼ç¤OµL½a
¥H¤W 1 2 3 ¸ê°T½Ð°Ñ¦Ò¨È·à±d2019¦~12¤ëªk»¡·| ¦³ÃöASLAN004 ²³ø , 4 ½Ð°Ñ¦Ò¤½¥q2018¦~12¤ëªk»¡·|ASLAN004 ²³ø)
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¦³¿ù½Ð§ó¥¿
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/23 ¤U¤È 04:59:05
²Ä 2070 ½g¦^À³
|
¥xÁÞ¤j¡A
±zªº¤ÀªR¬O¹ïªº¡C ¤W¦¸¥Îªº¬O¦ô¾P°â°ª®p,¬G¥Î³Ì°ª10%¥h¦ôºâ¡C
¥¼¨ÓAslan004 , «Ü¦³¼ç¤O¡A¦p¤½¥q©Ò«ÅºÙ¦P¯Å³Ì¨Î¡C ¤½¨p¥ß«OÀI¤½¥q³W©w¡A¦¨¥»§CªºÃĪ«¥ý¥Î¡A aslan004 ¥|¶g¥´¤@°w¡A«Â¤O±j¤j µ´¹ïÀu¥ý©ódupliumab ,¥Ø«e¬Ý¨Ó¬O¯uªº¾÷·|°ª¡C ´Nµ¥µÛ¬Ý¦UÁ{§Éªºµ²ªG¨ÓÅçÃÒ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/23 ¤U¤È 04:26:22
²Ä 2069 ½g¦^À³
|
¤Ñ©R¤j ¨È·à±d½Í§P¹Î¶¤«Ü·|±ÂÅv½Í§P, 1.25»õ¬ü¤¸´N¦VCSL¨ú±o ASLAN004 ¥þ²y¶}µo¡B»s³y»P°Ó«~¤ÆÅv§Q (¯f±w¤H¤f¼ÆÃe¤j) ³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷( ³o»ò°ªªº¼úÀyª÷¬O§_¬Ý¦n¥¼¨Óªº¾P°â°ª®pª÷ÃBµû¦ô¥X¨Óªº?) Ó¤H»{¬°¥¼¨ÓÃÄ«~¤W¥««á¨Ì¾P°â²bÃB¤À¼hµ¹CSLªºÅv§Qª÷Royalty¬O¦Ê¤À¤§4¦Ü10% ¤ñ¤Ñ©R¤j«e´X¤Ñ¤À¨Éªº¸ê°T¦Ê¤À¤§7.5 ¦Ü 10% ÁÙ§C
¨È·à±dASLAN004¦p¦³¦A±ÂÅv¨ä¥L¥Í§Þ¤½¥q°õ¦æ¤T´ÁÁ{§É®ÉÀ³¨Ì¾Ú×q¦X¬ù¥Iµ¹CSL«eª÷3000¸U¬ü¤¸, ¨½µ{ª÷³Ì°ª 9500¸U¬ü¤¸ »P¤Î³Ì°ª¹F6.55»õ¬ü¤¸¤§¾P°â¨½µ{ª÷(·|¤£·|¬O¤W¥««áªº¾P°â¼úª÷?) ¥H¤Î¤W¥««á¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ10%¤§Åv§Qª÷(Royalty) Ó¤H»{¬°¥¼¨ÓÃÄ«~¤W¥««á¨Ì¾P°â²bÃB¤À¼hµ¹CSLªºÅv§Qª÷¬O¦Ê¤À¤§4¦Ü10%
¨È·à±d2019¦~5¤ë31¤é»PCSL×qASLAN004 ¦X¬ù±ø´Ú¡A ¨È·à±d-KY ±N©ó ASLAN004 ¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥I CSL ºµ§´Ú¶µ 3,000 ¸U¬üª÷¡CCSL ±N¥i¦¬¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü 10%¤§Åv§Qª÷
Ó¦ì¼Æ§C¦ì¼Æ(¦Ê¤À¤§ 1 2 3 )
Ó¦ì¼Æ¤¤¦ì¼Æ(¦Ê¤À¤§ 4 5 6 )
Ó¦ì¼Æ°ª¦ì¼Æ(¦Ê¤À¤§ 7 8 9 )
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¦³¿ù½Ð§ó¥¿ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/23 ¤U¤È 03:07:54
²Ä 2068 ½g¦^À³
|
¸ÕÅç¼Æ¾Ú«ü¥X ASLAN004 §¹¥þ§í¨î¨ü¾¹°T¸¹¶Ç»¼©Ò»Ýªº³Ì§C¿@«×(trough level)¤ñ²{¦³ªvÀø¤è ¦¡©Ò»Ýªº¿@«×§C¡A¿@«×®t¶Z¶W¹L¤@Ӽƶq¯Å¡C¡]2019/06/04·s»D½Z)
¡X¡X¡X¡XASLAN004 ²Ä¤@´Á°·±d¤HÅé¹êÅç©Ò±o«n¼Æ¾Ú¤§¤@¡C¡X¡X¡X¡X-
***Aslan004©Ò»Ý§í¨îIL13R£\1¨ü¾¹¤§¿@«×¤ñDupliumab §í¨îIL4R£\, ®t¤@Ӽƶq¯Å¡]10¿)ªº¿@«×******
¥ÎÃĶq&ÀW²v±N¤j´T¤U°. Dupliumab 300mg x9°w(16¶g¡A¨C¤G¶g¤@°w)=2700mg¡]¤W¥«) Aslan004 ¥i¯à200~250mgx4°w¡]16,¶g¨C¥|¶g¤@°w)=800mg~1000mg¡]¤½¥q¦ôp) ****************
Lebrikizumab 2b ¤¤-««×AD Á{§Éªº«ü¼Ð(2019/3¤ë¤½¥¬) ¡An=280¤H ¤wµý©úIL13 °tÅé§í¨î¾¯¡A¤G´ÁÁ{§É¦¨¥\¡C¥|¶g¤@°wªºÀø®Ä¤£¨È©óDupliumab ¤G¶g¤@°w¡C
(¤@).250 mg Q2W(¨â¶g¤@°w)/16¶g EASI-50 81.0%*** EASI-75 60.6%*** EASI-90 44.0%*** IGA0/1 44.6%**
¤G).250 mg Q4W(¥|¶g¤@°w)/16¶g EASI-50 77.0%** EASI-75 56.1%** EASI-90 36.1%** IGA0/1 33.7%*
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X 2019¦~ 6¤ë4¤é¤½§i¼Æ¾Ú½Ð¤j®an¥Î¤ß¬Ý ¨È·à±d¤½¥q¡A2019/06/04·s»D½Z
¨È·à±d-KY «Å¥¬§¹¦¨ ASLAN004 ²§¦ì©Ê¥Ö½§ª¢¤@´ÁÁ{§É¸ÕÅç - ³æ¤@¾¯¶q»¼¼W¸ÕÅ礧³Ì«áµ²ªGÅã¥Ü ASLAN004 @¨ü©Ê¨}¦n¡A¥i§¹¥þ§í¨î¤U´å¤¶½è¡A¥ÎÃÄÀW²v¥i±æ ¬°¨C¤ë¤@¦¸ 2019 ¦~ 6 ¤ë 4 ¤é¡A·s¥[©Y ¡V »EµJ©óÁ{§É¶¥¬q¸~½F¤Î§K¬Ì¾Ç¤§Á{§É¶¥¬q¥Íª«»sÃĤ½¥q¨È·à±d-KY (NASDAQ:ASLN, TPEx:6497)¤µ¤é«Å¥¬¶¶§Q§¹¦¨ ASLAN004 ³æ¤@¾¯¶q»¼¼W¸ÕÅç(SAD) ¨Ã¤½¥¬ ASLAN004 ¥H¥Ö¤Uª`®gµ¹ÃĤ覡¤§²Ä¤G ³¡¤À¸ÕÅç¼Æ¾Ú¡C¦¹¸ÕÅç°w¹ï°·±d¨ü¸ÕªÌ¶i¦æ¦P¯Åº¨£ªvÀø©Ê§ÜÅé ASLAN004 ¤§ÃĪ«´ú¸Õ¡C ASLAN004 ¬°¥þ¤H·½³æ®è§ÜÅé¡AÂê©w IL-13 ¨üÅé£\1 ¦¸³æ¦ì (IL-13R£\1)¥HªýÂ_¨âºØ«P¶iµoª¢ªº²ÓM¿E¯À IL-4 ©M IL-13¡CIL-4 »P IL-13 ¬O¤Þµo¦p¥Ö½§µo¬õ©M·kÄoµ¥²§¦ì©Ê¥Ö½§ª¢¯gª¬ªºÃöÁä¦]¯À¡C
¨È·à±d-KY °õ¦æªø³Å«iªí¥Ü¡G¡u¤@´Á¸ÕÅ窺³Ì«á¼Æ¾Ú¦A¦¸¥[²`§Ú̹ï©ó ASLAN004 ¦¨¬°²§¦ì©Ê¥Ö½§ª¢¦P¯Å ³Ì¨ÎÀøªkªº«H¤ß¡A¥B¥H¤W¼Æ¾ÚÅý§Ú̯à°÷¨³³t¦a¦b¤µ¦~µy±ß±N¬ãµo¶iµ{±À¶i¦Ü¦h¾¯¶q»¼¼W¸ÕÅç¡C ASLAN004 µL½×¥HÀR¯ßª`®g©Î¥Ö¤Uª`®gªº¤è¦¡µ¹ÃÄ¡A¬Ò®i²{¨}¦nªº@¨ü©Ê¡A¨ÃµL¤£¨}¤ÏÀ³¤§±¡§Îµo¥Í¡C §Ú̬۫H ASLAN004 Àu²§ªºÃĪ«¯S©Ê¥i¥H¬°²§¦ì©Ê¥Ö½§ª¢¯f±w´£¨Ñ¤@Ó¥ÎÃÄÀW²v¸û§CªºªvÀø¤è¦¡¡B¤ñ°_²{¦³ªvÀø¤è ¦¡§ó¬°«K§Qªºµ¹Ãij~®|¡AÂǦ¹´î»´²§¦ì©Ê¥Ö½§ª¢¯f±w»P¾ãÅéÂåÀøÅé¨tªºt¾á¡C¡v
¨È·à±d-KY ©ó 2019 ¦~ 3 ¤ë¤½¥¬²Ä¤@³¡¤À¸ÕÅç ASLAN004 ¥HÀR¯ßª`®g¤è¦¡µ¹ÃĤ§¼Æ¾Úµ²ªG¡C ²Ä¤G³¡¤À¸ÕÅç¼Æ¾Ú Åã¥Ü ASLAN004 ¥H¥Ö¤Uª`®gµ¹ÃĦb©Ò¦³¾¯¶q¤U¬Ò®i²{¨}¦n@¨ü©Ê¡A¨ÃµL¥X²{¥ô¦óÄY«¤£¨}¨Æ¥ó¦Ó¾ÉPªvÀø¤¤ Â_ªº±¡ªpµo¥Í¡A¶È¦³¤@¦W¨ü¸ÕªÌ¥X²{»´·Lª`®g³¡¦ì·kÄo¡A¦ý¯gª¬¦b 24 ¤p®É¤º§Y¸Ñ°£¡C °w¹ï¤U´å¤¶½è©Ò¶i¦æ¤§ ¤ÀªRÅã¥Ü¡A¦bµ¹ÃĪº¤@¤p®É¤º¡A¥]¬A¦b¹L±Ó©Êµoª¢¤ÏÀ³¤¤§êºt«n¨¤¦â¤§¤¶½è¡§ÁC»Ä¤Æ STAT6 (pSTAT6)¡¨§Y ¨ü¨ì§¹¥þ§í¨î¡A¥B¤@ÃĪ«°Ê¤O¦±½u¹Ï(pharmacokinetic profile)Åã¥Ü ASLAN004 ªºµ¹ÃÄÀW²v¥i±æ¬°¨C¤ë¤@¦¸¡C ¯S §Oȱoª`·Nªº¬O¡A¸ÕÅç¼Æ¾Ú«ü¥X ASLAN004 §¹¥þ§í¨î¨ü¾¹°T¸¹¶Ç»¼©Ò»Ýªº³Ì§C¿@«×(trough level)¤ñ²{¦³ªvÀø¤è ¦¡©Ò»Ýªº¿@«×§C¡A¿@«×®t¶Z¶W¹L¤@Ӽƶq¯Å¡C¡]®t10¿¡A¥ÎÃĶq/ÀW²v±N¤j´T¤U°)
³o¶µ¼Æ¾Ú¦b¨È·à±d-KY ©ó 2019 ¦~ 5 ¤ë 31 ¤é«Å¥¬»P CSL ×q¦X¬ù¨ú±o ASLAN004 ¥þ²y¬ãµo¡B»s³y»P°Ó«~¤ÆÅv§Q «á¤½¥¬¡A¨È·à±d-KY ¤U¤@¨B±N©ó 2019 ¦~¤U¥b¦~±Ò°Ê°w¹ï¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¤§¦h¾¯¶q»¼¼W¸ÕÅç¡C ²§¦ì©Ê¥Ö½§ª¢¬°³Ì±`¨£ªº¥Ö½§¯e¯f¡A¥þ²y¶W¹L 2 »õ¦W¯f±w²`¨ü¦¹¯e¯fªº§xÂZ1 ¡A²§¦ì©Ê¥Ö½§ª¢ªº¯SÂI¬°¥Ö½§¬õ ¸~¡B«ùÄò·kÄo¡A¥i¯àÄY«¼vÅT¯f±w¥Í¬¡«~½è¡C°ª¹F¤T¤À¤§¤@¦¨¤H¯f±wªº¯f±¡µ{«×¹F¤¤«×¦Ü««×¡A²§¦ì©Ê¥Ö½§ ª¢²{¦³ªvÀø¤è¦¡¦³¡A¦Ó±±¨î¯f±¡¹ï¤j¦h¼Æ¯f±w¨Ó»¡³£·¥¨ã¬D¾Ô ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¤½¥q¦b²Ä¤@¦¸ASLAN004 °·±d¤HÅéÁ{§É¹êÅ礤¡A¤w§ä¨ì§í¨îIL13R £\1¨ü¾¹ªº¿@«×¤§¤HÅé¹êÅç¼Æ¾Ú¡C
¡]¤W¦¸Á{§É¤£¦P¾¯¶q¥´¤@°w¡AÆ[¹î85¤Ñ,16Ó®ÉÂI, Time Frame: Predose,1 hour, 2 hour, 4 hour, 8 hour, 24 hour, 72 hour, 168 hour, 240 hour and up to 3 months ]
¦¸n¦¨ªG«ü¼Ð¡G 1.PK°Ñ¼Æ¡G±q¹s®É¶¡¨ì³Ì«á¤@Ó¥i¶q¤Æ¿@«×®É¶¡ªº¦±½u¤U±¿n¡]AUC¡^[AUC¡]0-last¡^] [®É¶¡½d³ò¡Gµ¹ÃÄ«e¡A1¤p®É¡A2¤p®É¡A4¤p®É¡A8¤p®É¡A24¤p®É¡A 72¤p®É¡A168¤p®É¡A240¤p®É¥H¤Î³Ì¦h3Ó¤ë] µû¦ô³q¹LÀR¯ß¤º©Î¥Ö¤Uª`®g³~®|³æ¾¯µ¹ÃÄ«áASLAN004¦b°·±d§ÓÄ@ªÌ¤¤ªºÃÄ¥N°Ê¤O¾Ç¡]16Ӯɶ¡ÂI¡^
2.PK°Ñ¼Æ¡G¦ôpúA¤À§G¶q¡]Vss¡^[®É¶¡½d³ò¡GªAÃÄ«e¡A1¤p®É¡A2¤p®É¡A4¤p®É¡A8¤p®É¡A24¤p®É¡A72¤p®É¡A168¤p®É¡A240¤p®É¥H¤Î³Ì¦h3Ó¤ë] µû¦ô³q¹LÀR¯ß¤º©Î¥Ö¤Uª`®g³~®|³æ¾¯µ¹ÃÄ«áASLAN004¦b°·±d§ÓÄ@ªÌ¤¤ªºÃÄ¥N°Ê¤O¾Ç¡]16Ӯɶ¡ÂI¡^
3.PK°Ñ¼Æ¡G¥Ö¤U¥Íª«§Q¥Î«×¡]F¡^[®É¶¡½d³ò¡GªAÃÄ«e1¤p®É¡A2¤p®É¡A4¤p®É¡A8¤p®É¡A24¤p®É¡A72¤p®É¡A168¤p®É¡A240¤p®É¥H¤Î³Ì¦h3Ó¤ë] ¶È³q¹LSC³~®|³æ¦¸µ¹ÃÄ«áµû¦ôASLAN004¦b°·±d§ÓÄ@ªÌ¤¤ªºÃÄ¥N°Ê¤O¾Ç¡]16Ӯɶ¡ÂI¡^
4.PK°Ñ¼Æ¡G¾¯¶q¼Ð·Ç¤ÆCmax¡]Cmax /¾¯¶q¡^[®É¶¡½d³ò¡GªAÃÄ«e¡A1¤p®É¡A2¤p®É¡A4¤p®É¡A8¤p®É¡A24¤p®É¡A72¤p®É¡A168¤p®É¡A240¤p®É¥H¤Î³Ì¦h3Ó¤ë] µû¦ô³q¹LÀR¯ß¤º©Î¥Ö¤Uª`®g³~®|³æ¾¯µ¹ÃÄ«áASLAN004¦b°·±d§ÓÄ@ªÌ¤¤ªºÃÄ¥N°Ê¤O¾Ç¡]16Ӯɶ¡ÂI¡^
5.PK°Ñ¼Æ¡GAUC¡]AUC¡]0-inf¡^/¾¯¶q¡^[®É¶¡½d³ò¡Gµ¹ÃÄ«e¡A1¤p®É¡A2¤p®É¡A4¤p®É¡A8¤p®É¡A24¤p®É¡A72¤p®É¡A168¤p®É¡A240¤p®É¥H¤Î³Ì¦h3Ó¤ë] µû¦ô³q¹LÀR¯ß¤º©Î¥Ö¤Uª`®g³~®|³æ¾¯µ¹ÃÄ«áASLAN004¦b°·±d§ÓÄ@ªÌ¤¤ªºÃÄ¥N°Ê¤O¾Ç¡]16Ӯɶ¡ÂI¡^
Secondary Outcome Measures : 1.PK parameters: Area under the curve (AUC) from time zero to the time of the last quantifiable concentration [AUC(0-last)] [ Time Frame: Predose,1 hour, 2 hour, 4 hour, 8 hour, 24 hour, 72 hour, 168 hour, 240 hour and up to 3 months ] To assess the pharmacokinetics of ASLAN004 in healthy volunteers following single dose administration via IV or SC route (16 timepoints)
2.PK parameters: Estimate of volume of distribution at steady state (Vss) [ Time Frame: Predose,1 hour, 2 hour, 4 hour, 8 hour, 24 hour, 72 hour, 168 hour, 240 hour and up to 3 months ] To assess the pharmacokinetics of ASLAN004 in healthy volunteers following single dose administration via IV or SC route (16 timepoints)
3.PK parameters: Subcutaneous bioavailability (F) [ Time Frame: Predose,1 hour, 2 hour, 4 hour, 8 hour, 24 hour, 72 hour, 168 hour, 240 hour and up to 3 months ] To assess the pharmacokinetics of ASLAN004 in healthy volunteers following single dose administration via SC route only (16 timepoints)
4.PK parameters: Dose-normalized Cmax (Cmax/dose) [ Time Frame: Predose,1 hour, 2 hour, 4 hour, 8 hour, 24 hour, 72 hour, 168 hour, 240 hour and up to 3 months ] To assess the pharmacokinetics of ASLAN004 in healthy volunteers following single dose administration via IV or SC route (16 timepoints)
5.PK parameters: AUC (AUC(0-inf)/dose) [ Time Frame: Predose,1 hour, 2 hour, 4 hour, 8 hour, 24 hour, 72 hour, 168 hour, 240 hour and up to 3 months ] To assess the pharmacokinetics of ASLAN004 in healthy volunteers following single dose administration via IV or SC route (16 timepoints)
clinicaltrials.gov/ct2/show/NCT03721263
¥xÁÞ¤jªº µ²½×: ¸ÕÅç¼Æ¾Ú«ü¥X ASLAN004 §¹¥þ§í¨î¨ü¾¹°T¸¹¶Ç»¼©Ò»Ýªº³Ì§C¿@«×(trough level)¤ñ²{¦³ªvÀø¤è¦¡©Ò»Ýªº¿@«×§C¡A¿@«×®t¶Z¶W¹L¤@Ӽƶq¯Å (®t¶Z¤j©ó10¿ ) ÁöµMªi¨¦¤ô¥¤ñ²{¦³ªvÀø¤è¦¡©Ò»Ýªº¿@«×§C ¦ý±wªÌ¦å¬y¤¤ªºÃĪ«¶q¤´µM°ª¨ì¨¬¥HªvÀø ³o¬OASLAN004 ¦b²§¦ì©Ê¥Ö½§ª¢¤£»ÝÀWÁcµ¹ÃĪº«n¬ì¾ÇÃÒ¾Ú
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/7 ¤U¤È 10:43:48²Ä 1172 ½g¦^À³ 2019¦~6¤ë4¤é¤½§iªº ASLAN004 ²§¦ì©Ê¥Ö½§ª¢¤@´ÁÁ{§É¸ÕÅç
¥ÎÃÄÀW²v¸û§CªºªvÀø¤è¦¡+ °§C¾ãÅéÂåÀøÅé¨tªºt¾á + °Æ§@¥Î§C+ Àx¦sÄâ±a¤è«K ASLAN004 ¤@´Á¸ÕÅ窺³Ì«á¼Æªº½TÅý§Ú̹ï©ó¦¨¬°²§¦ì©Ê¥Ö½§ª¢¦P¯Å³Ì¨ÎÀøªkªº«H¤ß
¤½§i¤º¤å¦³¨âÓ±M¦³¦Wµü trough level »P ¼Æ¶q¯Å ?
trough level Àò±oªi¨¦(trough level )¿@«×ªº¥Øªº¬O¤°»ò¡H trough level¬O±wªÌ¦å¬y¤¤ÃĪ«ªº³Ì§C¤ô¥¡A¨Ã¥B¦b¬I¥Î¤U¤@¾¯ÃĪ«¤§«e´ú¶q¡C ø»sªi¨¦¤ô¥ªº¥Øªº¬O½T«O±wªÌ¦å¬y¤¤ªºÃĪ«¶q¤´µM°ª¨ì¨¬¥HªvÀø¡C ´úªi®p(peak level )¿@«×®É¡AÀ³¦bÃĪ«§¹¦¨§l¦¬¤Î¤À§G´Á«á©â¦å¡C ´úªi¨¦(trough level )¿@«×®É¡AÀ³¦b¤U¤@¦¸µ¹ÃÄ«e©â¦å
site.jah.org.tw/pha/pha_web/c11_drugsafe/pdf/%E8%97%A5%E7%89%A9%E6%B2%BB%E7%99%82%E7%9B%A3%E6%B8%AC%E6%8C%87%E5%BC%9510400708.pdf
¼Æ¶q¯Å ³q±`±¡ªp¤U¡A¼Æ¶q¯Å«ü¤@¨t¦C 10 ªº¾(¦¸¤è)¡A§Y¬Û¾F¨âӼƶq¯Å¤§¶¡¤ñ¬° 10¡C¨Ò¦p»¡¨â¼Æ¬Û®t¤TӼƶq¯Å¡A¨ä¹ê´N¬O»¡¤@ӼƤñ¥t¤@Ó¤j 1000 ¿¡C ¦p»¡¨â¼Æ¬Û®t¤GӼƶq¯Å¡A¨ä¹ê´N¬O»¡¤@ӼƤñ¥t¤@Ó¤j 100 ¿ ¦p»¡¨â¼Æ¬Û®t¤@Ӽƶq¯Å¡A¨ä¹ê´N¬O»¡¤@ӼƤñ¥t¤@Ó¤j 10¿
zh.wikipedia.org/wiki/%E6%95%B0%E9%87%8F%E7%BA%A7
µ²½×: ¸ÕÅç¼Æ¾Ú«ü¥X ASLAN004 §¹¥þ§í¨î¨ü¾¹°T¸¹¶Ç»¼©Ò»Ýªº³Ì§C¿@«×(trough level)¤ñ²{¦³ªvÀø¤è¦¡©Ò»Ýªº¿@«×§C¡A¿@«×®t¶Z¶W¹L¤@Ӽƶq¯Å (®t¶Z¤j©ó10¿ ) ÁöµMªi¨¦¤ô¥¤ñ²{¦³ªvÀø¤è¦¡©Ò»Ýªº¿@«×§C ¦ý±wªÌ¦å¬y¤¤ªºÃĪ«¶q¤´µM°ª¨ì¨¬¥HªvÀø ³o¬OASLAN004 ¦b²§¦ì©Ê¥Ö½§ª¢¤£»ÝÀWÁcµ¹ÃĪº«n¬ì¾ÇÃÒ¾Ú
ASLAN004 Àu²§ªºÃĪ«¯S©Ê¥i¥H¬°²§¦ì©Ê¥Ö½§ª¢¯f±w´£¨Ñ¤@Ó¥ÎÃÄÀW²v¸û§CªºªvÀø¤è¦¡¡B¤ñ°_²{¦³ªvÀø¤è ¦¡§ó¬°«K§Qªºµ¹Ãij~®|¡AÂǦ¹´î»´²§¦ì©Ê¥Ö½§ª¢¯f±w»P¾ãÅéÂåÀøÅé¨tªºt¾á (°Ñ¦Ò6¤ë4¤é¤½§i )
¥[¤W°Æ§@¥Î§C»PÀx¦sÄâ±a¤è«K ASLAN004 ¤@´Á¸ÕÅ窺³Ì«á¼Æªº½TÅý§Ú̹ï©ó¦¨¬°²§¦ì©Ê¥Ö½§ª¢¦P¯Å³Ì¨ÎÀøªkªº«H¤ß
¥H¤W¸ê°T¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/23 ¤U¤È 01:41:49
²Ä 2067 ½g¦^À³
|
°O¦í¥H¤Uªº¼Æ¾Ú¡AASLAN004 ,¤é«á¥²¶W¶V¥LÌ¡A¤è¦p¤½¥q©Ò¨¥¡A¦P¯Å³Ì¨Î¡C
2.Lebrikizumab 2b ¤¤-««×AD Á{§Éªº«ü¼Ð(2019/3¤ë¤½¥¬)
(¤@).250 mg Q2W(¨â¶g¤@°w)/16¶g EASI-50 81.0%*** EASI-75 60.6%*** EASI-90 44.0%*** IGA0/1 44.6%**
¤G).250 mg Q4W(¥|¶g¤@°w)/16¶g EASI-50 77.0%** EASI-75 56.1%** EASI-90 36.1%** IGA0/1 33.7%* |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/23 ¤W¤È 10:55:23
²Ä 2066 ½g¦^À³
|
1.Dupliumab 3´Á ¤¤-««×AD, 2ÓSOLO1/SOLO2 Á{§Éªº«ü¼Ð(2016¤ë¤½¥¬)
(¤@).300 mg Q2W(¨â¶g¤@°w/16¶g) EASI-50 65%/69% EASI-75 51%/44% EASI-90 36%/30% IGA0/1 38%/36%
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 25%/22% EASI-75 15%/12% EASI-90 8%/7% IGA0/1 10%/8%
www.nejm.org/doi/full/10.1056/NEJMoa1610020?cookieSet=1
2.Lebrikizumab 2b ¤¤-««×AD Á{§Éªº«ü¼Ð(2019/3¤ë¤½¥¬)
(¤@).250 mg Q2W(¨â¶g¤@°w) EASI-50 81.0%*** EASI-75 60.6%*** EASI-90 44.0%*** IGA0/1 44.6%**
(¤G).250 mg Q4W(¥|¶g¤@°w) EASI-50 77.0%** EASI-75 56.1%** EASI-90 36.1%** IGA0/1 33.7%*
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 45.8% EASI-75 24.3% EASI-90 11.4% IGA0/1 15.3%
*p<0.05, **p<0.01, and ***p<0.001 versus placebo www.businesswire.com/news/home/20191017005896/en/Dermira-Presents-Data-Phase-2b-Study-Lebrikizumab -------------
Lebrikizumab 2b (¼Ð¹vµ²¦XIL13°tÅé) ¼Æ¾ÚÀu ©ó Dupliumab(¼Ð¹vµ²¦XIL4¨üÅé) . ¦ÓAslan004 ¼Ð¹vµ²¦XIL13¨üÅé,±NÀu©óLebrikizumab ¼Ð¹vµ²¦X IL13°tÅé.
¤é«áÁ{§É±N¤@¤@µý©ú¤§.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/23 ¤W¤È 08:29:27
²Ä 2065 ½g¦^À³
|
EASI-50 ¤TÃļƾÚ: ASLAN001 100% (1b/200mg/Q1W--3¦ì) Lebrikizumab EASI-50 81.0%(2b/250mg/Q2W)>Lebrikizumab EASI-50 77.0%(2b/250mg/Q4W) Dupliumab 71.4%(1b/300mg/Q1W)>Dupliumab 65%~69%(3phs/300mg/Q2W)
------ ¾÷ÂàMOA ASLAN001©MLebrikizumab©M Dupliumab, ¤@¼Ë¥ØªºªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡ªº°T®§¶Ç¾É,¹vÂI¤£¤@¼Ë. 12¤ë13¤éªk»¡·| p.8, ¼Ð¹vÃĪ«µ²¦X¦b¨üÅé¤WÀu©óµ²¦X°tÅé¤W.¬Û¹ï©ó¹ï·Ó²Õ¼W¥[ÃĮħó¦h.(¹êµý) p.9, ¼Ð¹vÃĪ«µ²¦X¦bIL13¤ñµ²¦X¦bIL4 ,¥i°§CÅ餺©Ò»ÝªºÃĪ«¿@«×. (Lebrikizumab 250mg/¤G´ÁÁ{§É ²z½×¤W:ASLAN004 ¾¯¶q ±N< Lebrikizumab 250mg ,©Î³\200mg~250mg ±N¬OASLAN004³Ì¨Î.
-------------------------------------------- ASLAN001 ¾÷ÂàMOA : ÂǥѻPIL-13 ¨üÅéR£\1¦ìµ²¦X ¡A ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡ªº°T®§¶Ç¾É¡C
Lebrikizumab¾÷ÂàMOA: Lebrikizumab ¬O«²Õªº IgG4 §ÜÅé¡A ÂǥѻPIL-13 °tÅé¤Wªº B¡BC Á³±Û¤Wªº§Üìªí¦ìµ²¦X ¡A ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡ªº°T®§¶Ç¾É¡C
Dupilumab ¬O«²Õªº IgG4 §ÜÅé¡A¦]¬°»P IL-4R£\ µ²¦X¡A©Ò¥H¯à¦P®ÉªýÂ_ IL-4 ¤Î IL-13 »P²Ä¤@«¬¤Î²Ä¤G«¬¨üÅ骺µ²¦X¡C ªýÂ_IL-4R£\ »P yC ¤§¶¡°T®§¶Ç¾É¡CªýÂ_²Ä¤@«¬¨üÅéµ²¦X¡C¡]¥i¯à²£¥Í²´·ú结¼Òª¢°Æ§@¥Î¤§ì¦]¡^ ªýÂ_IL-4R£\ »P IL-13R£\1¤§¶¡°T®§¶Ç¾É¡CªýÂ_²Ä¤G«¬¨üÅéµ²¦X¡C
---------- 1.Lebrikizumab 2b Á{§Éªº«ü¼Ð(2019/3¤ë¤½¥¬)
(¤@).250 mg Q2W(¨â¶g¤@°w) EASI-50 81.0%*** EASI-75 60.6%*** EASI-90 44.0%*** IGA0/1 44.6%**
(¤G).250 mg Q4W(¥|¶g¤@°w) EASI-50 77.0%** EASI-75 56.1%** EASI-90 36.1%** IGA0/1 33.7%*
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 45.8% EASI-75 24.3% EASI-90 11.4% IGA0/1 15.3%
*p<0.05, **p<0.01, and ***p<0.001 versus placebo www.businesswire.com/news/home/20191017005896/en/Dermira-Presents-Data-Phase-2b-Study-Lebrikizumab |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/22 ¤U¤È 11:09:46
²Ä 2064 ½g¦^À³
|
²z½×¤W ASLAN004 ¦UÀø®Ä«ü¼Ð±NÀu©ó Lebrikizumab
¦ÓLebrikizumab 2b Á{§Éªº«ü¼Ð , ¤wÀu©ó dupilumab.
About the Lebrikizumab Phase 2b Study
The randomized, double-blind, placebo-controlled, parallel-group Phase 2b study was designed to evaluate the safety and efficacy of lebrikizumab as monotherapy compared with placebo and establish a dosing regimen for the Phase 3 program in patients with moderate-to-severe atopic dermatitis. The study enrolled 280 patients ages 18 years and older with moderate-to-severe atopic dermatitis at 57 sites in the United States. Three different lebrikizumab treatment dosing arms were evaluated, compared to a placebo arm, with patients randomized in a 3:3:3:2 fashion as follows:
Group 1: A loading dose of 250 mg of lebrikizumab at baseline (day 0), followed by 125 mg of lebrikizumab every four weeks. Group 2: A loading dose of 500 mg of lebrikizumab at baseline (day 0), followed by 250 mg of lebrikizumab every four weeks. Group 3: A loading dose of 500 mg of lebrikizumab at baseline (day 0) and week 2, followed by 250 mg of lebrikizumab every two weeks. Group 4: Placebo at baseline (day 0) and every two weeks thereafter. The inclusion criteria for patients enrolled in this study included the presence of chronic atopic dermatitis for at least one year, an Eczema Area and Severity Index (EASI) score of 16 or greater, an Investigator¡¦s Global Assessment (IGA) score of 3 or 4 (on a 5-point scale ranging from 0 to 4) and body surface area (BSA) involvement of at least 10 percent at screening and baseline.
The primary endpoint of the study was the percent change in EASI from baseline to week 16. Secondary endpoints that were evaluated during the 16-week treatment period included: the proportion of patients with a 75 percent improvement from baseline in EASI score (EASI-75); the proportion of patients with a reduction of 2 or more points in IGA score from baseline to a final score of 0 (clear) or 1 (almost clear) (IGA0/1); the proportion of patients achieving EASI-50 and EASI-90; changes in pruritus (itch) and sleep loss scores from baseline, each scored using a numerical rating scale (NRS); and the proportion of patients with an improvement in pruritus NRS score (on an 11-point scale) of at least 4 points from baseline.
Newly Presented Lebrikizumab Phase 2b Study Results Presented at Fall Clinical Dermatology Conference
Initial topline findings from the Phase 2b study were previously announced in March 2019, showing that across all doses evaluated, lebrikizumab demonstrated dose-dependent and statistically significant improvements in the primary endpoint, the mean percent change in EASI score from baseline to week 16.
The data being presented highlight secondary endpoints assessing measures spanning the range of signs and symptoms of atopic dermatitis, including skin lesions (the proportions of patients achieving EASI-50, EASI-75, EASI-90 and IGA0/1) and pruritus (mean percent change in pruritus NRS score and the proportion of patients achieving an improvement of at least 4 points in pruritus NRS score) over the 16-week treatment period. Key findings include the following:
Skin Lesions
A response was observed as early as the first on-treatment visit at week 4 for all atopic dermatitis severity scores. Lebrikizumab demonstrated a dose-dependent response across each of the EASI-50, EASI-75, EASI-90 and IGA0/1 endpoints, with marked improvement at both the 250 mg every two weeks (Q2W) and 250 mg every four weeks (Q4W) doses. A greater proportion of lebrikizumab- versus placebo-treated patients achieved EASI-50, EASI-75, EASI-90 and IGA0/1 at week 16, with statistically significant improvements seen with lebrikizumab as follows: EASI-50 EASI-75 EASI-90 IGA0/1 250 mg Q2W 81.0%*** 60.6%*** 44.0%*** 44.6%** 250 mg Q4W 77.0%** 56.1%** 36.1%** 33.7%* 125 mg Q4W 66.4% 43.3% 26.1% 26.6% Placebo 45.8% 24.3% 11.4% 15.3% *p<0.05, **p<0.01, and ***p<0.001 versus placebo Pruritus (Itch)
Dose-dependent improvements in pruritus, as reported by patients, were observed as early as day 2 and continued through week 16. By week 16, patients receiving lebrikizumab at doses of 125 mg Q4W, 250 mg Q4W and 250 mg Q2W reported mean improvements in pruritus NRS score of 36.9% (p<0.01), 48.6% (p<0.001) and 61.8% (p<0.001), compared to a mean worsening of 6.8% in patients receiving placebo. The proportion of patients reporting an improvement of at least 4 points in pruritus NRS score was highest in the 250 mg Q2W group, reaching 51.9% by week 4 and at week 16, 70.0% (p<0.001 vs. placebo). As expected, based on prior experience, lebrikizumab was generally well-tolerated, with a safety profile consistent with that observed in prior studies in more than 4,000 patients. Adverse events observed in lebrikizumab-treated patients were primarily mild to moderate in severity and infrequently led to treatment discontinuation. The most common adverse events reported across the lebrikizumab 250mg Q2W, 250mg Q4W and 125mg Q4W dosing arms were upper respiratory tract infection (2.7%, 11.3% and 8.2%, respectively, vs. 5.8% for placebo), nasopharyngitis (12.0%, 2.5% and 5.5%, respectively, vs. 3.8% for placebo), headache (5.3%, 1.3% and 4.1%, respectively, vs. 5.8% for placebo) and injection site pain (5.3%, 3.8% and 0.0%, respectively, vs. 1.9% for placebo). Rates of herpes viral infections (which includes oral herpes, herpes zoster, genital herpes, herpes simplex, and eczema herpeticum) were 2.7%, 5.0% and 2.7%, respectively, vs. 3.8% for placebo) and conjunctivitis (2.7%, 3.8% and 1.4%, respectively, vs. 0.0% for placebo) were low. Across all studies of lebrikizumab conducted to date in atopic dermatitis, conjunctivitis has been reported at low rates similar to those in patients receiving placebo.
¡§Our goal with lebrikizumab is to develop a best-in-disease therapy for patients with moderate-to-severe atopic dermatitis that not only improves the severity of disease, but that is also safe and convenient,¡¨ said Eugene A. Bauer, M.D., chief medical officer at Dermira and a dermatologist. ¡§These results support our belief that specifically targeting IL-13 with lebrikizumab has the potential to deliver on all of these objectives and thus help address the substantial unmet medical need in this prevalent, debilitating condition.¡¨
Based on the Phase 2b study results, Dermira recently announced the initiation of a Phase 3 clinical development program to further evaluate lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis.
www.businesswire.com/news/home/20191017005896/en/Dermira-Presents-Data-Phase-2b-Study-Lebrikizumab
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/22 ¤U¤È 05:29:57
²Ä 2063 ½g¦^À³
|
¥H¤W¤å³¹¡AÂà¶K¦Û Áª÷ªe ¥ý¥Íªººô¸ô¤å³¹.
Aslan004 , ¬O¶Q¡H¬O½â ? À³¨ú¡HÀ³±Ë¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/22 ¤U¤È 05:21:59
²Ä 2062 ½g¦^À³
|
¶Q¤W·¥«h¤Ï½â¡A½â¤U·¥«h¤Ï¶Q¡A¶Q¥X¦pÁT¤g¡A½â¨ú¦p¯]¥É¡A°]³f±ý¨ä¦æ¦p¬y¤ô¡C
«Åª¥v°O³f´Þ¦C¶Ç¡I
¥xªÑ¯¸¤W12000ÂI¡A¤@®É¤§¶¡¦¨¬°¥þ¥x°Q½×ªºµJÂI¡A¦]¬°¥xªÑ¸g¾ú¤F30¦~ªº·³¤ë¡AÁ`ºâ¬O¦^¨ì°ª¦ì¡C§Ú·Q¨ì30¦~«e¡A·í¤j®a¦pè¦p¾Kªº®ÉÔ¡A§Ú¬O³Ì¦°Û°I¥xÆWªº¤H¡A§Ú»{¬°¥xÆW®£©È´X¤Q¦~¤£·|½¨¡A¨º¦~¹L¦~«á¡A§Ú¥hªá½¬ºtÁ¿¡A¨º®É¥¿¬y¦æù¤j¦öªº¡uÅʦ±1990¡v¡A§Ú説¥xÆWªº¸êª÷±N¤jÁ|¥~¬y¡A¥xÆWW¤é¤l¨Ó¤F¡A¤j®a³£¤£¬Û«H¡C ³o¨â¦~¡A¬ü¤¤¶T©ö¾Ô¶}¥´¡A¤j®a³£«Ü´dÆ[¡A§Ú§i¶D¤j®a¥xÆW½öµÛ¤]·|¦n¡A¦ý¤j®a³£¤£¬Û«H¡A°Û°I¥xÆWªº¤ñ¤ñ¬Ò¬O¡A¯S§O¬O¬Fªv¤Hª«¡C³o30¦~¨Ó¡A¥xÆWªº¸êª÷¬y¶i¡B¬y¥X¹³¤ô¤@¯ë¡A¨M©w¤F¥xÆWªº©R¹B¡C³oÓ¯«Åè¥Î¥q°¨¾Eªº¥v°O³f´Þ¦C¶Ç¨Óªí¹F³Ì²M·¡¡C §Ú³Ì³ßÅw³f´Þ¦C¶Ç¤Wªº¤@¬q¸Ü¡u¶Q¤W·¥«h¤Ï½â¡A½â¤U·¥«h¤Ï¶Q¡A¶Q¥X¦pÁT¤g¡A½â¨ú¦p¯]¥É¡A°]³f±ý¨ä¦æ¦p¬y¤ô¡C¡v¥Î¥Õ¸Ü¨Ó説¡Aª«¶Q¨ì·¥ÂI¡An¹³ÁT¤g¯ë½æ±¼¡A¦P¼Ë½â¨ì·¥P¡An¹³¯]¥É¤@¯ë¶R¤J¡A°]³f¹B¦æn¹³¬y¤ô¤@¯ë¡C ¥Î³oÓ¨¤«×¬Ý¥xÆWªº¸gÀÙ¡A¤]¬O¦p¦¹¡A·í¥xÆWªº¤H¡A¥xÆWªº¿ú·½·½¤£µ´¬y¦V¤¤°ê¤j³°¡A¥xÆW¸gÀÙ·íµM§xµ~¡C¥xªÑ¦b¸UÂI¥H¤U¡A¥¿³B¦b½â¤U·¥ª¬ºA¡A¦ý¤H¤H±ó¤§¦p½ªá¢¡C²{¦b¤ô¤£¬y¡A¤H¤]¤£¦A¥X¨«¤F¡A¥xÆWªº®ð¦â¬Ý³vº¥¦nÂà¡C¹L¥hªÑ¥«¥»¯q¤ñ°¾§C¡A¥æ©ö¶q¤Ö¡AªÑ¥«¤£®¶¡A³o¨â¦~¥xÆW²×©ó§áÂà¦H¶Õ¡AªÑ¥«¬OÃoµ¡¡A¹D²z«Ü®e©ö©ú¥Õ¡C ³o¦¸¥xªÑ«ªð¸U¤G¡Aµ²ºc©M30¦~«e§¹¦¨¤£¤@¼Ë¡A¬O¥x¿n¹qªºADR¤£Â_©Ô°ªªÑ»ù±a°Ê¾ãÓ¥b¾ÉÅéªÑ©b¹£¡A¥xªÑ¥¿¦b®i²{ª¿®qªº«Â¤O¡A¥xÆWªº¸gÀÙµo®i¤~¥¿n¸ó¥XÃöÁä¤j¨B¡A¶Q½â§¹¥þ¦b¨CÓ¤H¤ß¤¤ªºµûÂ_¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/22 ¤U¤È 03:04:48
²Ä 2061 ½g¦^À³
|
ASLAN004 ¤½¥¬ªº¤TÓÁ{§É¼Æ¾Ú¦³¦h«n©O¡H¬°¤°»ò¤½¥q説¨S¹w´Á¦³¦p¦¹°ªªºªí²{¡I
1b·§©À©ÊÁ{§ÉEASI°§C50%¥H¤W±wªÌªº¤ñ²v¤§PK SLAN004 100% VS. Dupilumab 71.4%
a.ASLAN004 200mg ,3¦ì¡A100% ¬ÒEASI°§C50%¥H¤W¡A 3¦ìEASI¤À§O°§C85%/70%/59%, ¥ÎÃÄ4~6¶g¡C
½Ð¬Ý¥H¤U ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X-
Dupliumab ·§©À©À©ÊÁ{§É¼Æ¾Ú VS ¤T´ÁÁ{§É¼Æ¾Ú PK ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- 1.·§©À©ÊÁ{§É¼Æ¾Ú¡C2013¦~3¤ë2¤é¤½¥¬
¹êÅç²Õ 300mg ,n=21 , EASI°§C50%¥H¤WªÌ :71.4% ¹ï·Ó²Õ,n=16 , EASI°§C50%¥H¤WªÌ :18.8%
¨C¶g¤@°w¡A¦@¥´¥|°w¡C
2. ¤T´ÁÁ{§É(SOL1&SOL2)¼Æ¾Ú : 2016¦~,10¤ë¤½¥¬¥¿¦V¼Æ¾Ú
1.SOL1, ¤Q¤»¶gªvÀø ,300mg A.¨C¶g¤@°w ,¦@17°w ¹êÅç²Õ 300mg n=223 , EASI°§C50%¥H¤WªÌ :61%= 136/223 ¹ï·Ó²Õ,n=224 , EASI°§C50%¥H¤WªÌ :25%:=55/224
B.¨C¤G¶g¤@°w ,¦@ 9°w ¹êÅç²Õ 300mg n=224 , EASI°§C50%¥H¤WªÌ :69%= 154/224
2.SOL2, ¤Q¤»¶gªvÀø ,300mg A.¨C¶g¤@°w ,¦@17°w ¹êÅç²Õ 300mg n=239 , EASI°§C50%¥H¤WªÌ :61%= 146/233 ¹ï·Ó²Õ,n=236 , EASI°§C50%¥H¤WªÌ : 22%:=52/236
B.¨C¤G¶g¤@°w ,¦@ 9°w ¹êÅç²Õ 300mg n=233 , EASI°§C50%¥H¤WªÌ :65%= 152/233
ªí¤G¡C www.nejm.org/doi/full/10.1056/NEJMoa1610020?cookieSet=1
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X Dupliumab ·§©À©ÊÁ{§É21¦ì300mg¹êÅç²Õ±wªÌªºEASI °§C50%¥H¤Wªº¤ñ²v71.4% ©M ¤T´ÁÁ{§É¸ÕÅçµ²ªG, ¨C¶g¤@°w61%/61%, ®t²§ 17%(71.4%/61%)
©M¤T´Á ¨C2¶g¤@°w69%/65% , ¤À§O®t²§103%/109% , ¦³¬Û·í±µªñªºÁZ®Äµ²ªG¡C
¡X¡X¡X- Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis Update: Dupixent (dupilumab) Now FDA Approved - March 28, 2017 Facebook Twitter Email to a friend Print this page Phase 1b Data Presented at Late Breaking Session of 71st Annual Meeting of the American Academy of Dermatology
PARIS and TARRYTOWN, N.Y., March 02, 2013, 2013 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.
A responder analysis demonstrated that at week 4, 54.5% of patients treated with the 150mg dose and 71.4% of patients treated with the 300mg dose achieved a reduction in EASI score of 50% or greater compared to 18.8% with placebo (p<0.05).
the Phase 1b trials included 67 patients randomized to three different doses of dupilumab (75mg, n=8; 150mg, n=22; 300mg, n=21) and placebo (n=16).
www.drugs.com/clinical_trials/sanofi-regeneron-report-positive-proof-concept-data-dupilumab-il-4r-alpha-antibody-atopic-dermatitis-15200.html |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/22 ¤W¤È 07:54:04
²Ä 2060 ½g¦^À³
|
¤¤¡B««×ADÀøµ{¦¨¥» 3ÃÄPK¼ÒÀÀ¡C
ASLAN004 ¨C¤ë¤@°wªº«Â¤O¬Æ¤j¡A¦¨¥»³Ì§C¡A§Y¨Ï2¶g¥´¤@°w¡A¤D¬O³Ì§C¦¨¥»¡AÄvª§¤O¶W¯Å±j¡C
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K 16¶gÁ`¥ÎÃĶq(mg)x³æ»ù(¬ü¤¸/mg)/Àø®Ä(³Ì¨Î¤ÏÀ³IGA=0/1)
¤T´ÁÁ{§Éªº¥Dn«ü¼ÐIGA =0/1 Proportion of patients with a Investigators Global Assessment (IGA) score of 0 or 1 and a reduction in this measure of at least 2 points at week 16. [ Time Frame: Week 16 ]
¬ü°ê¤½/¨p¥ß«OÀI¤½¥q¬O¨Ì¾ÚÀøµ{¦¨¥»¡A¨Ó®Ö·Ç¥ÎÃıƧǡC ¦¨¥»§CªºÀu¥ý¨Ï¥Î¡C
16¶gÀøµ{¦¨¥» 1.Dupliumab 9°wx1500¬ü¤¸(300mg)/0.35(IGAÀø®Ä0/1) =38,500¬ü¤¸
2.Bermekimab 8针x2000¬ü¤¸(400mg)/0.53(°²³]Dupilumab IGA0.35/0.66=0.53)=30,200¬ü¤¸
3.ASLAN004 4°wx1250¬ü¤¸(250mg)/0.4(°²³]È) =12¡A500¬ü¤¸
¥H¤W°²³] 1.¼Ð¹vÃĪ«¨Cmgªº¾P°â³æ»ù¦Pdupilumab 5¬ü¤¸¡C 2.¼Ð¹vµ²¦X©óIL13Àø®ÄÀu©óIL4¡C°²³]ASLAN004 IGA0/1=0.4,Aslan004¨C¤ë¥´¤@°w¡C 3.dupilumab IGA 0/1 ¥Ø«e约35%¡A³Ì¨Î¤ÏÀ³¡C ESAI°§C75% Duplimab 47%/Bermekimab71%=66% ±ÀºâBermekimabIGA 0/1=0.35/0.66=0.53
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/21 ¤U¤È 11:33:05
²Ä 2059 ½g¦^À³
|
Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting
ˆý „J „´ „¨ „¥ †qEmail ƒ}Print Friendly †WShare
March 01, 2019 11:44 ET | Source: XBiotech Inc.
•Rapid and significant reduction in skin lesions, 66% (p<0.001) and 76% (p<0.001) mean reduction in EASI score in 4 and 7 weeks, respectively. •Rapid and significant resolution of worst itch and pain, 57% (p<0.001) and 61% (p<0.001) mean reduction within 4 weeks, respectively. •Substantial mean reduction of worst itch and pain 71% (p<0.001) and 84% (p<0.001) within 7 weeks, respectively.
AUSTIN, Texas, March 01, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that breakthrough results from its Phase 2 clinical trial of its antibody therapy, bermekimab, are being presented tomorrow at a late-breaking oral presentation during the annual meeting of the American Academy of Dermatology (AAD) being held in Washington, DC. The presentation titled, ¡§Bermekimab is a Rapid and Effective Treatment for Atopic Dermatitis (AD)¡¨ will take place on Saturday, March 2 at 1:10pmET in Ballroom A and will be presented by international dermatology expert, and lead researcher in the development of approved therapies for atopic dermatitis, Eric Simpson, M.D, M.C.R. Professor of Dermatology at Oregon Health & Science University, School of Medicine.
The results being presented by Dr. Simpson demonstrate that bermekimab treatment resulted in rapid and significant improvement of disease in patients with moderate-to-severe AD. After only 7 weeks of treatment, 71% of patients that received a 400mg bermekimab weekly regimen had at least 75% reduction in their disease, as measured by the Eczema Area and Severity Index (EASI) score (this compares to 44-51% of patients achieving 75% improvement in EASI score after 16 weeks therapy as reported for two Phase III clinical trials for the existing FDA approved biological drug for AD). Moreover, within 7 weeks, using patient reported Numerical Rating Scale (NRS) for itch and pain, patients receiving the 400mg bermekimab treatment regimen had 71% reduction in itch and an 84% reduction in pain (this compares to 36-41% reduction in itch [pain was not reported] after 16 weeks of treatment with the existing approved therapy for AD).
XBiotech CEO John Simard commented, ¡§We are thrilled to have Dr. Simpson present these findings at the AAD tomorrow. We expect these results to enable the advancement of a new and very important treatment for what is a rather under appreciated disease in terms of its severity and wide-spread impact on the lives of people around the world.¡¨
In the study, 38 patients in two treatment groups received a low (200mg) or high (400mg) dose of bermekimab once weekly for either a 4 or 7-week treatment regimen, respectively. There was statistically and clinically significant improvement in treatment response for key measures of disease severity in the high dose versus the low dose group.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/21 ¤U¤È 11:19:48
²Ä 2058 ½g¦^À³
|
¥xÁÞ¤j¡A
Ävª§¤O¤ÀªR¡A
(a)Bermekimab ¥Î¶q400mg,Y2¶g¤@°w¡A16¶g,8,针¡A¦@3200mg. ¥ÎÃĶq°ª¡A¦¨¥»°ª¡C (b)YASLAN004 ¥¼¨Ó250mg¨C¤ë¤@°wx4Ó¤ë=1000mg
(a)/(b)=3.2¿¡CxÀø®Ä®t²§(°²³]EASI °75%¤§¤ñ²v®t²§60%=dupilumab45%/bermekimab75% )=1.92¿
¦P¼Ë¬Ò¬OAD§í¨î¾¯¼Ð¹v¡AASLAN004¦³¶W§CªºªvÀø¦¨¥»¡C «D±`üLªºÄvª§¤O¡C
§Cªº¾ãÅé¥ÎÃĦ¨¥»¥h¸`¬Ù«OÀIªº¿ú¬OÄvª§¤O¡A«D±`«D±`«n¡C ¥¼¨ÓASLAN004¤@Ó¤ë¤@°w¡A¬O«Ü«¤jªºÄvª§¤O¡C
¥H¤W«Ü¦h¼Æ¾Ú¡A«Ü¦h°²³]¡A¥¼¨Ó¬Ò·|变°Ê¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis clinicaltrials.gov/ct2/show/NCT04021862
Detailed Description: This is a phase II, randomized, double-blind, placebo-controlled study of bermekimab in patients with moderate to severe atopic dermatitis. The primary objective of the study is to analyze the safety and efficacy of different dose regimens of bermekimab compared to placebo treatment in adult patients with moderate-to-severe AD. The study is multicenter and will consist of three groups:
Treatment Arm 1: Bermekimab every week (qw)
Treatment Arm 2: Bermekimab every other week (q2w)
Arm 3 (Placebo): Placebo every week (qw) Study Type : Interventional (Clinical Trial) Estimated Enrollment : 90 participants Allocation: Randomized Intervention Model: Sequential Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis Estimated Study Start Date : November 2019 Estimated Primary Completion Date : July 2020 Estimated Study Completion Date : September 2020
û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/12/18 ¤U¤È 09:27:30²Ä 2027 ½g¦^À³ Bermekimab »P ASLAN004 ¦bÀã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI)µû¤À ªì¨B PK
Bermekimab Àã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI)µû¤À % Change from Baseline ( phase 2 ) Group 200mg N=10 ²Ä4©P¬ù¤U°¦Ê¤À¤§20 Group 400mg N=28 ²Ä7©P¬ù¤U°¦Ê¤À¤§75
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/21 ¤U¤È 02:55:42
²Ä 2057 ½g¦^À³
|
¬ü°ê¤ÀªR®v©|¥¼±NASLAN001ªº谮¦b»ùȺâ¤J. ¨È·à±d©ú¦~ªì±Nn¦VFDA¥Ó½Ð30~40¤H¤G缐Áx¹DÀù¡A¿z¿ïHER¥Íª««ü¼Ðªº¼Ï¶sÁ{§É¡AY¦¨¥\¡A¥Ø¼Ð»ù·|¦A¦¸¤j´T½Õ¤É¡C ¥t¥~aslan004 ·§©À©ÊÁ{§É¸ÕÅç¡A«e¤G¾¯¶q¤½¥¬µ²ªG¡C ¥ç¬O½Õ¤É¥Ø¼Ð»ùªº®ÉÂI¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/21 ¤U¤È 01:33:41
²Ä 2056 ½g¦^À³
|
www.tipranks.com/stocks/asln/price-target Analyst Price Target on ASLN $6.50 ¡¶ (196.80% Upside) Based on 2 analysts offering 12 month price targets for Aslan Pharmaceuticals in the last 3 months. The average price target is $6.50 with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 196.80% increase from the last price of $2.19.
ASLNªº¤ÀªR®v¥Ø¼Ð»ù $ 6.50 ¡¶¡]196.80¢H¤Wº¦ªÅ¶¡¡^ °ò©ó2¦ì¤ÀªR®v¦b¹L¥h3Ӥ뤤¬°Aslan Pharmaceuticals´£¨Ñªº12Ó¤ë¥Ø¼Ð»ù®æ¡C ¥§¡¥Ø¼Ð»ù¬°6.50¬ü¤¸¡A³Ì°ª¹w´ú¬°8.00¬ü¤¸¡A³Ì§C¹w´ú¬°5.00¬ü¤¸¡C ¥§¡»ù®æ¥Ø¼Ð¤ñ³Ì·s»ù®æ$ 2.19¤Wº¦196.80¢H¡C
l ¬ü°ê¤ÀªR®vµ¹¨È·à±dADR¥¼¨Ó12Ó¤ë¥Ø¼Ð»ù 5~8¬ü¤¸/ªÑ. §é¦X¥xªÑ30~48¤¸/ªÑ. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/20 ¤U¤È 09:29:56
²Ä 2055 ½g¦^À³
|
§ùÁת¢ª`®g¾¯ 300 ²@§J DUPIXENT solution for injection 300mg ¤¤¤åª© ¥é³æ
www.ktgh.com.tw/Public/tbDrug/201905241612517055.pdf
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/20 ¤U¤È 03:33:00
²Ä 2054 ½g¦^À³
|
¥xÁÞ¤j¡A¦P·N±zªº¨£¸Ñ
×¥¿¤@ ASLAN004 ªº¥¼¨Ó»ùÈ ¥i¯àÅܤƦp¤U:
1.·§©À©ÊÁ{§É¦¨¥\,MOA¾÷Âà½T¥ß. ¦¹®É°ê»Ú±ÂÅv³Ì·sªvÀø¤¤-««×AD ¼Ð¹v¦æ±¡ «eª÷7.5»õ¬ü¤¸. + ¨½µ{¸O资ª÷ 6»õ¬ü¤¸.+¾P°â¤À¼í?
(©ú¦~3-5¤ë«Å¥¬,aslan004 ·§©À©ÊÁ{§É´Á¤¤³ø§i,«e¤G¾¯¶q200mg/250~300mg??)
(Y¹³Xbiotech±ÂÅvbermekimab, ¥H¤W¦©°£CSL¤À1.25»õ¬ü¤¸¡]²Ä¤T´ÁÁ{§É3000¸U¬ü¤¸¡Ï¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷) ASLAN ±N¦³«eª÷ :²{ª÷¦¬¤J7.5-1.25=6.35»õ¬ü¤¸ ,¨È·à±d²bÈ°¨¤W¼W¥[6.35»õ¬ü¤¸¡C
2.Lebrikizumab2b´ÁÁ{§É¦¨¥\ : ¤µ¦~3¤ë,Dermira «Å§GLebrikizumab ¤G´ÁADÁ{§É¼Æ¾Ú¥¿¦V.ªÑ»ù¼W¥[3~4»õ¬ü¤¸. (¤£¥Î©MCSL¤À,aslan ¥i¯àªº¿W¦ë,¹wp2021¦~©³ aslan004§¹¦¨¤G´ÁÁ{§É)
3.¤T´ÁÁ{§É¦¨¥\ :???(¹wp2023¦~¤¤, aslan004§¹¦¨¤T´ÁÁ{§É)
4.FDA®Ö·ÇÃĵý:Dupilumab 2017¦~,ªÑ²¼ 3~7¤ë¥«È¼W¥[140»õ¬ü¤¸,·í®É¥«³õ»{¬°°ª峄¾P°â±N¹F50»õ¬ü¤¸. ¥Ø«e¤w¦ô°ª峄¾P°â110»õ¬ü¤¸. (CSLn¤À7.5%~10%¾P°â¤À¼í ,Y¦ô°ª峄¾P°â30»õ¬ü¤¸, ²b§Q30%, 9»õ¬ü¤¸, ¥ç§YCSL¤À±¼1/3 , aslan004 ¥«È¥i¹F 30»õ¬ü¤¸x2.8x2/3=56»õ¬ü¤¸)
(¹wp2024¦~¦~©³, aslan004 ¨úµý)
©Ò¥HÁo©úªº²H°¨¿ü ¤£·|»´©ö´©Åv¥Xaslan004 .
------------------------------- 2019/12/09 ,XbiotechÉO强¥Í(JNJ.US)ºX¤Uªº¸â´Ë¥Íª«§Þ术¤½¥q(JanssenBiotech)签¸p¤F¤@项协议¡A¦P·N¥X°â¨ä临§É§Üª¢·s药bermekimabªº¥þ²y°Ó业±Â权¡C ®ÚÕu该协议ªº条´Ú¡A强¥Í将获±obermekimabªº©Ò¦³权§Q¡FXbiotech将´£«e获±o7.5亿¬ü¤¸ªº预¥I´Ú¡A¦}将获±o¦Ü¦h6亿¬ü¤¸ªº潜¦b¨½µ{¸O资ª÷ . |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/20 ¤U¤È 01:59:09
²Ä 2053 ½g¦^À³
|
¤Ñ©R¤j
×q¦X¬ù±N¨ú¥NÂù¤èì¥ý©ó2014¦~5¤ëñq¤§¦X¬ù¡C¨È·à±dÂà¥XASLAN004±ÂÅv¦X¬ù¦b¤º©Ò¦³¦¬¤J¤£¥²¦Aµ¹CSL40%¦Ü50%
¨È·à±d-KY ¦V CSL ¨ú±o ASLAN004 ¥þ²y°Ó«~¤Æ©Ò¦³Åv - CSL »P¨È·à±d-KY ×qì±ÂÅv¦X¬ù¡ACSL ±N±Â¤©¨È·à±d-KY ASLAN004 ¥þ²y¶}µo¡B»s³y»P°Ó«~¤ÆÅv§Q
2019 ¦~ 5 ¤ë 31 ¤é¡A·s¥[©Y ¡V »EµJ©óÁ{§É¶¥¬q¸~½F¤Î§K¬Ì¾Ç¤§Á{§É¶¥¬q¥Íª«»sÃĤ½¥q¨È·à±d-KY (NASDAQ:ASLN, TPEx:6497)¤µ¤é«Å¥¬»P CSL (CSL Limited)×q±ÂÅv¦X¬ù¡A¨ú±o ASLAN004 ©ó©Ò¦³¾AÀ³¯g¤§¥þ²y¶} µo¡B»s³y»P°Ó«~¤ÆÅv§Q¡A×q¦X¬ù±N¨ú¥NÂù¤èì¥ý©ó 2014 ¦~ 5 ¤ëñq¤§¦X¬ù¡C
×q¦X¬ù; ®Ú¾Ú×q¦X¬ù±ø´Ú¡A¨È·à±d-KY ±N©ó ASLAN004 ¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥I CSL ºµ§´Ú¶µ 3,000 ¸U¬üª÷¡CCSL ±N¥i¦¬ ¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì ¼Æ¦Ü 10%¤§Åv§Qª÷
ì¦X¬ù: ®Ú¾Úì¦X¬ù¤º®e¡A¨È·à±d-KY À³ºÉ¬ãµo ASLAN004 ¦Ü·§©À©ÊÅçÃÒ(proof-of-concept)§¹¦¨¤§ ¸q°È¨Ã´M§ä°õ¦æ¤T´ÁÁ{§É¸ÕÅç¤Î°Ó«~¤Æ¤§¦X§@¹Ù¦ñ¡CCSL ±N¥i¦¬¨ú¥]¬AÂà¥X±ÂÅv¦X¬ù¦b¤º©Ò¦³ ASLAN004 ¦¬¤J ¤§ 40%¦Ü 50%
Ó¤H¸ÑŪ: ¬JµM×q¦X¬ù¨ú¥NÂù¤èì¥ý©ó2014¦~5 ¤ëñq¤§¦X¬ù, ¤]´N¬OCSL ±N¤£·|¦¬¨ú¥]¬AÂà¥X±ÂÅv¦X¬ù¦b¤º©Ò¦³ ASLAN004 ¦¬¤J¤§ 40%¦Ü 50%(¨È·à±dÂà¥XASLAN004 ±ÂÅv¦X¬ù¦b¤º©Ò¦³¦¬¤J¤£¥²¦Aµ¹CSL 40%¦Ü 50% )
³oÂI½Ð¸¤H¤j ¤Ñ©R¤j¦A¦V¤½¥q½T»{¤@¤U?
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/20 ¤U¤È 01:41:12
²Ä 2052 ½g¦^À³
|
ASLAN004 ªº¥¼¨Ó»ùÈ ¥i¯àÅܤƦp¤U:
1.·§©À©ÊÁ{§É¦¨¥\,MOA¾÷Âà½T¥ß. ¦¹®É°ê»Ú±ÂÅv³Ì·sªvÀø¤¤-««×AD ¼Ð¹v¦æ±¡ «eª÷7.5»õ¬ü¤¸. + ¨½µ{¸O资ª÷ 6»õ¬ü¤¸.+¾P°â¤À¼í?
(©ú¦~3-5¤ë«Å¥¬,aslan004 ·§©À©ÊÁ{§É´Á¤¤³ø§i,«e¤G¾¯¶q200mg/250~300mg??)
(Y¹³Xbiotech±ÂÅvbermekimab, ¥H¤W¦©°£CSL¤À¤@¥b, ASLAN ±N¦³«eª÷ :²{ª÷¦¬¤J7.5/2=3.75»õ¬ü¤¸ ,©Ò¥H¬ü°ê¤ÀªR®v¦ôASLAN ADR 8¬ü¤¸,¥¼¨Ó¤@¦~¥Ø¼Ð»ù,¤£¬O¶Ã¦ôªº.)
2.Lebrikizumab2b´ÁÁ{§É¦¨¥\ : ¤µ¦~3¤ë,Dermira «Å§GLebrikizumab ¤G´ÁADÁ{§É¼Æ¾Ú¥¿¦V.ªÑ»ù¼W¥[3~4»õ¬ü¤¸. (¤£¥Î©MCSL¤À,aslan ¥i¯àªº¿W¦ë,¹wp2021¦~©³ aslan004§¹¦¨¤G´ÁÁ{§É)
3.¤T´ÁÁ{§É¦¨¥\ :???(¹wp2023¦~¤¤, aslan004§¹¦¨¤T´ÁÁ{§É)
4.FDA®Ö·ÇÃĵý:Dupilumab 2017¦~,ªÑ²¼ 3~7¤ë¥«È¼W¥[140»õ¬ü¤¸,·í®É¥«³õ»{¬°°ª峄¾P°â±N¹F50»õ¬ü¤¸. ¥Ø«e¤w¦ô°ª峄¾P°â110»õ¬ü¤¸. (¥H¤WCSLn¤À¤@¥b ,Y¦ô°ª峄¾P°â30»õ¬ü¤¸, aslan¤À 30/2*2.8=42»õ¬ü¤¸) (¹wp2024¦~¦~©³, aslan004 ¨úµý)
------------------------------- 2019/12/09 ,XbiotechÉO强¥Í(JNJ.US)ºX¤Uªº¸â´Ë¥Íª«§Þ术¤½¥q(JanssenBiotech)签¸p¤F¤@项协议¡A¦P·N¥X°â¨ä临§É§Üª¢·s药bermekimabªº¥þ²y°Ó业±Â权¡C ®ÚÕu该协议ªº条´Ú¡A强¥Í将获±obermekimabªº©Ò¦³权§Q¡FXbiotech将´£«e获±o7.5亿¬ü¤¸ªº预¥I´Ú¡A¦}将获±o¦Ü¦h6亿¬ü¤¸ªº潜¦b¨½µ{¸O资ª÷ .
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/20 ¤W¤È 10:54:25
²Ä 2051 ½g¦^À³
|
¨È·à¤jªÑªF¦³¦h±j¤j!!!!
1.Àq§J¤½¥q¡]^»y¡GMerck & Co., Inc.¡^[
ªÑ²¼2019/Dec./19, ¥«È¬üª÷2281»õ¬üª÷, Market Cap $228.17B
2.·s¥[©Y²H°¨¿ü: ¥þ²y§ë¸ê³¡¦ì 6¥ü¥x¹ô(¬ù2000»õ¬üª÷)
¤£¥Î¾á¤ß¨È·à±dªº°]°È!
nª`·Nªº¬O: Aslan004 ¦³µLÄvª§¤O! Aslan001 ¦³µLÄvª§¤O! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/20 ¤W¤È 10:47:43
²Ä 2050 ½g¦^À³
|
1.Àq§J¤½¥q¡]^»y¡GMerck & Co., Inc.¡^[
ªÑ²¼2019/Dec./19, ¥«È¬üª÷2281»õ¬üª÷, Market Cap $228.17B
2.·s¥[§£²H°¨¿ü: ¥þ²y§ë¸ê³¡¦ì 6¥ü¥x¹ô(¬ù2000¬üª÷)
1+2 ¨È·à¤jªÑªF¦³¦h±j¤j!!!!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/20 ¤W¤È 09:02:33
²Ä 2049 ½g¦^À³
|
Àq§J¤½¥q¡]^»y¡GMerck & Co., Inc.¡^[
ªÑ²¼2019/Dec./19, ¥«È¬üª÷2281»õ¬üª÷, Market Cap $228.17B
www.marketwatch.com/investing/stock/mrk
¨È·à±dªº´I¸³¨Æ/¤jªÑªF
Àq¨FªF¡]^»y¡GMerck Sharp & Dohme¡AMSD¡^¡A¦b¬ü°ê©M¥[®³¤jºÙ¬°Àq§J¤½¥q¡]^»y¡GMerck & Co., Inc.¡^[3]¡A¬O¤@®a¬ü°êªº»sÃÄ¥ø·~¡A¦P®É¤]¬O¥@¬É¤W³Ì¤jªº»sÃÄ¥ø·~¤§¤@¡CÀq§J¤½¥qÁ`³¡¦ì©ó¬ü°ê·s¿A¦è¦{³Í¥§º¸¨U«ä¡C[4] Àq§J¤½¥q§@¬°¼w°êÀq§J¶°¹Î¡]1668¦~³Ð«Ø¡^ªº¤l¤½¥q«Ø¥ß©ó1891¦~¡C²Ä¤@¦¸¥@¬É¤j¾Ô´Á¶¡¡AÀq§J¤½¥q³Q¬ü°ê¬F©²¦¬ÁÊ¡A¨Ã¥B«á¨Ó¿W¥ß¬°¬ü°ê¤½¥q¡C 2009¦~¡AÀq¨FªF©M¥ýÆF¸¶¶®¦X¨Ö¡C[5]¥H¥«È¤Î¦¬¤Jp¡AÀq¨FªF¬O¥@¬É²Ä¤C¤j»sÃÄ¥ø·~¡C
Àq¨FªF¡]Àq§J¤½¥q¡^¥þ²y¦@¦³û¤u¬ù83,000¤H¡]ºI¦Ü2012¦~12¤ë31¤é¡^¡C
zh.wikipedia.org/wiki/%E9%BB%98%E5%85%8B%E8%97%A5%E5%BB%A0
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/20 ¤W¤È 06:32:37
²Ä 2048 ½g¦^À³
|
°l¤j¡A
¦^¨ì2010¦~¡A§Ú̩ꪺ¦íRegen吗¡H §Ṳ́̾°»ò±M·~¡H
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K Regeneron Pharmaceuticals Inc. ¥t¤@Ó¤jÃÄEYLEA® (aflibercept) , 2011/11¤ë,¤@ÓªvÀø²´·ú¶À´³³¡¯fÅÜ,¤W¥«, 2019¦~/¤µ¦~¥i½æ70»õ¬ü¤¸.
±q2011¦~26¬ü¤¸,¤jº¦4¦~¨ì,2015¦~, ªÑ»ù526¬ü¤¸.
¥Ø«e¥«È410»õ¬ü¤¸,¤µ¦~À禬ªñ100»õ¬ü.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G°l·10148822 |
µoªí®É¶¡:2019/12/19 ¤U¤È 11:02:19
²Ä 2047 ½g¦^À³
|
¤Ñ©R¤j¡Aµy¦ªººÃ°Ý·PÁ¦^ÂÐ
¦Ñ¹ê»¡¡A²H°¨¸òÀq§JªºÁy±§ÚÁÙ¯uı±o¤w¸g³Q¥´ªº¤£ª¾¸~¨ìþ¨à¥h¤F🤣🤣🤣 ¤£»¡¥xÆWªº¦h¼Æ§ë¸ê¤H¤£¬Ý¦n¨È·à±d«e´º¡A´N³s§Úèè¥h¬Ý¤F¤Ö¼Æ°ê¥~ºô¤Íªº¹ï¸Ü ¤]¬O»Ä·È·Èªº,·íµM¤]±a¦³ºØ±Úª[µøªº¨ý¹D~ ¬Æ¦ÜÁÙ¦³¤HÁ¿¬ü°ê¨ºÃä¥Í§Þ¦³¨Ç¤½¥q«á¨Ó¨è·NÂ\Äê¡AµM«á¤U¥«¦b«·s¤W¥«...²³æ»¡´N¬O°ÛÁö°Õ~ ²¦³º±q±¾µP¨ì²{¦b³£¨S¦³¦¨ÁZ¥i¨¥¡I ¦ý¬O§Ú·Q²H°¨¿ü¤JªÑ¤£·|³æ¯Â¦]¬°¬O°ê®a¦Û¤vªº¤½¥q¡A¯Âºé°µ±¤l³o»ò²³æ¦Ó¤w¡I ¤@©wÁÙ¦³³\¦h§ÚÌ©Ò¤£ª¾ªºì¦]¥H¤Î¬Ýªk¸ò¨¤«×¡I ´Nµ¥µÛ¨È·à±d¥¼¨Ó½¨¡A¦b¦n¦n¥h¥´Áy¤£ºÞ¬O°ê¤ºÁÙ¬O°ê¥~ªº»Ä¥Á¤F~ ¥t¥~¤]³vº¥¦³¤£¤Ö°ê¥~¤ÀªR®v¥H¤Î¾÷ºc¶}©l¬Ý¦n¨È·à±dªº¥¼¨Ó¤F¡I §Ṳ́£¥Î¹L«×´dÆ[¡A¦ý¤]§O¤Ó¼ÖÆ[¥h¬Ý«ÝÅo¡I ¥t¥~¤Ñ©R¤j¤j±z´£ªº³oÓ Regeneron Pharmaceuticals Inc. ¥t¤@Ó¤jÃÄEYLEA® (aflibercept) , 2011/11¤ë,¤@ÓªvÀø²´·ú¶À´³³¡¯fÅÜ,¤W¥«, 2019¦~/¤µ¦~¥i½æ70»õ¬ü¤¸.
±q2011¦~26¬ü¤¸,¤jº¦4¦~¨ì,2015¦~, ªÑ»ù526¬ü¤¸.
¥Ø«e¥«È410»õ¬ü¤¸,¤µ¦~À禬ªñ100»õ¬ü. ³o¤½¥q½T¹ê«Ü¼F®`¡A¤£¹L¥L¬O¤@±øÀsªº¤½¥q ±qµo²{,µo©ú,¬ãµo,¥Í²£,³c°âµ¥µ¥³£¤w¸g¥i¥H¦Ûµ¹¦Û¨¬¤F °£¤F¤£¥Î¦A¨ì¥«³õ¶Ò¸ê¥~¡AÁٯ൹ªÑªF¤À¬õ ³o¤½¥q³W¼Ò¦b¬ü°êÁÙ¬O¤¤«¬¤½¥q¦Ó¤w¡AªÑ»ù¤w¸g370¦h¤F ¨È·à±d¯uªº¬O¤p«¬¤½¥q¡A¤£¸Ø±iªº»¡¡A¦pªG¬üªÑ¯àº¦¨ì100¤¸ §ÚÁÙ¯uªº°µ¹Ú¤]·|¯º©O🙈 ¥Lªº002ÁöµM¦³ÂàÅýµ¹¤H¤F¡A¦ý¤]n¹ï¤è¯uªº¦³«ùÄò¬ãµo¥H¤Î«áÄò³c°â¤~·|¦³¿ú¶i¨Ó¡I ¦pªG¨S¦³ªº¸Ü¡A¨È·à±dÁÙ¬O¥u¯à°®Àü²´¦Ó¤w... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/19 ¤U¤È 10:30:21
²Ä 2046 ½g¦^À³
|
¤Ñ©R¤j Ó¤H»{¬°¨È·à±dªº¯S¦â±Mªø ÃĪ«¶}µo ¨ÖÁÊ»P±ÂÅv·¾³q½Í§P Àu¨qªº^»y¯à¤O ¸gÀçºÞ²z¹Î¶¤±Mªø¯S§O¬OCEO±Mªø ¤jªÑªFµ²ºc
°ê¥~¤p«¬¥Í§Þ¤½¥q±`±`¦]¬°¤@ÓÃĪº¶}µo¼ç¤O¦Ó³Q°ª»ù¨ÖÁÊ, ¨È·à±d¤£±Æ°£³oÓ¥i¯à,«e´£¬O¶}µoªº²£«~½u¨ã¦³±j¤jÄvª§¤O
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/19 ¤U¤È 09:49:01
²Ä 2045 ½g¦^À³
|
¥xÁÞ¤j¡A
Aslan004 ¦Ü¤Ö¬ü°ê区¤£·|±ÂÅv¡C ²H°¨锡+Àq§JÃļt n°µÓ¤d¤H¤T´Á¡A没¿ú°µ¡C ·|³Q¯º¦º¡C
°ß¤@¥i¯à40-50»õ¬ü¤¸¡A³Q¨ÖÁÊ¡C
¤~¦³¥i¯à¡C·s¥[©Y¤]¤£¥Î¦Aµo®i¥Íp²£·~¡C
Àq§JµLAD¼Ð¹v¡A¦¬Áʳ̨Υi¯à¡C ¥H¤WÓ¤H¬Ýªk¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/19 ¤U¤È 06:14:02
²Ä 2044 ½g¦^À³
|
¥xÁÞ¤j,
www.marketwatch.com/investing/stock/derm
Dermira Inc. ¥Ø«e4»õ¬üª÷¸ê¥»ÃB, ´N±qROCHE ,2017,08,08 ¶R¤ULebrikizum¡A ¨Ó°µAD.
¤µ¦~3 ¤ë°µ§¹¤G´ÁÁ{§É ,ªÑ»ùº¦3-4»õ¬ü¤¸.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/19 ¤U¤È 05:57:40
²Ä 2043 ½g¦^À³
|
¹ï¤p«¬¥Í§Þ¤½¥q¦Ó¨¥ ¨È·à±dASLAN003 »P ASLAN004 ¤£·|¦Û¤v°µ phase3
XBiotech ¦b2´ÁÁ{§É¤U¥b¶¥¬q ( ÁÙ¨S¯u¥¿§¹¦¨¤G´Á ) ´N±N Bermekimab ¥H7.5»õ¬ü¤¸²{ª÷( À³¸Ó¬Oupfront payment)¡A¦A¥[¤W6»õ¬ü¤¸¨½µ{ª÷¡A¦Xp°ª¹F13.5»õ¬ü¤¸Á`±ÂÅvµ¹¼b¥ÍºX¤U¤l¤½¥qJanssen¡AÀ³¸ÓÁÙ·|¦³¾P°âÅv§Qª÷Royalty , ±µ¤U¨ÓÁÙ¨S§¹¦¨ªº¤G´ÁÁ{§É¥ÑJanssen ¥X¿ú°µ§¹Á{§É
Ó¤H²q´ú¨È·à±dÀ³·|¿í´` XBiotech ³oÓ¼Ò¦¡ ¬ãµo¨ì¤G´Á´N±N³oÁû±ÂÅv¥X¥h, Åý³oÁû¦³Ävª§¤OªºÃĪ«¨Ï¤½¥q²æL´«°©,§Öªº¸Ü§¹¦¨proof of concept´N¦³¥i¯à±ÂÅv, ²z¥Ñ¦p¤U: A ¨È·à±d»Ýn§ïµ½Åé½èÅý¤½¥q²æL´«°© ¦³¦nªº±ÂÅv±ø¥ón«O´¤
B ¨Ì¾Ú°ê»Ú±ÂÅv½Í§PªºÁͶզnªF¦è¤j®a·mµÛn ¶V«á´Á±ÂÅv»ù½X¶V§C
C 2018¦~·sÃıÂÅv®×±ÂÅvª÷ÃB¶W¹L¤Q»õ¬ü¤¸¦@32¥ó, ¨ä¤¤«e20¦W¤¤¦³¦Ê¤À¤§¤»¤Q¤¦bÁ{§É«e±ÂÅv , ¦Ê¤À¤§¤Q¤¦b¤G´Á±ÂÅv, ¤]´N¬O»¡¦Ê¤À¤§80ªº·sÃıÂÅvµo¥Í¦bPhase2¤§«e,¤j¤jÄAÂФj®aªº»{ª¾, ²Ä¤G¤Q¦WÁ`±ÂÅvª÷12.5»õ¬ü¤¸°_¸õ, «e¤T¦WÁ`±ÂÅvª÷¤¶©ó 35»õ¬ü¤¸-49.5 »õ¬ü¤¸ ¤§¶¡
D Âê¦n¤£n»´©ö³Q¬~±¼¥H§K«á®¬²ö¤Î,¦³¹Ú³Ì¬ü¿v¹Ú½ñ¹ê, ¬ü¹Ún¦b¦³¼Æ¾Ú¤½§i«á¤~¯à¿v¹Ú½ñ¹ê ¤@¨B¤@¸}¦L
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/19 ¤U¤È 04:11:13
²Ä 2042 ½g¦^À³
|
°l¤j,
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/12/18 ¤U¤È 12:53:08²Ä 2022 ½g¦^À³ ªø§ëªº´A¤O
Regeneron Pharmaceuticals Inc. ,Dupilumab 2017.03~07 ¤W¥«,¤½¥q¥«È¤jº¦140»õ ·í®É¥«³õ¦ô°ª峄¾P°â50»õ¬ü¤¸
Regeneron Pharmaceuticals Inc. ¥t¤@Ó¤jÃÄEYLEA® (aflibercept) , 2011/11¤ë,¤@ÓªvÀø²´·ú¶À´³³¡¯fÅÜ,¤W¥«, 2019¦~/¤µ¦~¥i½æ70»õ¬ü¤¸.
±q2011¦~26¬ü¤¸,¤jº¦4¦~¨ì,2015¦~, ªÑ»ù526¬ü¤¸.
¥Ø«e¥«È410»õ¬ü¤¸,¤µ¦~À禬ªñ100»õ¬ü.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G°l·10148822 |
µoªí®É¶¡:2019/12/19 ¤U¤È 03:54:30
²Ä 2041 ½g¦^À³
|
èè¬Ý¤F004¥DnÄvª§¹ï¤âªºªÑ»ùµo²{XBiotech lnc¸òRegeneronªºªÑ»ù¥i¥H»¡¬O¤Ñ®t¦a»·ªü¡I ¤@Ó²{¦bªÑ»ù¬O19.89¬ü¤¸¥t¤@Ӫѻù¬O371.36¬ü¤¸ «ç»ò¤GӪѻù®t¨º»ò¦h¡H ³£±µªñ¤G¤Q¿¤F... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G°l·10148822 |
µoªí®É¶¡:2019/12/19 ¤U¤È 03:36:38
²Ä 2040 ½g¦^À³
|
¶ZÂ÷·sÃÄ®Öã¥|¦~¥b¨ì¤¦~ ¤j¬ù¬O2024¦~ªº6-12¤ë ·Q½Ð°Ý²{¦b«ù¦³ªº¤H¡A·Q©êªø´Á¨Ó»¡¡I §AÌ·|«ùÄò©ê¨ì¨º®É¶Ü¡H ²{¦b©h¥B¤£½×³Ì«á¦¨ªG¦nÃa¨Ó»¡... ¦n·íµM¨ì®ÉªÑ»ù¤w¸g¤£ª¾º¦¨ìþÃä¥h¤F¡I ¤£¦n¤]¥i¯à´£«eª¾¹D¡A¦Ó¥BªÑ»ù«®À¡A¤]¤£·|¨ì¨ºÃä¤F~
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/19 ¤U¤È 02:41:02
²Ä 2039 ½g¦^À³
|
¨È·àAslan004 ¨Ì dupilumab ¸ô®|, Â÷·sÃÄ®Ö凖ªº¸ô¡A¬ù4¥b¡ã5¦~¡C Â÷¤T´ÁÁ{§É¦¨¥\¤T¦~¥b¡C
¡X¡X¡X¡X¡X ¤µ¦~10¤ë¶}©l°µ¤¤¤@««×AD¤T´ÁÁ{§Éªº𠃊ebrikizum¡Aµ²¦XIL13°tÅé¡A ¦P¼ËªýÂ_IL-4R£\ »P IL-13R£\1¤§¶¡°T®§¶Ç¾É¡C
Lebrikizum¡A2Ó¤T´ÁÁ{§É¤H¼Æ800¤H¡A ¤j¬ù¥u¦³Dupliumab(1500¤H), 800/1500=54% ¡C
Lebrikizum ¤W¶gDec./10¤w¨ú±oFDA§Ö³t¼f¬d¸ê®æ¡CFast Track Designation
Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis December 10, 2019 08:30 AM Eastern Standard Time
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- Development History and FDA Approval Process for Dupixent Date Article
Mar 28, 2017 Approval FDA Approves Dupixent (dupilumab) for Eczema¡]Moderate-to-Severe Atopic Dermatitis)¡C FDA®Öã¤W¥«
Mar 4, 2017 Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent (dupilumab) in Moderate-to-Severe Atopic Dermatitis ¥Ñ¤GÓ¤T´Á¤¤¡A¦X¨Ö¥¼§¹¥þ¤ÏÀ³¦Ó¯d¤UªvÀø¡ÏTCS , ¤@¦~Á{§É¸ÕÅç¡A«Å¥¬¥¿¦V¼Æ¾Ú¡C
Sep 26, 2016 Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA FDAµ¹¤©Àu¥ý¼f¬d¡C
Jun 6, 2016 Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients.
¥Ñ¤GÓ¤T´Á¤¤¡A¦X¨Ö¥¼§¹¥þ¤ÏÀ³¦Ó¯d¤UªvÀø¡ÏTCS , ¤@¦~Á{§É¸ÕÅç¡A¶}©l¡C
Apr 1, 2016 Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Two Phase 3 Trials in Inadequately Controlled Moderate-To-Severe Atopic Dermatitis Patients ¤½¥¬¤GÓ¤T´ÁÁ{§É¡Aµ²ªG¥¿¦V¼Æ¾Ú¡C
Nov 20, 2014 Sanofi And Regeneron Announce That Dupilumab Has Received FDA Breakthrough Therapy Designation In Atopic Dermatitis ¨ú±oFDA¡Aªº¬ð¯}©ÊÀøªk¡ABTD
Oct 20, 2014 Sanofi And Regeneron Announce Start Of Phase 3 Study Of Dupilumab in Patients With Atopic Dermatitis ¤T´ÁÁ{§É¶}©l
Jul 9, 2014 Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab for Atopic Dermatitis «Å¥¬¤G´ÁÁ{§Éµ²ªG¡A¼Æ¾Ú¥¿¦V¡C
Mar 4, 2013 Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis «Å¥¬·§©À©ÊÁ{§É¡A¼Æ¾Ú¥¿¦V¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/19 ¤U¤È 01:38:25
²Ä 2038 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/12/19 ¤W¤È 11:38:28
²Ä 2037 ½g¦^À³
|
To ¥xÁÞ¤j,
¸É¥R»¡©ú¡AÀ³¸Ó¬O»¡¨È·à±d¬O¦b¶}°Ò¸s®q¨ºÃäµù¥Uªº¡AµM«áÁ`³¡³]¦b·s¥[©Y¡A²{¦bÀ³¸Ó¬O§â²{ª÷¶×¨ì·s¥[©YÁ`³¡¡AÅý·s¥[©YÁ`³¡¨ºÃä¥i¥H¹B¥Î¡A±À°ÊÁ{§É¸ÕÅç¡B¸gÀç¶O¥Îµ¥µ¥¡A¤½§i¥u¬On»¡©ú¦³³o¥ó¨Æ±¡µo¥Í¡A¥i¯à¥b¦~©Î¬O¤@©u³£·|¶i¦æ¤@¦¸³o¼Ëªº¤½§i¡A©Ò¥H¨ä¹ê¤£«n¡C
Thanks, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/12/19 ¤W¤È 11:32:21
²Ä 2036 ½g¦^À³
|
To ¥xÁÞ¤j¡A
¹ï²bÈ´£¤É¨S¦³¥Î»¡¡A¥u¬O³æ¯Â§â¿ú¼·¨ì¤l¤½¥q¥h¦Ó¤w¡A³o¦U¥H«e¤]µo¹L¦n´X¦¸¤½§i¡A¥u¬O¥À¤½¥q¸ò¤l¤½¥q³æ¯Âªº°]°È¥æ¬y¦Ó¥H¡A²bÈpºâÁÙ¬On¬Ý¤½¥q±b¤Wªº²{ª÷¡B¦³§Î¸ê²£¡BµL§Î¸ê²£¦©±¼t¶Å¡A¦A¥h°£µo¦æªºÁ`ªÑ¼Æ¡A¤~¯àpºâ¥X¨Ó¡A¤½¥q¥Ø«eÀ³¸Ó¤]ÁÙ¦bpºâ²bÈ¡A§Ú·Q12¤ëÀ³¸Ó¨S¦³¨ä¥L¦¬¤J¤F§a¡A§Ú¥u¯à»¡²bÈÀ³¸Ó·|¸¨¦b 5+-10%¡A¦³¾÷·|²æÂ÷¥þÃB¥æ³ÎªÑ¡A¤£¹Lªk»¡·|¤W´£¨ì¡A²bÈn¤j´T´£¤É¥i¯ànµ¥¤U¤@¦¸ªº¼W¸ê¤F¡A§Ú·Q¦pªG©ú¦~´Á¤¤¼Æ¾Ú¤£¿ù¡AÀ³¸Ó´N°¨¤W¦A¶i¦æ¤U¤@¦¸ªº¼W¸ê¡C
Thanks, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/19 ¤W¤È 11:19:00
²Ä 2035 ½g¦^À³
|
·sÃĶ}µoªº¦¨¥\ : ¦b©ó¥«³õ¬°¾P°â¦¨¥\¬°³Ì«áµûÂ_.EPS ³Ì¯à¥Nªí.
Ävª§¤O!Ävª§¤O!Ävª§¤O!
¤@.ÃÄ®Ä:Aslan004 ±NÀu©óDupilumab/Lebrikizumab/. Tralokinumab
¾Ç³N³ø§i¼Ð¹vµ²¦XIL13 Àu©ó µ²¦XIL4 ,ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡°T®§¶Ç¾É. ....onlinelibrary.wiley.com/doi/pdf/10.1111/all.13954 -------Overall, this growing body of evidence suggests that AD is an IL-13-, rather than IL-4-, driven disease... CONCLUSION There is currently strong evidence that in AD, IL-13 is significantly more expressed than IL-4 in lesional skin and is therefore one of the key drivers in this condition. IL-13 has a large impact on the epidermal barrier function and the local immune response............] 1.Á{§É¸ê®Æ¤ñ¸û: 1.1 1bÁ{§ÉEASI°§C50%¥H¤W±wªÌªº¤ñ²v¤§PK
SLAN004 100% VS. Dupilumab 71.4%
a.ASLAN004 200mg ,3¦ì¡A100%EASI°§C50%¥H¤W¡C (§¹¦¨4-5¶g)¡A3¦ìEASI¤À§O°§C¤§¤ñ¨¯85%/70%/59%
b.DupilumabÅTÀ³ªÌ¤ÀªRÅã¥Ü¡A¦b²Ä4¶g¡A±µ¨ü150mg¾¯¶qªvÀøªº±wªÌ¤¤¦³54.5¢Hªº±wªÌ©M±µ¨ü300mg¾¯¶qªvÀøªº±wªÌ¤¤¦³71.4¢HªºEASI±o¤À°§C¤F50¢H©Î§ó°ª¡A¦Ó¦w¼¢¾¯¬°18.8¢H¡]p<0.05¡^
1.2 ·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/12/18 ¤U¤È 09:27:30²Ä 2027 ½g¦^À³ Bermekimab »P ASLAN004 ¦bÀã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI)µû¤À ªì¨B PK
Bermekimab Àã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI)µû¤À % Change from Baseline ( phase 2 ) Group 200mg N=10 ²Ä4©P¬ù¤U°¦Ê¤À¤§20 Group 400mg N=28 ²Ä7©P¬ù¤U°¦Ê¤À¤§75
ASLAN004 EASI Àã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI)µû¤À % Change from Baseline ( phase1 ) 200mg N= 6
¤w¤½§i¨ä¤¤¤T¦W¯f±wªºÀã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI)µû¤À¤À§O¤U° 85%¡B70%¤Î 59% , ¥§¡¤U°71% EASI µû¤À¦b²Ä¥|¶g«ùÄò¤U°¡A¹w´Á¦b 6 ¦Ü 8 ¶g¹F¨ì³Ì¤jÀø®Ä,¤£ª¾¹D¦b 6 ¦Ü 8 ¶g·|¤£·|¶W¶V Bermekimab ? ¥uª¾¹D ASLAN004 ¨Ï¥Î³Ì§C¾¯¶q »PBermekimab ¨Ï¥Î³Ì°ª¾¯¶q ¦bÀã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI)µû¤À¤U°´T«×«Ü±µªñ
XBiotech ±N Bermekimab ¥H7.5»õ¬ü¤¸²{ª÷( À³¸Ó¬Oupfront payment)¡A¦A¥[¤W6»õ¬ü¤¸¨½µ{ª÷¡A¦Xp°ª¹F13.5»õ¬ü¤¸Á`±ÂÅvµ¹¼b¥ÍºX¤U¤l¤½¥qJanssen¡AÀ³¸ÓÁÙ·|¦³¾P°âÅv§Qª÷Royalty (¨È·à±dÀ³¦n¦n¬ãµo³oÁû¦³Ävª§¤OªºÃĪ«Åý¤½¥q²æL´«°©)
¤G.¥ÎÃĦ¨¥».
Dupilumab ¤G¶g¥´¤@°w,¨C¤ë¥ÎÃÄ3000¬ü¤¸,16¶g¼Ð·ÇªvÀø (¥¼¨Ó¾P°â°ª®p110»õ¬ü¤¸.)
Aslan004 ©MDupilumab¤@¼ËªýÂ_³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¤§¸ô®| : ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡°T®§¶Ç¾É¡CªýÂ_²Ä¤G«¬¨üÅéµ²¦X¡C
¹w©w¥|¶g¥´¤@°w,¥ÎÃĦ¨¥»´î¥b¾÷·|.
¬ü°ê¬F©²¤Î¨p¤H«OÀI,«K©yªºÃÄ¥ý¥Î¤Ñµ¦¤U, ³o¦æ¾P¦¨¥\®e©ö«×¤j¼W.
¤T.°Æ§@¥Î Aslan004 °Æ§@¥Î:µLDupilumab ²´·úµ²½¤ª¢...(¦]¬°Dupilumab ªýÂ_IL-4R£\ »PyCµ²¦X,ªýÂ_²Ä¤@«¬¨üÅéµ²¦X)¡C
(4)35% Dupilumab ±wªÌ¹F³Ì¨Î¤ÏÀ³. 40% Dupilumab ±wªÌ¤@¦~¤º¤¤Â_¨Ï¥Î(discontinued)
---------
¾÷Âà MOAªº¤ñ¸û,«D±`«n.
¤U¦C¥|ºØ¼Ð¹vÃĪ«¡A¦P¼ËªýÂ_³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¤§¸ô®| : ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡°T®§¶Ç¾É¡CªýÂ_²Ä¤G«¬¨üÅéµ²¦X¡C
1.Dupilumab¾÷ÂàMOA: ¤w¤W¥«2¦~¥b
Dupilumab ¬O«²Õªº IgG4 §ÜÅé¡A¦]¬°»P IL-4R£\ µ²¦X¡A©Ò¥H¯à¦P®ÉªýÂ_ IL-4 ¤Î IL-13 »P²Ä¤@«¬¤Î²Ä¤G«¬¨üÅ骺µ²¦X¡C
ªýÂ_IL-4R£\ »P yC ¤§¶¡°T®§¶Ç¾É¡CªýÂ_²Ä¤@«¬¨üÅéµ²¦X¡C¡]¥i¯à²£¥Í²´·ú结¼Òª¢°Æ§@¥Î¤§ì¦]¡^ ªýÂ_IL-4R£\ »P IL-13R£\1¤§¶¡°T®§¶Ç¾É¡CªýÂ_²Ä¤G«¬¨üÅéµ²¦X¡C
2.Lebrikizumab¾÷ÂàMOA:¡]¤µ¦~10¤ë¶}©l¤T´ÁÁ{§É¡^ Lebrikizumab ¬O«²Õªº IgG4 §ÜÅé¡AÂÇ¥Ñ »P IL-13 °tÅé¤Wªº B¡BC Á³±Û¤Wªº§Üìªí¦ìµ²¦X ¡A ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡ªº°T®§¶Ç¾É¡C
3. Tralokinumab ¾÷ÂàMOA: ¡]¤T´Á¸Ñª¼¤W¶g¹LÃö¡^ Tralokinumab¬O«²Õªº IgG4 §ÜÅé¡AÂÇ¥Ñ »P IL-13 °tÅé¤Wªº A ¤Î D Á³±Ûªº§Üìªí¦ìµ²¦X ¡AªýÂ_ IL-13 °tÅé»P ¨üÅéIL-13R£\1 ¤Î IL-13R£\2 µ² ¦X¡C ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡°T®§¶Ç¾É
4.Aslan004 ¾÷ÂàMOA :
ÂÇ¥Ñ »P IL-13 ¨üÅéIL-13R£\1 µ² ¦X¡CªýÂ_²Ä¤G«¬¨üÅéµ²¦X¡C ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡°T®§¶Ç¾É
--------- s23.q4cdn.com/229915008/files/doc_presentations/2019/Dermira-IR-Pres-Sept-2019_FINAL_92219_web.pdf
Dermira 2019.09 ¤½¥q²¤¶¤¤,¦³¤T¤jADÃÄ(Dupilumab/Lebri/Tralokinumab)¸Ô²Óªº¤ñ¸û p.23 35% Dupilumab ±wªÌ¹F³Ì¨Î¤ÏÀ³. 40% Dupilumab ±wªÌ¤@¦~¤º¤¤Â_¨Ï¥Î(discontinued)
35% of patients treated with Only with dupilumab responseachieve an optimal respons ¡V In a real -world setting, 40% of patients dupliumab therapy discontinued within 1 y.
------------- °ê»Ú ¼Ð¹vªvÀø¤¤-««×²§¦ì©Ê¥Öª¢AD¤§±ÂÅv:
¤@.2016¦~,LEO Pharma©ó2016¦~±qªü´µ§Q±d¡]LSE¡GAZN¡^Àò±o¤F¥Ö½§¯e¯f¤¤ªºtralokinumabªºÅv§Q¡A¸Ó¥æ©ö¯A¤Î¦V^°ê-·ç¨å»sÃÄ¥¨ÀY¹w¥I1.15»õ¬ü¤¸¡A¥H¤Î°ª¹F10»õ¬ü¤¸ªº°Ó·~¬ÛÃö¨½µ{¸O©M²£«~¾P°âªº¯S³\Åv¨Ï¥Î¶O¤ñ¨Ò¤£¶W¹L¦Ê¤À¤§¤Q
LEO Pharma reveals positive top-line Phase III results for tralokinumab(¤T´ÁADÁ{§É¤w¸Ñª¼¦¨¥\,2019/12 ¤ë) ²Ä¤@ÓÂê©wIL13 °tÅé¤À§OªýÂ_»PIL13¨üÅé¨üÅé£\1¦¸³æ¦ì (¥çºÙ¬°IL-13R£\1) ¤ÎªýÂ_¨üÅé£\2¦¸³æ¦ì (¥çºÙ¬°IL-13R£\2) µ²¦X¡A ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
¤G.2017/08/08 (2019/10 ¤T´ÁÁ{§É¶}©l) Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv«eª÷8000¸U¬ü¤¸¡A2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. Áô§t28»õ¬ü¤¸³Ì°ª¾P°âÃB.
Âê©wIL13 °tÅ餧¼Ð¹v ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
¤G¤§¤@ , 2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q.
Out-License and Other Agreements Almirall Agreement
2019¦~6¤ë30¤é¬°1.10»õ¬ü¤¸¡A¨½µ{ª÷+¾P°â¨½µ{ª÷?+¾P°â¤À¼í? ¨ä¤¤¥]¬A¡G¡]i¡^3000¸U¬ü¤¸ªº«e´Á´ÁÅv¶O; ¡]ii¡^5,000¸U¬ü¤¸ªº´ÁÅv¦æÅv¶O¡F ¡]iii¡^3000¸U¬ü¤¸ªº¨½µ{¸O
¤T.2019/05/31 , CSL ±ÂÅv ASLAN004 µ¹ ¨È·à±d, «eª÷+¨½µ{ª÷ 1.25»õ¬üª÷ +§t³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷=7.8»õ¬üª÷+ ¥[¾P°â¤À¼í<= 10%.
Âê©wIL13-13R£\1 ¤§¼Ð¹v
¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
¥|.2019/12/09 ,XbiotechÉO强¥Í(JNJ.US)ºX¤Uªº¸â´Ë¥Íª«§Þ术¤½¥q(JanssenBiotech)签¸p¤F¤@项协议¡A¦P·N¥X°â¨ä临§É§Üª¢·s药bermekimabªº¥þ²y°Ó业±Â权¡C
®ÚÕu该协议ªº条´Ú¡A强¥Í将获±obermekimabªº©Ò¦³权§Q¡FXbiotech将´£«e获±o7.5亿¬ü¤¸ªº预¥I´Ú¡A¦}将获±o¦Ü¦h6亿¬ü¤¸ªº潜¦b¨½µ{¸O资ª÷¡CXbiotech还将³q过ÉO强¥Í签订ªº¥Í产¨Ñ应©M临§ÉªA务协议¡A¦b¥¼来两¦~创³y§ó¦h¦¬¤J¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/19 ¤W¤È 11:00:45
²Ä 2034 ½g¦^À³
|
¸¤H¤j ¥À¤½¥q§â¿ú¼·µ¹¤l¤½¥q ½Ö¬O¥À¤½¥q¡A½Ö¬O¤l¤½¥q¡H¦pªG¥xÆW¬O¤l¤½¥q ¹ï¥xÆW¨È·à±d6497²Ä¥|©u²bÈ ·|´£¤É¶Ü¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/19 ¤W¤È 09:50:42
²Ä 2033 ½g¦^À³
|
²H°¨¿ü¤½¶}¥«³õ¶R¶i¥iÁקK¤º½u¥æ©ö¤§·ÀI.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/19 ¤W¤È 09:32:52
²Ä 2032 ½g¦^À³
|
¸¤H¤j, ®Ú¾Ú¥h¦~¼W¸êADR, ²H°¨¿ü±q¤½¶}¥«³õ¶R1250¤dªÑ,¥§¡8.9¬ü¤¸, ¦¨¥æ¤é´Á¬ù¦b,2018,5¤ë©³. ©Ò°ï´ú.
¥»¦¸ADR¼W¸ê,¨È·à¤½§i, ¤½§i¥»¤½¥q©ó2019¦~12¤ë03¤é«Å¥¬§¹¦¨¬ü°ê¦s°U¾ÌÃÒq»ù¡C¥»¤½¥q«Å§i©Ó¾P¤½¶}µo¦æ¡@ 5,124,527³æ¦ì¬ü°ê¦s°U¾ÌÃÒ(¡§ADSs¡¨)¡A¥»¦¸µo¦æ¤§¬ü°ê¦s°U¾ÌÃÒq©w¤§¨C³æ¦ì¹ê»Ú µo¦æ»ù®æ¬üª÷2.5¤¸¡A¨C³æ¦ì¬ü°ê¦s°U¾ÌÃÒªí¹ü¥»¤½¥q´¶³qªÑ5ªÑ¡C
------ ¥»¤½¥q¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¤§µo¦æ±ø¥ó¦p¤U¡G (1) µo¦æ¤½¥q¡G¨È·à±dªÑ¥÷¦³¤½¥q (2) µo¦æºØÃþ¡G²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ (3) µo¦æÁ`ª÷ÃB¡G¬üª÷14,733,015¤¸ (4) µo¦æÁ`¼Æ¡G¹ê»Úµo¦æ³æ¦ì¼Æ¬°5,893,206³æ¦ì¡A¨C³æ¦ì¬ü°ê¦s°U¾ÌÃÒªí¹ü¥»¤½¥q ´¶³qªÑ5ªÑ¡AÁ`¹ê»Úµo¦æ´¶³qªÑªÑ¼Æ¬°29,466,030ªÑ¡C (5) ¨C³æ¦ìµo¦æ»ù®æ¡G¬üª÷2.5¤¸ (6) ¨CªÑ»ù®æ¡G§é¦X¬°·s»O¹ô¬ù15.24¤¸(«ö¬üª÷§I·s»O¹ô¶×²v=30.48)¡C (7) µo¦æ¤é´Á¡G108/12/06 (8) ¥æ©ö¦aÂI¡G¨º´µ¹F§JÃÒ¨é¥æ©ö©Ò (9) µo¦æ¦aÂI¡G¬ü°ê (10)¦s°U»È¦æ¡G¼¯®Ú¤j³q»È¦æ (11)q»ù¤é¡G108/12/03 (12)¥»¦¸²{ª÷¼W¸ê°ò·Ç¤é¡G¥»¦¸²{ª÷¼W¸êµo¦æ·sªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ©ó 108¦~12¤ë06¤é¦¬¨¬ªÑ´Ú¡A¨Ãq108¦~12¤ë06¤é¬°²{ª÷¼W¸ê°ò·Ç¤é¡C ------------
¨È·à±d-KY²{¼Wµo¦æ·sªÑ°Ñ»P¬ü°ê¦s°U¾ÌÃÒµo¦æ®×¡A¼W¸ê·sªÑ12/13°_¤WÂd¶R½æ (108/12/10 11:19:50)
¤½¶}¸ê°TÆ[´ú¯¸¤½§i
(6497)¨È·à±d-KY-¥»¤½¥q108¦~«×²{ª÷¼W¸êµo¦æ·sªÑ°Ñ»P¬ü°ê¦s°U¾ÌÃÒµo¦æ¤WÂd¤é´Á¤½§i
¤@¡B¥»¤½¥q¥H²{ª÷¼W¸êµo¦æ·sªÑ°Ñ»P¬ü°ê¦s°U¾ÌÃҮסA·~¸g¤¤¥¡»È¦æ¥~¶×§½¥Á°ê108¦~10¤ë07¤é¥x¥¡¥~¥î¦r²Ä1080035383¸¹¨ç¤Îª÷¿ÄºÊ·þºÞ²z©eû·|¥Á°ê108¦~11¤ë05¤éª÷ºÞÃÒµo¦r²Ä1080334435¸¹¨çº[¬ü°êÃÒ¨é¥æ©ö©eû·|¥Á°ê108¦~12¤ë3¤é®Öã¥Ó³ø¥Í®Ä¦b®×¡A¨Ã¦V°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß¬¢½Ð¦P·N¦Û¥Á°ê108¦~12¤ë13¤é(¬P´Á¤)¥¿¦¡¤WÂd¶R½æ¡C
¤G¡B¯÷±N¼W¸ê·sªÑ¤WÂd¦³Ãö¨Æ¶µ¤½§i©ó«á¡G (¤@)ì¤wµo¦æªÑ²¼¡G´¶³qªÑ160,488,940ªÑ¡A¨CªÑ±ÃB·s»O¹ô10¤¸¡A¦@p·s»O¹ô1,604,889,400¤¸¾ã¡C (¤G)¥»¦¸²{ª÷¼W¸ê¤WÂdªÑ²¼¡G´¶³qªÑ29,466,030ªÑ¡A¨CªÑ±ÃB·s»O¹ô10¤¸¡A¦@p·s»O¹ô294,660,300¤¸¾ã¡C (¤T)²Öp¤WÂdÁ`ªÑ¼Æ¡G´¶³qªÑ¦@p189,954,970ªÑ¡A¨CªÑ±ÃB·s»O¹ô10¤¸¡Ap·s»O¹ô1,899,549,700¤¸¾ã¡C (¥|)¼W¸ê·sªÑÅv§Q¸q°È¡G»P¤wµo¦æ´¶³qªÑªÑ¥÷¬Û¦P¡C (¤)ªÑ²¼Ã±ÃÒ¾÷ºc¡G¥»¦¸²{ª÷¼W¸ê±ÄµL¹êÅé¤è¦¡µo¦æ¡A¬G¤£¾A¥Î¡C (¤»)ªÑ°È¥N²z¾÷ºc¡G (1) ¸s¯qª÷¹©ÃÒ¨éªÑ¥÷¦³¤½¥qªÑ°È¥N²z³¡ (2) ¦a§}¡G¥x¥_¥«¤j¦w°Ï´°¤Æ«n¸ô¤G¬q97¸¹B2 (3) ¹q¸Ü: (02)2702-3999¡C
¤T¡B¥»¦¸¼W¸êªÑ²¼¹wp©ó¥Á°ê108¦~12¤ë13¤é(¬P´Á¤)¤WÂd¡A¨Ã±ÄµL¹êÅéµo¦æ¡C
®Ú¾Ú¨Ì¥H¤W¤½§i, Ó¤H²q´ú:
H.C. Wainwright ¦b12¤ë6¤é¥ý¥þ³¡ ¶R¤U¥»¦¸ASLAN ADR ¼W¸ê, ¶×´Úµ¹¨È·à±d.
¦A¤½¶}¥«³õ½æµ¹¤j¤á.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/12/19 ¤W¤È 09:09:51
²Ä 2031 ½g¦^À³
|
To ¤Ñ©R¤j,
Ãö©ó§A»¡©Ó¾P°ÓÂàÅý¡A½Ð°Ý¦³®ø®§¨Ó·½¥i¥H°Ñ¦Ò¶Ü? ¦pªG¦³¥i¥H½Ð§A¤À¨É¶Ü?
Thanks, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/19 ¤W¤È 08:49:33
²Ä 2030 ½g¦^À³
|
¥»¦¸ASLAN µo¦æADRªº©Ó销°Ó¡AH.C. Wainwright¡C ¬Q¤Ñ¤w¦b¤½¶}¥«³õ¡A½æ¥X给预¥ýn©Ó±µªº¤j户¡C ©Ò¥H¦¨¥æ¶q¡A¥i¥H©ñ¤j¨ì7000¤dªÑ¥H¤W¡C
¦~©³°]³ø´N¨ºÓ¤½¥q¼W¥[«ùªÑ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/12/19 ¤W¤È 08:15:18
²Ä 2029 ½g¦^À³
|
To ¿ûÅK¨k¤l,
¨ºÓ¥u¬O¥À¤½¥q§â¿ú¼·µ¹¤l¤½¥qªº°Ê§@¦Ó¤w¡A¸ò¤§«eADR¼W¸ê®×µLÃö¡A³oºØ°]°È©Ê¤½§i¨C©u¥i¯à³£·|¦³¡A¤£¬O«Ü«nªº¡A¤£¥Î¤Ó¦b·N!
Thanks, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2019/12/18 ¤U¤È 09:52:36
²Ä 2028 ½g¦^À³
|
tw.mobi.yahoo.com/finance/%E5%85%AC%E5%91%8A-%E4%BA%9E%E7%8D%85%E5%BA%B7-ky%E8%91%A3%E4%BA%8B%E6%9C%83%E6%A0%B8%E5%87%86%E5%B0%8D%E5%AD%90%E5%85%AC%E5%8F%B8aslan-pharmaceuticals-pte-095705486.html
³o¦³¤°»ò·N¸q©O¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/18 ¤U¤È 09:27:30
²Ä 2027 ½g¦^À³
|
ÁÂÁ ¤Ñ©R¤j Timchan516 ¤j »P¦U¦ì¤j¤jªº¸ê°T¤À¨É ÃĪ«¬ãµo¤£¥²ÁûÁûÃij£¦¨¥\ ¥un¦³¤@Áû¨Ï¥Î¤H¤f²³¦hªºÃĪ«¬ãµo¦¨¥\´N¨¬¥HÅý¤½¥q²æL´«°©
Bermekimab »P ASLAN004 ¦bÀã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI)µû¤À ªì¨B PK
Bermekimab Àã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI)µû¤À % Change from Baseline ( phase 2 ) Group 200mg N=10 ²Ä4©P¬ù¤U°¦Ê¤À¤§20 Group 400mg N=28 ²Ä7©P¬ù¤U°¦Ê¤À¤§75
ASLAN004 EASI Àã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI)µû¤À % Change from Baseline ( phase1 ) 200mg N= 6
¤w¤½§i¨ä¤¤¤T¦W¯f±wªºÀã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI)µû¤À¤À§O¤U° 85%¡B70%¤Î 59% , ¥§¡¤U°71% EASI µû¤À¦b²Ä¥|¶g«ùÄò¤U°¡A¹w´Á¦b 6 ¦Ü 8 ¶g¹F¨ì³Ì¤jÀø®Ä,¤£ª¾¹D¦b 6 ¦Ü 8 ¶g·|¤£·|¶W¶V Bermekimab ? ¥uª¾¹D ASLAN004 ¨Ï¥Î³Ì§C¾¯¶q »PBermekimab ¨Ï¥Î³Ì°ª¾¯¶q ¦bÀã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI)µû¤À¤U°´T«×«Ü±µªñ
XBiotech ±N Bermekimab ¥H7.5»õ¬ü¤¸²{ª÷( À³¸Ó¬Oupfront payment)¡A¦A¥[¤W6»õ¬ü¤¸¨½µ{ª÷¡A¦Xp°ª¹F13.5»õ¬ü¤¸Á`±ÂÅvµ¹¼b¥ÍºX¤U¤l¤½¥qJanssen¡AÀ³¸ÓÁÙ·|¦³¾P°âÅv§Qª÷Royalty (¨È·à±dÀ³¦n¦n¬ãµo³oÁû¦³Ävª§¤OªºÃĪ«Åý¤½¥q²æL´«°©)
¸Û¦p Timchan516¤j©Ò¤À¨É: 004¹ï©ó200mgªº¾¯¶q´N¦³«D¹w´Áªº¦¨ªG Åý¤ÀªR®v½Õ¥Ø¼Ð»ù5~8¶ô¤£µ¥ (À³¬O«üADR ) ¤ÀªR®v¸É¥R»¡¡A¦¹¥~¡AASLAN004¬O¦w¥þªº¡A¨S¦³¤¤Â_©ÎÄY«¤£¨}¨Æ¥óªº³ø¾É
400mg N= 6 ¤w¶}©l¦¬®×ÁÙ¥¼¤½§i¼Æ¾Ú
600mg N= 6 ÁÙ¥¼¶}©l¦¬®×
200mg ¨ì 600mg ¤À¤T²Õ Ó¤H²q´ú¬O200 400 600 ?
¤w¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/18 ¤U¤È 08:41:23
²Ä 2026 ½g¦^À³
|
×¥¿¤@¡A ¤U¦C¥|ºØ¼Ð¹vÃĪ«¡A¦P¼ËªýÂ_³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¤§¸ô®| : ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡°T®§¶Ç¾É¡CªýÂ_²Ä¤G«¬¨üÅéµ²¦X¡C
1.Dupilumab¾÷ÂàMOA: ¤w¤W¥«2¦~¥b
Dupilumab ¬O«²Õªº IgG4 §ÜÅé¡A¦]¬°»P IL-4R£\ µ²¦X¡A©Ò¥H¯à¦P®ÉªýÂ_ IL-4 ¤Î IL-13 »P²Ä¤@«¬¤Î²Ä¤G«¬¨üÅ骺µ²¦X¡C
ªýÂ_IL-4R£\ »P yC ¤§¶¡°T®§¶Ç¾É¡CªýÂ_²Ä¤@«¬¨üÅéµ²¦X¡C¡]¥i¯à²£¥Í²´·ú结¼Òª¢°Æ§@¥Î¤§ì¦]¡^ ªýÂ_IL-4R£\ »P IL-13R£\1¤§¶¡°T®§¶Ç¾É¡CªýÂ_²Ä¤G«¬¨üÅéµ²¦X¡C
2.Lebrikizumab¾÷ÂàMOA:¡]¤µ¦~10¤ë¶}©l¤T´ÁÁ{§É¡^ Lebrikizumab ¬O«²Õªº IgG4 §ÜÅé¡AÂÇ¥Ñ »P IL-13 °tÅé¤Wªº B¡BC Á³±Û¤Wªº§Üìªí¦ìµ²¦X ¡A ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡ªº°T®§¶Ç¾É¡C
3. Tralokinumab ¾÷ÂàMOA: ¡]¤T´Á¸Ñª¼¤W¶g¹LÃö¡^ Tralokinumab¬O«²Õªº IgG4 §ÜÅé¡AÂÇ¥Ñ »P IL-13 °tÅé¤Wªº A ¤Î D Á³±Ûªº§Üìªí¦ìµ²¦X ¡AªýÂ_ IL-13 °tÅé»P ¨üÅéIL-13R£\1 ¤Î IL-13R£\2 µ² ¦X¡C ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡°T®§¶Ç¾É
4.Aslan004 ¾÷ÂàMOA :
ÂÇ¥Ñ »P IL-13 ¨üÅéIL-13R£\1 µ² ¦X¡CªýÂ_²Ä¤G«¬¨üÅéµ²¦X¡C ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡°T®§¶Ç¾É¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/18 ¤U¤È 08:35:54
²Ä 2025 ½g¦^À³
|
¤U¦C¥|ºØ¼Ð¹vÃĪ«¡A¦P¼ËªýÂ_³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¤§¸ô®| : ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡°T®§¶Ç¾É¡CªýÂ_²Ä¤@«¬¨üÅéµ²¦X¡C
1.Dupilumab¾÷ÂàMOA: ¤w¤W¥«2¦~¥b
Dupilumab ¬O«²Õªº IgG4 §ÜÅé¡A¦]¬°»P IL-4R£\ µ²¦X¡A©Ò¥H¯à¦P®ÉªýÂ_ IL-4 ¤Î IL-13 »P²Ä¤@«¬¤Î²Ä¤G«¬¨üÅ骺µ²¦X¡C
ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡°T®§¶Ç¾É¡CªýÂ_²Ä¤@«¬¨üÅéµ²¦X¡C¡]¥i¯à²£¥Í²´·ú结¼Òª¢°Æ§@¥Î¤§ì¦]¡^ ªýÂ_IL-4R£\ »P yC¤§¶¡°T®§¶Ç¾É¡CªýÂ_²Ä¤G«¬¨üÅéµ²¦X¡C
2.Lebrikizumab¾÷ÂàMOA:¡]¤µ¦~10¤ë¶}©l¤T´ÁÁ{§É¡^ Lebrikizumab ¬O«²Õªº IgG4 §ÜÅé¡AÂÇ¥Ñ »P IL-13 °tÅé¤Wªº B¡BC Á³±Û¤Wªº§Üìªí¦ìµ²¦X ¡A ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡ªº°T®§¶Ç¾É¡C
3. Tralokinumab ¾÷ÂàMOA: ¡]¤T´Á¸Ñª¼¤W¶g¹LÃö¡^ Tralokinumab¬O«²Õªº IgG4 §ÜÅé¡AÂÇ¥Ñ »P IL-13 °tÅé¤Wªº A ¤Î D Á³±Ûªº§Üìªí¦ìµ²¦X ¡AªýÂ_ IL-13 °tÅé»P ¨üÅéIL-13R£\1 ¤Î IL-13R£\2 µ² ¦X¡C ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡°T®§¶Ç¾É
4.Aslan004 ¾÷ÂàMOA :
ÂÇ¥Ñ »P IL-13 ¨üÅéIL-13R£\1 µ² ¦X¡CªýÂ_²Ä¤G«¬¨üÅéµ²¦X¡C ªýÂ_IL-4R£\ »P IL-13R£\1 ¤§¶¡°T®§¶Ç¾É¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/18 ¤U¤È 04:53:06
²Ä 2024 ½g¦^À³
|
¥xÁÞ¤j,
¨Ì·Ó Janssen(´´Ë)±N¦VXBiotech¤ä¥I7.5»õ¬ü¤¸ªº²{ª÷¡C¦¹¥~¡AXBiotech¥i¯à·|¦¬¨ì°ª¹F6»õ¬ü¤¸ªº¼ç¦b¨½µ{¸O¥I´Ú¡C +¾P°â¤À¼í?
ASLAN004 ¦³®t¤£¦hªº»ùÈ/2 ,¤@¥bCSL, ¬O·í¦~´¼Àº3.5¿¥H¤W. ¥«ÈȦh¤~?
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/12/18 ¤W¤È 08:53:37²Ä 2018 ½g¦^À³ ¥xÁÞ¤j, Upon closing, Janssen will make a cash payment of $750 million to XBiotech. In addition, XBiotech may receive up to $600 million in potential milestone payments. XBiotech expects to generate additional revenue from the manufacturing supply agreement and clinical services agreement with Janssen over the next two years. ¥æ©ö§¹¦¨«á¡A´´Ë±N¦VXBiotech¤ä¥I7.5»õ¬ü¤¸ªº²{ª÷¡C¦¹¥~¡AXBiotech¥i¯à·|¦¬¨ì°ª¹F6»õ¬ü¤¸ªº¼ç¦b¨½µ{¸O¥I´Ú¡C XBiotech¹wp¦b¥¼¨Ó¨â¦~¤º±N±q»PJanssenªº»s³y¨ÑÀ³¨óij©MÁ{§ÉªA°È¨óij¤¤Àò±oÃB¥~¦¬¤J¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2019/12/18 ¤U¤È 02:24:44
²Ä 2023 ½g¦^À³
|
¥H¤U«ÂI´N¬O 004¹ï©ó200ªº¾¯¶q´N¦³«D¹w´Áªº¦¨ªG Åý¤ÀªR®v½Õ¥Ø¼Ð»ù5~8¶ô¤£µ¥ ¤ÀªR®v¸É¥R»¡¡A¦¹¥~¡AASLAN004¬O¦w¥þªº¡A¨S¦³¤¤Â_©ÎÄY«¤£¨}¨Æ¥óªº³ø¾É¡C¥LÁÙ«ü¥X¡AASLN¥¿¦b¶i¦æASLAN003¦b«æ©ÊÅè¼Ë¥Õ¦å¯f¤¤ªºII´Á¬ã¨s¡CTenthoff»¡¡A³o¨âºØÃĪ«©Î¨âºØÃĪ«³£¥i¯à¥Nªí¦X§@¾÷·| ¥H¤U¨ä¥Lªº«ÂI±Ôz¤j®aÀ³¸Ó³£¤w¸gª¾¹D¤F ! ©Ò¥H¤£¦h°µ»¡©ú¤F !!
ASLN stock continued to rise in after-hours trading on December 17, 2019. ASLN stock continues to attract buyers after the H.C. Wainwright¡¦s price target hike back on December 10, 2019.
ASLN stock in the 15-minute time frame shows an incredible move that continued in after-hours trading (brows shaded area) on December 17, 2019. On December 10, 2019, H.C. Wainwright analyst Yi Chen raised Aslan Pharmaceuticals¡¦ price target to $5 from $2 and reiterates a Buy rating on the shares.Low-dose ASLAN004 demonstrateed positive efficacy and safety in atopic dermatitis, Chen tells investors in a research note. These early signs of efficacy are very encouraging as 200 mg is the lowest dose cohort in the study, and the observed efficacy has yet to peak, Chen tells investors in a research note.
On December 2, 2019, Piper Jaffray analyst Edward Tenthoff upgraded Aslan Pharmaceuticals to Overweight from Neutral with a price target of $8, up from $1. The stock in premarket trading is up 85%, or $3.24, to $7.06. The company reported preliminary Phase I multiple-ascending dose data on subcutaneous ASLAN004 to treat moderate-to-severe atopic dermatitis, and in the lowest dose cohort, three evaluable patients experienced at least 60% reduction in the Eczema Area Severity Index score at one month, Tenthoff tells investors in a research note. Further, ASLAN004 was safe with no discontinuations or serious adverse events reported, the analyst adds. He also notes that Aslan is also conducting a Phase II study of ASLAN003 in acute myeloid leukemia. Both or either drug could represent partnering opportunities, says Tenthoff.
On December 1, 2019, ASLAN Pharmaceuticals announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose, or MAD, study of ASLAN004 for the treatment of moderate-to-severe atopic dermatitis, or AD. ASLAN004 is a first-in-class fully human monoclonal antibody that binds to the IL-13 receptor alpha1 subunit (IL-13Ralpha1), blocking signalling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of AD, such as redness and itching of the skin. The first patient was enrolled into the double blind study at Changi General Hospital in Singapore on 22 October 2019. As of November 29, 6 patients had been treated in the lowest dose cohort and 3 have completed at least one month of dosing. In a review of unclean blinded data, the Eczema Area and Severity Index, or EASI, scores of the 3 patients were reduced by 85%, 70% and 59% from baseline and the EASI score continued to fall at 4 weeks with maximal efficacy expected at 6 to 8 weeks. ASLAN004 was well-tolerated and, to date, there have been no serious adverse events or treatment discontinuations. Corresponding changes were seen in other measures of efficacy. The data monitoring committee, or DMC, will meet in late December, after which the second dose cohort is expected to open. The randomised, double-blind, placebo-controlled MAD study will evaluate 3 doses of ASLAN004 delivered subcutaneously and will be followed by an expansion cohort at the most efficacious dose. Each dose cohort will contain up to 6 patients on ASLAN004 and 2 patients on placebo, and the expansion cohort will contain 12 patients on ASLAN004 and 6 patients on placebo. Patients are dosed weekly for 8 weeks to determine safety and the maximal efficacy of ASLAN004. The study will recruit up to 50 moderate-to-severe atopic dermatitis patients and study completion is expected in the second half of 2020, with interim results expected in early 2020.
Dr Mark McHale, Head of R&D, ASLAN Pharmaceuticals, said: ¡§We are pleased to report encouraging preliminary data from this study of ASLAN004. Whilst the data remains early, we had not anticipated to observe such pronounced improvements in patients enrolled into the lowest dose cohort. We look forward to the second dose cohort opening following the DMC meeting in December and further interim data in early 2020.¡¨
Atopic dermatitis is the most common dermatological disease, affecting over 200 million patients worldwide, characterized by red inflamed skin and severe daytime and night-time itching, which can severely impact patients¡¦ quality of life. Up to one-third of adult atopic dermatitis patients are considered moderate to severe, for which currently available therapeutics are limited and management is challenging in the majority of cases. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/18 ¤U¤È 12:53:08
²Ä 2022 ½g¦^À³
|
ªø§ëªº´A¤O
Regeneron Pharmaceuticals Inc. ,Dupilumab 2017.03~07 ¤W¥«,¤½¥q¥«È¤jº¦140»õ ·í®É¥«³õ¦ô°ª峄¾P°â50»õ¬ü¤¸
Regeneron Pharmaceuticals Inc. ¥t¤@Ó¤jÃÄEYLEA® (aflibercept) , 2011/11¤ë,¤@ÓªvÀø²´·ú¶À´³³¡¯fÅÜ,¤W¥«, 2019¦~/¤µ¦~¥i½æ70»õ¬ü¤¸.
±q2011¦~26¬ü¤¸,¤jº¦4¦~¨ì,2015¦~, ªÑ»ù526¬ü¤¸.
¥Ø«e¥«È410»õ¬ü¤¸,¤µ¦~À禬ªñ100»õ¬ü. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/12/18 ¤W¤È 11:46:23
²Ä 2021 ½g¦^À³
|
2.33 USD +0.25 (12.02%) ¤w¦¬½L: 12¤ë17¤é ¤U¤È7:59 [EST] ¡P §K³dÁn©ú ¦¬½L»ù 2.80 +0.47 (20.17%)
©Ç«v¤]¨S¤°®ø®§? ¥u¤@¤Ñ±q2.33-0.25=2.08º¦¨ì2.8(+34%) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/12/18 ¤W¤È 11:37:36
²Ä 2020 ½g¦^À³
|
asln 2.80 +0.47 (20.17%) ¤µ±ß¤j·§¤S¬O¨ë¿E°ª¼é¤£Â_??? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/18 ¤W¤È 09:34:02
²Ä 2019 ½g¦^À³
|
ÁÂÁ¤ѩR¤j»¡©ú¡A¥H©x¤èª©¬°¥D¡A³o¼Ë¬Ý°_¨Ó ¬O¥H7.5»õ¬ü¤¸²{ª÷¡A¦A¥[¤W§¹¦¨¤T´Á¡A¥Ó½ÐÃÄÃÒ¡A¤W¥«µ¥¨½µ{ª÷6»õ¬ü¤¸¡A¦Xp°ª¹F13.5»õ¬ü¤¸Á`±ÂÅv®×¡AÀ³¸ÓÁÙ·|¦³¾P°âÅv§Qª÷Royalty? ¥u¬O¤ñ²v¥¼ª¾¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/18 ¤W¤È 08:53:37
²Ä 2018 ½g¦^À³
|
¥xÁÞ¤j, ±z»~¸Ñ¤F.XBiotech·s¤å½Z Upon closing, Janssen will make a cash payment of $750 million to XBiotech. In addition, XBiotech may receive up to $600 million in potential milestone payments. XBiotech expects to generate additional revenue from the manufacturing supply agreement and clinical services agreement with Janssen over the next two years. ¥æ©ö§¹¦¨«á¡A´´Ë±N¦VXBiotech¤ä¥I7.5»õ¬ü¤¸ªº²{ª÷¡C¦¹¥~¡AXBiotech¥i¯à·|¦¬¨ì°ª¹F6»õ¬ü¤¸ªº¼ç¦b¨½µ{¸O¥I´Ú¡C XBiotech¹wp¦b¥¼¨Ó¨â¦~¤º±N±q»PJanssenªº»s³y¨ÑÀ³¨óij©MÁ{§ÉªA°È¨óij¤¤Àò±oÃB¥~¦¬¤J¡C
AUSTIN, Texas, Dec. 07, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (XBIT) announced today that it has entered into a definitive agreement with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, to sell XBiotech¡¦s novel antibody (bermekimab) that neutralizes interleukin-1 alpha (IL-1⍺). IL-1⍺ promotes disease-causing inflammation in a wide range of medical conditions. Janssen will acquire all rights to bermekimab under the terms of the agreement, and XBiotech will be free to use its True Human Antibody discovery program to develop new antibody therapeutics that target IL-1⍺ to treat non-dermatological diseases. XBiotech plans to re-enter clinical development expeditiously with a next generation anti-IL-1⍺ therapeutic.
Following the acquisition, XBiotech will use its proprietary manufacturing technology to produce clinical supplies of bermekimab for Janssen under a supply agreement. In addition, XBiotech will contract with Janssen to provide clinical trial operation services to complete two ongoing Phase II clinical studies evaluating bermekimab in Hidradenitis Suppurativa and Atopic Dermatitis.
Upon closing, Janssen will make a cash payment of $750 million to XBiotech. In addition, XBiotech may receive up to $600 million in potential milestone payments. XBiotech expects to generate additional revenue from the manufacturing supply agreement and clinical services agreement with Janssen over the next two years.
XBiotech plans to use a portion of the proceeds from this transaction to fund discovery and development of its next generation True Human anti-IL-1⍺ antibody program. Additionally, a portion of the revenue will be dedicated to advancing other antibody therapeutics in XBiotech¡¦s pipeline. The Company is also planning to use part of the proceeds in a capital transaction, such as a stock repurchase, subject to board review and approval.
John Simard, XBiotech¡¦s President & CEO, stated, ¡§We are proud that Janssen has chosen bermekimab as an agent it believes could have an important impact. We believe their acquisition will enable recognition and increase awareness of the full potential of this first-in-class therapeutic. This transaction also provides us the opportunity to showcase our powerful True Human antibody discovery platform, which we are now utilizing to pursue next generation anti-Il-1⍺ antibody therapeutics to treat multiple areas of unmet need outside of dermatology.¡¨
The acquisition of bermekimab provides further validation of the foundational science behind targeting IL-1a as a means to block disease-causing inflammation. Clinical and pre-clinical research suggests blocking IL-1a may be used to treat a number of chronic and acute inflammatory conditions, including skin disease, heart disease, heart attack, stroke, rheumatological disease, gastrointestinal diseases, and cancer.
Simard further stated, ¡§The cash infusion from the bermekimab transaction will enable XBiotech to accelerate our True Human antibody pipeline. The Company will also have sufficient cash to support a significant capital transaction, which could provide for a non-dilutive liquidity event for our valued shareholders who have supported XBiotech¡¦s pioneering work.¡¨
The transaction is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and is expected to close shortly after HSR approval.
2019¦~12¤ë7¤é¡A±o§JÂÄ´µ¦{¶ø´µ¥Å-¥þ²yXBiotech Inc.¡]XBIT¡^¤µ¤Ñ«Å¥¬¤w»P±j¥ÍªºJanssen»sÃĤ½¥qJanssen Biotech¡AInc.¹F¦¨³Ì²×¨óij¡A¥X°âXBiotechªº¤¤©M¥Õ¤¶¯À-1£\¡]IL-1 that¡^ªº·s«¬§ÜÅé¡]bermekimab¡^¡C IL-1⍺¥i¦b¦hºØÂåÀø±ø¥ó¤U«P¶i¤Þ°_¯e¯fªºª¢¯g¡C Janssen±N®Ú¾Ú¸Ó¨óijªº±ø´ÚÀò±obermekimabªº©Ò¦³Åv§Q¡AXBiotech±N¦Û¥Ñ¨Ï¥Î¨äTrue Human Antibodyµo²{p¹º¨Ó¶}µo°w¹ïIL-1 newªº·s§ÜÅéÀøªk¡A¥HªvÀø«D¥Ö½§¯f¡C XBiotechp¹º¨Ï¥Î¤U¤@¥N§ÜIL-1⍺ªvÀø¾¯¨³³t«·s¶i¤JÁ{§É¶}µo¡C
¦¬Áʤ§«á¡AXBiotech±N®Ú¾Ú¤@¶µ¨ÑÀ³¨óij¡A¨Ï¥Î¨ä±M¦³ªº»s³y§Þ³N¬°Janssen¥Í²£¨©¹p§J³æ§ÜªºÁ{§É¥Î«~¡C¦¹¥~¡AXBiotech±N»PJanssenñq¦X¦P¡A´£¨ÑÁ{§É¸ÕÅç¾Þ§@ªA°È¡A¥H§¹¦¨¨â¶µ¥¿¦b¶i¦æªºII´ÁÁ{§É¬ã¨s¡A¥Hµû¦ô¨©¹p¯]³æ§Ü¦b¤ÆÁw©Ê¦½¸¢ª¢©M¯SÀ³©Ê¥Öª¢¤¤ªº§@¥Î¡C
¥æ©ö§¹¦¨«á¡A´´Ë±N¦VXBiotech¤ä¥I7.5»õ¬ü¤¸ªº²{ª÷¡C¦¹¥~¡AXBiotech¥i¯à·|¦¬¨ì°ª¹F6»õ¬ü¤¸ªº¼ç¦b¨½µ{¸O¥I´Ú¡C XBiotech¹wp¦b¥¼¨Ó¨â¦~¤º±N±q»PJanssenªº»s³y¨ÑÀ³¨óij©MÁ{§ÉªA°È¨óij¤¤Àò±oÃB¥~¦¬¤J¡C
XBiotechp¹º±N¦¹¦¸¥æ©öªº³¡¤À¦¬¯q¥Î©ó¨ä¤U¤@¥NTrue Human§ÜIL-1£]§ÜÅép¹ºªºµo²{©M¶}µo¡C¦¹¥~¡A³¡¤À¦¬¤J±N±Mªù¥Î©ó±À¶iXBiotech²£«~½u¤¤ªº¨ä¥L§ÜÅéÀøªk¡C¤½¥qÁÙp¹º±N³¡¤À©Ò±o´Ú¶µ¥Î©ó¸ê¥»¥æ©ö¡A¨Ò¦p¦^ÁʪѲ¼¡A¦ý¶·¸g¸³¨Æ·|¼f¬d©M§åã¡C
XBiotechÁ`µôݺ®u°õ¦æ©xJohn Simardªí¥Ü¡G¡§§ÚÌ«Ü°ª¿³Janssen¿ï¾Übermekimab§@¬°¨ä»{¬°¥i¯à¨ã¦³«n¼vÅTªº¥N²z¡C§Ú̬۫H¡A¥L̪º¦¬ÁʱN¨Ï¤H̹ï³oºØ¤@¬yÀøªkªº¥þ³¡¼ç¯à±o¨ì»{¥i¨Ã´£°ª»{ÃÑ¡C³o¶µ¥æ©öÁÙ¬°§ÚÌ´£¨Ñ¤F®i¥Ü±j¤jªºTrue Human§ÜÅéµo²{¥¥xªº¾÷·|¡A§Ú̲{¦b¥¿¦b§Q¥Î¸Ó¥¥x¨Ó´M¨D¤U¤@¥N§ÜIl-1£]§ÜÅéÀøªk¡A¥HªvÀø¥Ö½§¯f¾Ç¤§¥~ªº³\¦h¥¼º¡¨¬»Ý¨Dªº»â°ì¡C¡¨
§B¹p§J³æ§ÜªºÀò±o¬°¹v¦VIL-1a§@¬°ªý¤îP¯f©Êª¢¯gªº¤â¬q´£¨Ñ¤F°ò¦¬ì¾Çªº¶i¤@¨BÅçÃÒ¡CÁ{§É©MÁ{§É«e¬ã¨sªí©ú¡AªýÂ_IL-1a¥i¥H¥Î©óªvÀø³\¦hºC©Ê©M«æ©Êª¢¯g¡A¥]¬A¥Ö½§¯f¡A¤ßż¯f¡A¤ßż¯f¡A¤¤·¡A·Àã¯f¡AG¸z¹D¯e¯f©MÀù¯g¡C
Simard¶i¤@¨Bªí¥Ü¡G¡§³q¹Lbermekimab¥æ©öÀò±oªº²{ª÷ª`¤J±N¨ÏXBiotech¥[§Ö§Ú̪ºTrue Human§ÜÅé¶}µo¬yµ{¡C¸Ó¤½¥qÁÙ±N¦³¨¬°÷ªº²{ª÷¨Ó¤ä«ù¤@¶µ«¤jªº¸ê¥»¥æ©ö¡A³o¥i¥H¬°¨º¨Ç¤ä«ùXBiotech¶}©Ý©Ê¤u§@ªº´L¶QªÑªF´£¨Ñ«Dµ}ÄÀ©Ê¬y°Ê©Ê¬¡°Ê¡C¡¨
¸Ó¥æ©ö¶·¿í¦uºD¨Ò¦¨¥æ±ø¥ó¡A¥]¬A®Ú¾Ú¡m«¢¯S-´µ¬ì¯S-ù}¿Õ¤Ï¦«©Ô´µ§ï¶iªk¡nªº§åã¡A¨Ã¦³±æ¦b°ªÅK§åã«á¤£¤[§¹¦¨¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/18 ¤W¤È 08:47:02
²Ä 2017 ½g¦^À³
|
¥H¤U±ÂÅv¸ê°T¥i¥Hµû¦ôASLAN004ªº»ùÈ¶È¨Ñ°Ñ¦Ò XBiotech ¥H 7.5»õ ¬ü¤¸±N¦b¬ãµo¤¤¤G´ÁÁ{§Éªº²§¦ì©Ê¥Ö½§ª¢bermekimab »P¼b¥ÍºX¤U¤l¤½¥qJanssen ¹F¦¨¨óij¡A¦pªGJansen¦A¶}µo¥Ö½§¯f¥H¥~ªº¾AÀ³¯g¦b°Ó«~¤Æ®É»Ýn¦A¥Iµ¹Biotech 6»õ¬ü¤¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/18 ¤W¤È 08:01:45
²Ä 2016 ½g¦^À³
|
¤Z¨Æ¦³¤H¥ýª¾¹D¡C
²Ä¤@¾¯¶q200mg,结ªG¡C ¥«³õ¶}©ln¥ý¤ÏÀ³¤F¡C ¯ÂÄݲq´ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/18 ¤W¤È 07:35:05
²Ä 2015 ½g¦^À³
|
Roger ¥S¡A¦
1.ASLAN004·§©À©ÊÁ{§É¶Õ¥²º}«G¹LÃö 2.ASLAN001¡A30-40¤HªºÁ{§É¡A¿z¿ï¦¸±Ú¸s¡AY¹LÃö¡A¦¹®É·í¦~ªº4147¬O¡A2014¦~ªì¡A¥«È400»õ¥x¹ô¡A·íµM¥L¥ý¦³BTD¡C
¥¼¨Ó004AD¤G´ÁÁ{§É+001枢钮Á{§É¡A»ùÈ«D¤Z¡C ¥«³õ¦ÛµM¤ÏÀ³¡C
¤½¥q»Ýn¶Ò资¤F¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/12/18 ¤W¤È 06:14:14
²Ä 2014 ½g¦^À³
|
¤Ñ¥S,¦¤W¦n! asln stock¦ü¦³öt·¦A°_¤§¶Õ??? 2.33 USD +0.25 (12.02%) ½L«á2.48 +0.15 (6.44%)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/18 ¤W¤È 06:11:56
²Ä 2013 ½g¦^À³
|
§ó¥¿1
1bÁ{§ÉEASI°§C50%¥H¤W±wªÌªº¤ñ²v¤§PK
SLAN004 100% VS. Dupilumab 71.4%
1.ASLAN004 200mg ,3¦ì¡A100%EASI°§C50%¥H¤W¡C (§¹¦¨4-5¶g)¡A3¦ìEASI¤À§O°§C¤§¤ñ¨¯85%/70%/59%
2.DupilumabÅTÀ³ªÌ¤ÀªRÅã¥Ü¡A¦b²Ä4¶g¡A±µ¨ü150mg¾¯¶qªvÀøªº±wªÌ¤¤¦³54.5¢Hªº±wªÌ©M±µ¨ü300mg¾¯¶qªvÀøªº±wªÌ¤¤¦³71.4¢HªºEASI±o¤À°§C¤F50¢H©Î§ó°ª¡A¦Ó¦w¼¢¾¯¬°18.8¢H¡]p<0.05¡^
1b´Á¬ã¨sªº¥Dn¥Øªº¬Oµû¦ôdupilumabªº¦w¥þ©Ê¡C¨ä¥L±´¯Á©Ê²×ÂI¥]¬AÃÄ¥N°Ê¤O¾Ç¡A¥Íª«¼Ð»xª«©M¥\®Ä°Ñ¼Æ¡C¥\®Ä¼Æ¾Úªí©ú¡A¨C¶g¥|¦¸¥Ö¤Uª`®gdupilumab¨C¶g150²@§J¡]mg¡^©Î300mg¶i¦æªvÀø¡A¥iÅãµÛ§ïµ½¯e¯f©M¯e¯f±o¨ì¾A·í±±¨îªº¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢¡]AD¡^±wªÌªºÅé¼x©M¯gª¬§½³¡¥ÎÃÄ¡C¨ãÅé¦Ó¨¥¡A»P¦w¼¢¾¯¬Û¤ñ¡A±q°ò½u¨ì²Ä4¶g¡A±µ¨üdupilumabªvÀøªº±wªÌªºÅéªí±¿n¡]BSA¡^µû¤À¡A¬ã¨sªÌÁ`Åéµû¦ô¡]IGA¡^µû¤À©MÀã¯l±¿nÄY«©Ê«ü¼Æ¡]EASI¡^§¡¦³ÅãµÛ§ïµ½¡]p <0.05 vs.¦w¼¢¾¯©Ò¦³±¹¬I©M¾¯¶q¡^¡C 300mg¾¯¶q²ÕªºBSA¡AIGA©MEASIµû¤À¦b²Ä8©P«O«ù¤FÅãµÛ§ïµ½¡]»P¦w¼¢¾¯¬Û¤ñ¡Ap <0.05¡^¡CÅTÀ³ªÌ¤ÀªRÅã¥Ü¡A¦b²Ä4¶g¡A±µ¨ü150mg¾¯¶qªvÀøªº±wªÌ¤¤¦³54.5¢Hªº±wªÌ©M±µ¨ü300mg¾¯¶qªvÀøªº±wªÌ¤¤¦³71.4¢HªºEASI±o¤À°§C¤F50¢H©Î§ó°ª¡A¦Ó¦w¼¢¾¯¬°18.8¢H¡]p <0.05¡^ ¡C³Ì±`¨£ªº¤£¨}¨Æ¥ó¬O»ó«|ª¢¡]¦w¼¢¾¯¬°19.6¢H¡A¦Ó¦w¼¢¾¯¬°12.5¢H¡^©MÀYµh¡]¦w¼¢¾¯¬°11.8¢H¡A¦Ó6.3¢H¡^¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/18 ¤W¤È 05:58:33
²Ä 2012 ½g¦^À³
|
ASLAN004 200% VS. Dupilumab 71.4% ---1b Á{§É EASI°§C50%
1.ASLAN004 200mg ,3¦ì¡A100% (§¹¦¨4-5¶g)
2.DupilumabÅTÀ³ªÌ¤ÀªRÅã¥Ü¡A¦b²Ä4¶g¡A±µ¨ü150mg¾¯¶qªvÀøªº±wªÌ¤¤¦³54.5¢Hªº±wªÌ©M±µ¨ü300mg¾¯¶qªvÀøªº±wªÌ¤¤¦³71.4¢HªºEASI±o¤À°§C¤F50¢H©Î§ó°ª¡A¦Ó¦w¼¢¾¯¬°18.8¢H¡]p<0.05¡^
1b´Á¬ã¨sªº¥Dn¥Øªº¬Oµû¦ôdupilumabªº¦w¥þ©Ê¡C¨ä¥L±´¯Á©Ê²×ÂI¥]¬AÃÄ¥N°Ê¤O¾Ç¡A¥Íª«¼Ð»xª«©M¥\®Ä°Ñ¼Æ¡C¥\®Ä¼Æ¾Úªí©ú¡A¨C¶g¥|¦¸¥Ö¤Uª`®gdupilumab¨C¶g150²@§J¡]mg¡^©Î300mg¶i¦æªvÀø¡A¥iÅãµÛ§ïµ½¯e¯f©M¯e¯f±o¨ì¾A·í±±¨îªº¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢¡]AD¡^±wªÌªºÅé¼x©M¯gª¬§½³¡¥ÎÃÄ¡C¨ãÅé¦Ó¨¥¡A»P¦w¼¢¾¯¬Û¤ñ¡A±q°ò½u¨ì²Ä4¶g¡A±µ¨üdupilumabªvÀøªº±wªÌªºÅéªí±¿n¡]BSA¡^µû¤À¡A¬ã¨sªÌÁ`Åéµû¦ô¡]IGA¡^µû¤À©MÀã¯l±¿nÄY«©Ê«ü¼Æ¡]EASI¡^§¡¦³ÅãµÛ§ïµ½¡]p <0.05 vs.¦w¼¢¾¯©Ò¦³±¹¬I©M¾¯¶q¡^¡C 300mg¾¯¶q²ÕªºBSA¡AIGA©MEASIµû¤À¦b²Ä8©P«O«ù¤FÅãµÛ§ïµ½¡]»P¦w¼¢¾¯¬Û¤ñ¡Ap <0.05¡^¡CÅTÀ³ªÌ¤ÀªRÅã¥Ü¡A¦b²Ä4¶g¡A±µ¨ü150mg¾¯¶qªvÀøªº±wªÌ¤¤¦³54.5¢Hªº±wªÌ©M±µ¨ü300mg¾¯¶qªvÀøªº±wªÌ¤¤¦³71.4¢HªºEASI±o¤À°§C¤F50¢H©Î§ó°ª¡A¦Ó¦w¼¢¾¯¬°18.8¢H¡]p <0.05¡^ ¡C³Ì±`¨£ªº¤£¨}¨Æ¥ó¬O»ó«|ª¢¡]¦w¼¢¾¯¬°19.6¢H¡A¦Ó¦w¼¢¾¯¬°12.5¢H¡^©MÀYµh¡]¦w¼¢¾¯¬°11.8¢H¡A¦Ó6.3¢H¡^¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/18 ¤W¤È 05:45:29
²Ä 2011 ½g¦^À³
|
Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Update: Dupixent (dupilumab) Now FDA Approved - March 28,2017
Phase 1b Data Presented at Late Breaking Session of 71st Annual Meeting of the American Academy of Dermatology
PARIS and TARRYTOWN, N.Y., March 02, 2013, 2013 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.
The primary objective of the Phase 1b studies was to assess the safety profile of dupilumab. Other exploratory endpoints included pharmacokinetic, biomarker, and efficacy parameters. The efficacy data showed that treatment with four weekly subcutaneous injections of dupilumab at either 150 milligrams (mg) or 300mg per week, significantly improved the signs and symptoms of patients with moderate-to-severe atopic dermatitis (AD) whose disease was not adequately controlled with topical medications. Specifically, patients treated with dupilumab had significant improvements in body surface area (BSA) score, Investigator Global Assessment (IGA) score, and Eczema Area Severity Index (EASI) from baseline to week 4 compared to placebo (p<0.05 vs. placebo for all measures and doses). The significant improvements in BSA, IGA, and EASI scores were maintained at week 8 in the 300mg dose group (p<0.05 vs. placebo). A responder analysis demonstrated that at week 4, 54.5% of patients treated with the 150mg dose and 71.4% of patients treated with the 300mg dose achieved a reduction in EASI score of 50% or greater compared to 18.8% with placebo (p<0.05). The most common adverse events (AEs) were nasopharyngitis (19.6% vs 12.5% for placebo) and headache (11.8% vs 6.3% for placebo).
Through blockade of IL-4R alpha, dupilumab modulates signaling of both the IL-4 and IL-13 pathway, which have been implicated in the pathophysiology of allergic disease, said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. We look forward to presenting additional data from a 12-week, Phase 2a trial in atopic dermatitis, as well as starting a larger Phase 2b trial with dupilumab in patients with atopic dermatitis, later this year.
Presented today in a late-breaking clinical trials session at the AAD meeting, the Phase 1b trials included 67 patients randomized to three different doses of dupilumab (75mg, n=8; 150mg, n=22; 300mg, n=21) and placebo (n=16). The primary objective of the Phase 1b studies was to assess the safety profile of dupilumab. Other endpoints included pharmacokinetic, biomarker, and efficacy parameters. Following the 4-week treatment period, patients in the studies were followed for an additional 4 weeks for a total of 8 weeks. ÁÉ¿Õµá©MRegeneron³ø§i¯SÀ³©Ê¥Öª¢¤¤IL-4R£\§ÜÅéDupilumabªº¶§©Ê·§©ÀÅçÃҼƾÚ
§ó·s¡GDupixent¡]dupilumab¡^²{¦bÀò±oFDA§åã-2017¦~3¤ë28¤é
1b´Á¼Æ¾Ú¦b¬ü°ê¥Ö½§¬ì¾Ç°|²Ä71©¡¦~·|±ß·|¤Wµoªí
¤Ú¾¤©M¯Ã¬ù¦{¶ð¨½´°¡A2013¦~3¤ë2¤é¡A2013¦~/ PRNewswire /-ÁÉ¿Õµá©M¦A¥Í¤¸»sÃĤ½¥q¤µ¤Ñ«Å¥¬¡A¨Ó¦Û¥Ö¬¥³æ§Üªº¨â¶µ1b´ÁÁ{§É¸ÕÅç¡]REGN668 / SAR231893¡^ªº¶×Á`¼Æ¾Ú¬°¥Ö¤U¬ã¨s©Ê°ª¿Ë©M¤O¦bÁÚªü±KÁ|¦æªº¬ü°ê¥Ö½§¯f¾Ç·|¡]AAD¡^²Ä71©¡¦~·|¤W¡A§ÚÌ´£¥X¤F°w¹ï¥Õ¤¶¯À4¨üÅé£\¨È°ò¡]IL-4R£\¡^ªº¥þ¤H·½§ÜÅéªvÀø¤è®×¡C
1b´Á¬ã¨sªº¥Dn¥Øªº¬Oµû¦ôdupilumabªº¦w¥þ©Ê¡C¨ä¥L±´¯Á©Ê²×ÂI¥]¬AÃÄ¥N°Ê¤O¾Ç¡A¥Íª«¼Ð»xª«©M¥\®Ä°Ñ¼Æ¡C¥\®Ä¼Æ¾Úªí©ú¡A¨C¶g¥|¦¸¥Ö¤Uª`®gdupilumab¨C¶g150²@§J¡]mg¡^©Î300mg¶i¦æªvÀø¡A¥iÅãµÛ§ïµ½¯e¯f©M¯e¯f±o¨ì¾A·í±±¨îªº¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢¡]AD¡^±wªÌªºÅé¼x©M¯gª¬§½³¡¥ÎÃÄ¡C¨ãÅé¦Ó¨¥¡A»P¦w¼¢¾¯¬Û¤ñ¡A±q°ò½u¨ì²Ä4¶g¡A±µ¨üdupilumabªvÀøªº±wªÌªºÅéªí±¿n¡]BSA¡^µû¤À¡A¬ã¨sªÌÁ`Åéµû¦ô¡]IGA¡^µû¤À©MÀã¯l±¿nÄY«©Ê«ü¼Æ¡]EASI¡^§¡¦³ÅãµÛ§ïµ½¡]p <0.05 vs.¦w¼¢¾¯©Ò¦³±¹¬I©M¾¯¶q¡^¡C 300mg¾¯¶q²ÕªºBSA¡AIGA©MEASIµû¤À¦b²Ä8©P«O«ù¤FÅãµÛ§ïµ½¡]»P¦w¼¢¾¯¬Û¤ñ¡Ap <0.05¡^¡C¤@¶µÅTÀ³ªÌ¤ÀªRÅã¥Ü¡A¦b²Ä4¶g¡A±µ¨ü150mg¾¯¶qªvÀøªº±wªÌ¤¤¦³54.5¢Hªº±wªÌ©M±µ¨ü300mg¾¯¶qªvÀøªº±wªÌ¤¤¦³71.4¢HªºEASI±o¤À°§C¤F50¢H©Î§ó°ª¡A¦Ó¦w¼¢¾¯¬°18.8¢H¡]p <0.05¡^ ¡C³Ì±`¨£ªº¤£¨}¨Æ¥ó¬O»ó«|ª¢¡]¦w¼¢¾¯¬°19.6¢H¡A¦Ó¦w¼¢¾¯¬°12.5¢H¡^©MÀYµh¡]¦w¼¢¾¯¬°11.8¢H¡A¦Ó6.3¢H¡^¡C
§ù¤ñ³æ§Ü³q¹LªýÂ_IL-4R£\¡A¥i½Õ¸`IL-4©MIL-13³q¸ôªº«H¸¹¶Ç¾É¡A³o»P¹L±Ó©Ê¯e¯fªº¯f²z¥Í²z¾Ç¦³Ãö¡C¡¨º®u¬ì¾Ç©xGeorge D. Yancopoulos³Õ¤hRegeneron©xûÝRegeneron LaboratoriesÁ`µô¡C¡§§ÚÌ´Á«ÝµÛ±q12¶gªº¯SÀ³©Ê¥Öª¢2a´ÁÁ{§É¸ÕÅ礤Àò±o§ó¦h¼Æ¾Ú¡A¨Ã¦b¤µ¦~±ß¨Ç®ÉÔ¶}©l¹ïdupilumabªvÀø¯SÀ³©Ê¥Öª¢±wªÌ¶i¦æ§ó¤jªº2b´ÁÁ{§É¸ÕÅç¡C ¡¨¡C
¤µ¤Ñ¦bAAD·|ijªº³Ì·sÁ{§É¸ÕÅç·|ij¤W¤¶²Ðªº1b´Á¸ÕÅç¥]¬A67¦ì±wªÌ¡AÀH¾÷¤À°t¤TºØ¤£¦P¾¯¶qªºdupilumab¡]75mg¡An = 8¡F 150mg¡An = 22¡F 300mg¡An = 21¡^©M¦w¼¢¾¯¡]n = 16¡^¡C 1b´Á¬ã¨sªº¥Dn¥Øªº¬Oµû¦ôdupilumabªº¦w¥þ©Ê¡C¨ä¥L²×ÂI¥]¬AÃÄ¥N°Ê¤O¾Ç¡A¥Íª«¼Ð»xª«©M¥\®Ä°Ñ¼Æ¡C¦b¬°´Á4¶gªºªvÀø´Á«á¡A¹ï¬ã¨s¤¤ªº±wªÌ¦AÀH³X4¶g¡A¦@8¶g¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/17 ¤U¤È 10:00:25
²Ä 2010 ½g¦^À³
|
¤Ñ©R¤j
CSL ±ÂÅv ASLAN004 µ¹¨È·à±d 1 «eª÷+¨½µ{ª÷= 1.25»õ¬üª÷ ¤~¹ï 2 ³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü 10%¤§Åv§Qª÷ ( Royalty ¬ù¦Ê¤À¤§7.5 )
aslanpharma.com/app/uploads/2019/05/190531_Press-Release_ASLAN004-CSL_CHN.pdf
®Ú¾Ú×q¦X¬ù±ø´Ú¡A¨È·à±d-KY ±N©ó ASLAN004 ¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥I CSL ºµ§´Ú¶µ 3,000 ¸U¬üª÷¡CCSL ±N¥i¦¬ ¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì ¼Æ¦Ü 10%¤§Åv§Qª÷¡C
¸¤H¤j ASLAN004 «ÂI¦b»¡¬Æ»ò? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/17 ¤U¤È 05:03:36
²Ä 2009 ½g¦^À³
|
°ê»Ú ¼Ð¹vªvÀø¤¤-««×²§¦ì©Ê¥Öª¢AD¤§±ÂÅv:
¤@.2016¦~,LEO Pharma©ó2016¦~±qªü´µ§Q±d¡]LSE¡GAZN¡^Àò±o¤F¥Ö½§¯e¯f¤¤ªºtralokinumabªºÅv§Q¡A¸Ó¥æ©ö¯A¤Î¦V^°ê-·ç¨å»sÃÄ¥¨ÀY¹w¥I1.15»õ¬ü¤¸¡A¥H¤Î°ª¹F10»õ¬ü¤¸ªº°Ó·~¬ÛÃö¨½µ{¸O©M²£«~¾P°âªº¯S³\Åv¨Ï¥Î¶O¤ñ¨Ò¤£¶W¹L¦Ê¤À¤§¤Q
LEO Pharma reveals positive top-line Phase III results for tralokinumab(¤T´ÁADÁ{§É¤w¸Ñª¼¦¨¥\,2019/12 ¤ë) ²Ä¤@ÓÂê©wIL13 °tÅé¤À§OªýÂ_»PIL13¨üÅé¨üÅé£\1¦¸³æ¦ì (¥çºÙ¬°IL-13R£\1) ¤ÎªýÂ_¨üÅé£\2¦¸³æ¦ì (¥çºÙ¬°IL-13R£\2) µ²¦X¡A ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
¤G.2017/08/08 (2019/10 ¤T´ÁÁ{§É¶}©l) Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv«eª÷8000¸U¬ü¤¸¡A2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. Áô§t28»õ¬ü¤¸³Ì°ª¾P°âÃB.
Âê©wIL13 °tÅ餧¼Ð¹v ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
¤G¤§¤@ , 2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q.
Out-License and Other Agreements Almirall Agreement
2019¦~6¤ë30¤é¬°1.10»õ¬ü¤¸¡A¨½µ{ª÷+¾P°â¨½µ{ª÷?+¾P°â¤À¼í? ¨ä¤¤¥]¬A¡G¡]i¡^3000¸U¬ü¤¸ªº«e´Á´ÁÅv¶O; ¡]ii¡^5,000¸U¬ü¤¸ªº´ÁÅv¦æÅv¶O¡F ¡]iii¡^3000¸U¬ü¤¸ªº¨½µ{¸O
¤T.2019/05/31 , CSL ±ÂÅv ASLAN004 µ¹ ¨È·à±d, «eª÷+¨½µ{ª÷=7.8»õ¬üª÷+ ¥[¾P°â¤À¼í<= 10%.
Âê©wIL13-13R£\1 ¤§¼Ð¹v
¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
¥|.2019/12/09 ,XbiotechÉO强¥Í(JNJ.US)ºX¤Uªº¸â´Ë¥Íª«§Þ术¤½¥q(JanssenBiotech)签¸p¤F¤@项协议¡A¦P·N¥X°â¨ä临§É§Üª¢·s药bermekimabªº¥þ²y°Ó业±Â权¡C
®ÚÕu该协议ªº条´Ú¡A强¥Í将获±obermekimabªº©Ò¦³权§Q¡FXbiotech将´£«e获±o7.5亿¬ü¤¸ªº预¥I´Ú¡A¦}将获±o¦Ü¦h6亿¬ü¤¸ªº潜¦b¨½µ{¸O资ª÷¡CXbiotech还将³q过ÉO强¥Í签订ªº¥Í产¨Ñ应©M临§ÉªA务协议¡A¦b¥¼来两¦~创³y§ó¦h¦¬¤J¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/17 ¤U¤È 04:37:10
²Ä 2008 ½g¦^À³
|
Gºô¬O¬G·N¡AÁÙ¬O¤£¤p¤ß? ³oÓ±ÂÅv¥u¼g6»õ¬ü¤¸!!!!! -----------------------------
Upon closing, Janssen will make a cash payment of $750 million to XBiotech. In addition, XBiotech may receive up to $600 million in potential milestone payments.
®ÚÕu该协议ªº条´Ú¡A强¥Í将获±obermekimabªº©Ò¦³权§Q¡FXbiotech将´£«e获±o7.5亿¬ü¤¸ªº预¥I´Ú¡A¦}将获±o¦Ü¦h6亿¬ü¤¸ªº潜¦b¨½µ{¸O资ª÷¡C
¾P°â¤À¼í?¥¼ª¾? ------- ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/12/11 ¤U¤È 07:26:38²Ä 1936 ½g¦^À³ °ê»ÚAD ªvÀø¼Ð¹v³Ì·s±ÂÅv.
¬üªÑÉÝ动 | 药ªÑXbiotech(XBIT.US)盘«e涨¶W130% «½S§Üª¢·s药获强¥Í(JNJ.US)买断
2019-12-09 22:00:21 来·½¡G亚汇ÊI¡@§@ªÌ¡G¤p亚 ¥´¦L ¦r号¡G¤p ¤j
12¤ë9¤é¡]©P¤@¡^¬üªÑ盘«e¡AºI¤î21:20¡A药ªÑXbiotech(XBIT.US)涨133.99%¡A报26.02¬ü¤¸¡C
Õu¥«场®ø®§¡AXbiotechÉO强¥Í(JNJ.US)ºX¤Uªº¸â´Ë¥Íª«§Þ术¤½¥q(JanssenBiotech)签¸p¤F¤@项协议¡A¦P·N¥X°â¨ä临§É§Üª¢·s药bermekimabªº¥þ²y°Ó业±Â权¡C
®ÚÕu该协议ªº条´Ú¡A强¥Í将获±obermekimabªº©Ò¦³权§Q¡FXbiotech将´£«e获±o7.5亿¬ü¤¸ªº预¥I´Ú¡A¦}将获±o¦Ü¦h6亿¬ü¤¸ªº潜¦b¨½µ{¸O资ª÷¡CXbiotech还将³q过ÉO强¥Í签订ªº¥Í产¨Ñ应©M临§ÉªA务协议¡A¦b¥¼来两¦~创³y§ó¦h¦¬¤J¡C
Bermekimab¬O§ÜIL-1£\单§J¶©§ÜÊ^¡A处¤_2´Á临§É开发¤¤¡A¥Î¤_ªv疗¯S应©Ê¥Öª¢©M¤Æ脓©Ê¦½¸¢ª¢¡C
¥¦¬O¥Ø«e¦b临§É开发¤¤°ß¤@¹v¦VIL-1aªº§ÜÊ^¡AÉO当«eªºªv疗¤è®×¬Û¤ñ¡A¨ã¦³§ó°ªªº¥\®Ä©M¦w¥þ©Ê¡C
XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen
GlobeNewswireDecember 7, 2019
XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen
AUSTIN, Texas, Dec. 07, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (XBIT) announced today that it has entered into a definitive agreement with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, to sell XBiotech¡¦s novel antibody (bermekimab) that neutralizes interleukin-1 alpha (IL-1⍺). IL-1⍺ promotes disease-causing inflammation in a wide range of medical conditions. Janssen will acquire all rights to bermekimab under the terms of the agreement, and XBiotech will be free to use its True Human Antibody discovery program to develop new antibody therapeutics that target IL-1⍺ to treat non-dermatological diseases. XBiotech plans to re-enter clinical development expeditiously with a next generation anti-IL-1⍺ therapeutic.
Following the acquisition, XBiotech will use its proprietary manufacturing technology to produce clinical supplies of bermekimab for Janssen under a supply agreement. In addition, XBiotech will contract with Janssen to provide clinical trial operation services to complete two ongoing Phase II clinical studies evaluating bermekimab in Hidradenitis Suppurativa and Atopic Dermatitis.
Upon closing, Janssen will make a cash payment of $750 million to XBiotech. In addition, XBiotech may receive up to $600 million in potential milestone payments. XBiotech expects to generate additional revenue from the manufacturing supply agreement and clinical services agreement with Janssen over the next two years.
XBiotech plans to use a portion of the proceeds from this transaction to fund discovery and development of its next generation True Human anti-IL-1⍺ antibody program. Additionally, a portion of the revenue will be dedicated to advancing other antibody therapeutics in XBiotech¡¦s pipeline. The Company is also planning to use part of the proceeds in a capital transaction, such as a stock repurchase, subject to board review and approval.
John Simard, XBiotech¡¦s President & CEO, stated, ¡§We are proud that Janssen has chosen bermekimab as an agent it believes could have an important impact. We believe their acquisition will enable recognition and increase awareness of the full potential of this first-in-class therapeutic. This transaction also provides us the opportunity to showcase our powerful True Human antibody discovery platform, which we are now utilizing to pursue next generation anti-Il-1⍺ antibody therapeutics to treat multiple areas of unmet need outside of dermatology.¡¨
The acquisition of bermekimab provides further validation of the foundational science behind targeting IL-1a as a means to block disease-causing inflammation. Clinical and pre-clinical research suggests blocking IL-1a may be used to treat a number of chronic and acute inflammatory conditions, including skin disease, heart disease, heart attack, stroke, rheumatological disease, gastrointestinal diseases, and cancer.
Simard further stated, ¡§The cash infusion from the bermekimab transaction will enable XBiotech to accelerate our True Human antibody pipeline. The Company will also have sufficient cash to support a significant capital transaction, which could provide for a non-dilutive liquidity event for our valued shareholders who have supported XBiotech¡¦s pioneering work.¡¨
The transaction is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and is expected to close shortly after HSR approval.
About XBiotech XBiotech is a fully integrated, global biopharmaceutical company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies. XBiotech currently is advancing a pipeline of therapies by harnessing naturally occurring antibodies from patients with immunity to certain diseases. Utilizing natural human immunity as a source of new medicines offers the potential to redefine the standards of care for a wide range of diseases. The discovery and manufacturing techniques which enable this were designed by and are exclusive to XBiotech. Headquartered in Austin, Texas, XBiotech also leads the development of innovative, proprietary manufacturing technology to reduce the cost and complexity of biological drug production. For more information, visit www.xbiotech.com.
Story continues
About True Human™ Therapeutic Antibodies XBiotech¡¦s True Human™ antibodies are the only available antibodies derived without modification from humans who possess natural immunity to certain diseases. (Unlike all commercially available antibodies, which are called ¡§Humanized¡¨ or ¡§Fully Human,¡¨ XBiotech¡¦s True Human™ antibodies are directly sourced from the natural human immune response for specific diseases without modification, and thereby have not been shown to cause immunogenicity.) With discovery and clinical programs across multiple disease areas, XBiotech¡¦s True Human antibodies have the potential to harness the body¡¦s natural immunity to fight disease with unprecedented safety, efficacy, and tolerability.
Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements, including declarations regarding management¡¦s beliefs and expectations, including with respect to XBiotech¡¦s strategic ambitions, regarding the expected timing of closing of the transaction with Janssen, filings and approvals relating to the transaction, the amount and timing of potential future milestone payments by Janssen, the mechanism of action and potential safety and efficacy of bermekimab, the anticipated timing of clinical studies with bermekimab, the progression and results of such studies, statements regarding the regulatory pathway for bermekimab and the timing of regulatory filings, and statements regarding any capital allocation decisions, including as to potential share repurchases. In some cases, you can identify forward-looking statements by terminology such as may, will, should, would, could, expects, plans, contemplate, anticipates, believes, estimates, predicts, projects, intend or continue or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the Risk Factors section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact Ashley Otero aotero@xbiotech.com 512-386-2930
finance.yahoo.com/news/xbiotech-announces-agreement-sell-true-080532684.html
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/12/17 ¤U¤È 01:00:27
²Ä 2007 ½g¦^À³
|
¬Q¤ÑªºGENETÃö©ó¨È·à±dªk»¡·|¤S¦³·s¤å³¹Åo! ¦³¿³½ìªº·à¤Í¡A¥i¥H¥h¬Ý¬Ý¡C ¥Dn¬OÁ¿004ªº³¡¤À!
www.genetinfo.com/investment/featured/item/33116.html |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/17 ¤W¤È 06:33:06
²Ä 2006 ½g¦^À³
|
¬ü°êªºAD¤¤¡B««×¡A¤d¸U¤H¥«Ô·¤w½T¥ß¡C 2027¦~¥þ²y¡A¬ü¡B欧¡B¤é210»õ¬ü¤¸AD¥«Ô·¡C ¼Ð¹v¥«³õ180»õ·s¼W¶]¤£±¼¡C Dupilumsb销°â°ªûß¡A¦ô¦U¹F110»õ¬ü¤¸¡C ¥Ø«e¤Á断¤¶¥Õ¯ÀIL13,¤ÎIL4¨ü¾¹¤§¶¡°T¸¹¶Ç»¼¡A¥|ӼйvÃĤ¤¡AASAN001¡A¦³³ÌüLªºÄvª§¤O¡C
ASAN001,¦¸±Ú¸s将«÷30-40¤H¡A枢钮¸ÕÅç¡C
¨È·àªÑªF±j¤j¡A¦³Àq§J¤jÃļt¬£ªº¸³¨Æ¡C
¦³Äv¤O±jªºÃĪ«+¥«³õû{¤j+资ª÷+¹Î¶¤ ¨ä¥L¥æ给¦Ñ¤Ñ¡AÅ¥¤Ñ¥Ñ©R¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/17 ¤W¤È 12:22:01
²Ä 2005 ½g¦^À³
|
n³¨¤p³½©ñÓ¥b¦~¤@¦~¬O¥i¥H²z¸Ñ¡An³¨¤¤³½¦Ü¤Ön©ñ¤G¦~¤T¦~¡A©ñ¤T¤¦~ªø½u·íµM¬On³¨¤j³½¡AÁA¸Ñ¦Û¤v¯S½è»P§ë¸ê®É¶¡ªº@¨ü«×¦A¨M©wn©ñ¦h¤[¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/16 ¤U¤È 10:57:06
²Ä 2004 ½g¦^À³
|
¤£ª¾¹Dn©ñ¦h¤[¡H ¦³»ùÈ´N¤@ª½©ñ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G°l·10148822 |
µoªí®É¶¡:2019/12/16 ¤U¤È 10:47:18
²Ä 2003 ½g¦^À³
|
¨CÓ¤Hªø´Á«ù¦³ªº®É¶¡³£¤£¦P¡A¤£ª¾¤Ñ©R¤j¤jªºªø§ë¤S¬O¦h¤[©O¡H ¹ï©ó¤@¯ëªº´²¤á¨Ó»¡¡A¤G¤T¦~¤w¸g¦³ÂIÄÝ©óªø´Á§ë¸ê¤F ¦ý¹ï©ó²H°¨¿ü¨Ó»¡¡A¤G¤T¦~¥u¬Oµu½u§ë¸ê §Ú¤µ¤Ñ¦³°Ý¤½¥qªºªÑ°È³oÓ°ÝÃD §Ú»¡²H°¨¿ü«ç»ò¦n¹³²@µL·Pı¡H ¦o¸ò§Ú»¡...¥L̬O°µªø½uªº¡A¹ï©ó³oµu½uªi°Ê·íµM¨S¦³·Pıªü~ ¦³¥h¬d²H°¨¿ü¤½¥qªº¦U¦ìÀ³¸Óª¾¹D¡A¥LÌ¥§¡«ù¦³®É¶¡¬O¤Q¦~¡I ©Ò¥H¦pªG¯uªºn§ë¸ê¨È·à±dªø½uªº¤H¡An¦³©êªø½uªº¤ß¸Ì·Ç³Æ¡I §ÚÌ°µªø½u¡A¬Ýªº¤£·|¬O¨º¤@ÂIÀò§Q¡A¦Ó¬OÅý¤H¤H¬Ýªº³£¯uªº·|¸r¼}ªºÀò§Q~ ¥u¬O¯uªº¥u¯à¥Î®É¶¡¤U¥h¿i¦Ó¤w... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/16 ¤U¤È 09:29:37
²Ä 2002 ½g¦^À³
|
¾÷ÂàMOA! ¾÷ÂàMOA! ¾÷ÂàMOA!
·í§A¹ý©³ÁA¸Ñ¥|¤jÃÄ¡A¦P¤@¥Øªº¥hªýÂ_¤¶¥Õ¯ÀIL4¤ÎIL13¤§¨ü¾¹R£\1¤§¶¡°T¸¹¶Ç»¼¡A´N¯àÁA¸Ñ¤½¥q»¡ASLAN004.ªºÀu¶Õ¬O¯uªº¡C
³o¬Oªø§ëªº°ò¥»¥\¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/16 ¤U¤È 01:38:52
²Ä 2001 ½g¦^À³
|
ªvÀø ¤¤-««×AD¾÷Âà :ªý断¤¶¥Õ¯ÀIl13 ¤ÎIL4¤§¶¡¨üÅéR£\1ªº°T¸¹¶Ç»¼
Dupilumab : ¶W¹L2000¤H¡A¹êÅç²ÕÅçµý¡A¤W¥«¤w½æ¥X¶W¹L30»õ¬ü¤¸¡C¡]¬ù8.3¸U¤H-¦~¡^ 丅ralokinumab : ¶W¹L 1500¤H¡A¹êÅç²ÕÅçµý¡C¤T´ÁÁ{§É¼Æ¾Ú¹LÃö¡C ¡X¡X¡X¡X¡X¡X- ¥t¥~¤W¶g²Ä¤GӼйvTraloinumab ªvÀøAD ,: ²Ä¤@ÓÂê©wIL13 °tÅé¤À§OªýÂ_»PIL13¨üÅé¨üÅé£\1¦¸³æ¦ì (¥çºÙ¬°IL-13R£\1) ¤ÎªýÂ_¨üÅé£\2¦¸³æ¦ì (¥çºÙ¬°IL-13R£\2) µ²¦X¡A ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà¡AAD¼Ð¹vÃĪ«¡C¤T´ÁÁ{§É¦¨¥\¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- AS𠃊AN004¤§¾÷ÂàÂǦ¹¤Wz¤G¤jÃÄ¥iµý©ú¡C¦¨¥\¥²µLºÃ¡C
ASLAN004 ª½±µ结¦XIL-13R£\1¡AªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà¡A
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¬°¤°»ò ASLAN004 200mg, ¤TÓªvÀø4-6¶gESAI¤U°¥§¡71%. ¬Ò«ô¤Wz¨â¤jÃÄ¡A¦P¤@ªýÂ_ªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§©Ò½ç¡C ¬°¦ó2014 ¦~¨È·à±d¯à©MCS𠃊ñ¤U¦@¦P¬ãµoªº¦X¬ù¡A2019¦~5¤ëñ¤U¡AÁô§t30»õ¬ü¤¸ªº°ª峯¾P°â¦X¬ù¡H ¨È·à¹Î¶¤±M·~¡A¸³¨Æªø·|°÷±j¡C
¤@¯ë§ë¸ê¤H¬Ý¨ì¬Olb¡A3¤H¹LÃö¡A±M®aªº²´¥ú¯uªº¤£¦P¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/16 ¤U¤È 12:21:15
²Ä 2000 ½g¦^À³
|
ARQULE ,INC¤W¶g³QMERCK (Àq§JÃļt)27»õ¬ü¤¸¨ÖÁÊ, ¥u¬°¦åÀù·sÃÄ1BÁ{§É,9¦ì¯f¤H¡A¤¤8¦ì(8/9) PR ,ªºARQ531 ÉIªABTK§í¨î¾¯ ·sÃÄ¡A¦åÀùªº¥þ²y¥«³õ¶È14»õ¬ü¤¸¡C
¥Î¤E¦ì1b Á{§É¡A¤U27»õ¬üª÷¡A¦¬ÁÊ¡C ·sÃÄ¥«³õ©M§A·Qªº¤£¤@¼Ë¡I¡I¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/16 ¤W¤È 11:59:47
²Ä 1999 ½g¦^À³
|
www.nejm.org/doi/full/10.1056/NEJMoa1610020 Dupilumab ¤GÓ¤T´ÁÁ{§É¡A EASI°§C¥§¡¤À¼Æ¹F70¤À, ¶·¨ì²Ä12¶g,¦p¹Ï¤G¡A¡]¨C¶g¥´¤@°w)
¦ÓASLAN004 ¤T¦ì¡A¥u¶·4~6¶g¡A
¦U¦ì¬Ý¬Ý½ÖÀu?Àu¦h¤Ö¶g?6¶g ¼Ë¥»¤Ó¤Ö¤F¡H ¤j®aµ¥µÛ¬Ý¡A ¾Ç²z¤W¬OªýÂ_IL13¨ü¾¹(¦p¡Aaslan001)Àu©óªýÂ_il4 ¨ü¾¹(dupilumab).¡A¤w¦³¦h½g±M·~³ø§i¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/16 ¤W¤È 11:02:52
²Ä 1998 ½g¦^À³
|
s23.q4cdn.com/229915008/files/doc_presentations/2019/Dermira-IR-Pres-Sept-2019_FINAL_92219_web.pdf
Dermira 2019.09 ¤½¥q²¤¶¤¤,¦³¤T¤jADÃÄ(Dupilumab/Lebri/Tralokinumab)¸Ô²Óªº¤ñ¸û p.23 35% Dupilumab ±wªÌ¹F³Ì¨Î¤ÏÀ³. 40% Dupilumab ±wªÌ¤@¦~¤º¤¤Â_¨Ï¥Î(discontinued)
35% of patients treated with Only with dupilumab responseachieve an optimal respons ¡V In a real -world setting, 40% of patients dupliumab therapy within 1 y. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2019/12/16 ¤W¤È 10:46:50
²Ä 1997 ½g¦^À³
|
www.genetinfo.com/investment/featured/item/33123.html
Carl Firth¦bªk»¡¦³°Ý¥²µª ¦ý³Q°l°ÝªÑ»ù¤j¶^¤jº¦²¤Å㪽¸ß°Ý¤½¥q·|¤£·|Å@½L¡A¤~Åã¥X¦³¨Ç¤£@»PµL©`¡C³o¦¸¨È·à±dªºªk»¡¡A¾ãÅé¨Ó»¡¥¶¶¦Ó¥B¾Ç¤F¤£¤Öª¾ÃÑ¡A¨ä¹ê¥xÆW·sÃĤ½¥q³£À³¸Ó¨Óťť¡A¨È·à±d¦b¦p¦ó¦b³sÄò¥¢±Ñ«á¡A§Ö³t«·s»EµJ·sªº¬ãµo¡A¦Ó¦bªk»¡¤S¦p¦ó¦V§ë¸ê¤H»¡©ú¡A³o¥xÆW¤½¥q¥i¥H°Ñ¦Ò¡A¦Ó¤£¬OÁ{§É¸ÕÅ祢±Ñ´NÀ~§b¤F¡A§¹¥þ¤£ª¾©Ò±¹¡C
³Å«i¤ß±¡¦³¨ÇÊØÊסBºò±i¡A³Ì«á¦bQA¤¤¡A§ë¸ê¤H¤@¦A¹ï¤½¥q¬O§_Å@½LÅý¥xÆWªÑ»ù¥i¥H°l¤W¬ü°êADR»ù®æ? ³Å«i²¤ÅãµL©`¡C¤ñ¸û¦³½ìªº¬O¡A²§¦ì©Ê¥Ö½§ª¢¤@´ÁÁ{§É¸ÕÅ禬¯Ç¤»Ó¤H¡AÁö¥¼¸Ñª¼¦ý¨ä¤¤¤TÓ¤Hªº¼Æ¾Ú¥i¥H§ïµ½¥§¡¯fª¬71%¡A®Ú¾Ú³Å«iªº»¡ªk¡A¬ü°êªº§ë¸ê¤H¬O¶R³æªº¡A¨º¥xÆW§ë¸ê¤H·|¶R³æ? ¥i¥H¶i¤@¨B°lÂܤ½¥q±N¦b2020¦~ªì¤½¥¬¥t¥~¨âÓ¸ÕÅç±Ú¸sªº´Á¤¤¼Æ¾Ú¡C
¦³Ãö³Å«i¦p¦ó±N¦Û®a¤½¥q·sÃÄ004¤ñÀÀ°ê»Ú¤j¼tÁÉ¿Õµá·sÃÄdupilumab(°Ó«~¦W Dupixent)¡A½Ð¬ÝGenet «áÄò³ø¾É¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/16 ¤W¤È 09:50:24
²Ä 1996 ½g¦^À³
|
Pªø§ëªÌ:
aslanpharma.com/¡K/17-12-06-Company-presentation-Micr¡K 2017¦~12¤ëªk»¡·| p.17 , ¥þ²yÁx¹DÀù³W¼Ò14»õ¬ü¤¸¡C
©ú¦~ªì ¤½¥q¥´ºâ¿zÀËHER®a±Ú¡A¥Íª«¼Ð°O ©MFDA¡A¨Ì¤§«ep¹º½Í30~40 ¤H¤p¸ÕÅ窺¼Ï¶s¸ÕÅç¡C (1)¨Ì¾Ú¬ã¨sHER®a±Û¦ûÁx¹DÀù70% , ¦©°£FGFR2 ªº¼Ð¹v¥«³õ10% ,³Ñ¬ù60%.
14»õx60%=8.4»õ¥«Ô·¡C
ASLAN001 MOS ¥Ø¼Ð12Ó¤ë(¤¤°ê¤j³°62¦ìÁ{§É,35% ,OS 12Ó¤ë) ¥Ø«e¤ÆÀøMOS6~6.8Ó¤ë¡C
(2)Y¿zÀËHER®a±Ú IHC+3/+2 , ¦A¦©°£FGFR2 ªº¼Ð¹v¥«³õ10% ,³Ñ¬ù40%. ASLAN001 MOS ¥Ø¼Ð16~17Ó¤ë(Ó¤H¦ôp)
14»õx40%x(16.5/12 MOSªº¼W¥[¤ñ)=7.7»õ¬ü¤¸
ASLAN001·sÃĤW¥«¥«È (7.7~8.4)x2(¦©°£¤ä¥I¤W´å±ÂÅv)=15.4~16.8»õ¬ü¤¸¡C ®É¶¡¦ôp3.¦~~3.5¦~
¥t¥~¥[¤WASLAN004 42»õ¬ü¤¸ªº¤W¥«¥«È¼ç¤O¡C
¤WzÁ{§É¬Ò¦¨¥\¥B·sÃĤW¥«¦¨¥\,«h5¦~¤º¨È·àY³Q¨ÖÁʪº»ùÈ°_½X55»õ¬ü¤¸¥H¤W.(Ó¤H¦ôp) ------------------ ARQULE ,INC¤W¶g³QMERCK (Àq§JÃļt)27»õ¬ü¤¸¨ÖÁÊ, ¥u¬°¦åÀù·sÃÄ1BÁ{§É,9¦ì¯f¤H¡A¤¤8¦ì(8/9) PR ,ªºARQ531 ÉIªABTK§í¨î¾¯ ·sÃÄ¡A¦åÀùªº¥þ²y¥«³õ¶È14»õ¬ü¤¸¡C
¨È·àªº²Ä¤G¤jªÑªFݸ³¨ÆAlnair investment¬OMerck ªº¦û49.5%®]¤½¥qShanghai MSD Pharmaceutical trading co.,ltd¡C
finance.yahoo.com/¡K/merck-buy-arqule-2-7b-144202149¡K
Merck & Co., Inc. MRK announced that it has entered into a definitive agreement to acquire Massachusetts-based small biopharmaceutical company ArQule, Inc. ARQL for $2.7 billion to boost its oncology portfolio. Under the terms of the deal, Merck has offered to buy all outstanding shares of ArQule for $20 per share in cash, representing a premium of almost 104% to the latter¡¦s Friday closing price of $9.66.
The acquisition of ArQule will strengthen Merck¡¦s oncology pipeline with the addition of some strategic assets including ARQ 531.
ArQule¡¦s lead pipeline candidate ARQ 531, an oral BTK inhibitor, is currently being evaluated in phase II dose expansion study for the treatment of B-cell malignancies. In early clinical studies, the candidate demonstrated a manageable safety profile and showed signs of anti-tumor activity for treating patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter¡¦s Transformation.
ArQule has several other pipeline candidates in early-stage development for addressing various types of indications, mainly cancer.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/16 ¤W¤È 06:39:01
²Ä 1995 ½g¦^À³
|
²Ä¤G¾¯¶q¡A¨Ìªk»¡·|¤W¡A¤½¥q»¡¡A¤w¶}©l©Û¶Ò¬I¥´¡C 2¤ë©³«e¦³¾÷·|¥´§¹8¶g¡C ¥Ñ©ó²Ä¤@¾¯¶q200mg,«e¤T¦ì®ÄªGÅãµÛ¡C Ó¤H²q´ú²Ä¤G¾¯¶q¥i¯à¥u»Ý250mg,
©M¨ä¥LÃÄ®t¤£¦h¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/16 ¤W¤È 06:28:14
²Ä 1994 ½g¦^À³
|
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
Dupixen ¾÷Âà¡K¡K°Ê¹º
³oÓ¾÷Âà±N³Ð³y110»õ¬ü¤¸ªº¦~¾P°â°ªûß¡C
§@¥Î¥Øªº¡Gªý断¤¶¥Õ¯ÀIl13 ¤ÎIL4¤§¶¡¨üÅ骺°T¸¹¶Ç»¼ ¨È·à±dASLAN004,¦P¼Ë¥i¹F¤Wz®ÄªG¡A¥u¬O¹vÂI¤£¦P¡C
¨C¤ë¥´¤@针¡A¨ú¥N¤Wz2¶g¥´¤@针ªº谮¤O¡C °Æ§@¥Î§ó§C¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/14 ¤U¤È 02:39:28
²Ä 1993 ½g¦^À³
|
www.slideshare.net/jtcancercenter/grothey-gi-malignancies-11111 P.70~78 ·íªì¶PÀù¥°µÂಾ©ÊGÀù ±q3807 HER2¡Ï¤¤¡A¿z¿ï¥X 584¤H¤À¨â²Õ°µ¤T´ÁÁ{§É¸ÕÅç. p.70
¨ä¤¤ IHC¡Ï3 ¦@256¤H, 256/584=44% IHC¡Ï2 ¦@159¤H, 159/584=27%
°µ§¹ORR47.3%
¤G缐Áx¹DÀù¤ñ¤@½uGÀù¥ûÀI.
§Æ±æ¤½¥qn¦³§â´¤ªº¥h°µÁ{§É¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/14 ¤U¤È 02:34:39
²Ä 1992 ½g¦^À³
|
°l·¤jªºÆ[©À«Ü¥¿½T, ²{¦b§ë¸ê¤H³£«Ü²z©Ê , ¹Ú·QÁ`¬O¦b¼Æ¾Ú¤§«á, ¤£·|¦b¼Æ¾Ú¤§«e,Ó¤H»{¬°ªÑ»ù¸ò¦a¾_¸gÀÙ¤@¼Ë«ÜÃø¹w´ú, ªÑ»ùnº¦¤]¤£¤@©w¦³²z¥Ñ, ¦Û»{¬°½æ¨ì°ª»ù¦³¤@¤Ñ¤]¥i¯à¥Î¼Æ¿ªº»ù®æ¶R¦^, ªÑ»ù°ª§C´Nºâ¨Æ«á¤]¤£¤@©w¯à¤ñ¸û¥X¨Ó, ªÑ»ù¬OÅܰʪº, ¨S¦³¤Hª¾¹D©ú¤Ñ·|µo¥Í¬Æ»ò¨Æ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/14 ¤U¤È 02:15:45
²Ä 1991 ½g¦^À³
|
ASLAN001 «e¦~¤G缐Áx¹DÀù¥Î¤@ÓI1b15¤Hªº¸ê®Æ¡AORR 3/15 ,¥h©MFDA½Í127¤H¡AÂùª¼¤Î¤¤°ê64¤Hªº¼Ï¶sÁ{§É¡C
¥Ø«e¤w¨ú±o¤¤°ê¤j³°61¤H¡Ï¥þ²y64¤H¡A¹êÅç²Õ¤Q63¤H¹ï·Ó²Õ¡AªºASLAN001Á{§É¸ê®Æ. ¨Ì¾Ú¨Æ¥ý´£¥X¦¸±Ú¸sÂX¥R¬ã¨sp¹º¡A¤½¥q»{¬°¦¸±Ú¸s¦U«ü¼Ð¦³§ïµ½ÁͶաC
¤½¥q±N¥Î¤Wz¸ê®Æ¥h©MFDA¨ó°Ó°µ¦¸±Ú¸sªº30~40 ªº¼Ï¶sÁ{§É¡AY²Å¦X«ü¼Ð¡A´N¥i°e¥ó¥Ó½ÐÃĵý¡C
«Øij¤½¥q¯à¦bHER±Ú¸s¥~¥[¤JIHC ¡Ï3 ¦Ü¤Ö¦û50%~60%¤ÎiHC +2 ¦û40%¨ì50%ªº¿zÀË¡A¦p¦¹¦¨¥\¾÷·|±N¤j¼W¡C
Áx¹DÀù¥«³õ30%~50%ªº¥«³õ¤~¬O¯u¥¿¼Ð¹vÃĪ«ªº¥«³õ¡CÓ¤H²L¨£
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªÅÄ_10148533 |
µoªí®É¶¡:2019/12/14 ¤U¤È 01:43:05
²Ä 1990 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G°l·10148822 |
µoªí®É¶¡:2019/12/14 ¤U¤È 01:33:38
²Ä 1989 ½g¦^À³
|
To T¤j §A»¡ªº¨S¿ù¡A§Ú»{¦P ¦ý¨º¤]³£¬O¹L¥h¦¡ ´N¦n¤ñ¹J¨ì¤@¦¸ª÷¿Ä®ü¼S¡AÃø¹D´Nn¥Ã»·°±º¢¤£«e¶Ü¡H ³o¦¸ªº¤jªÑªF«ùªÑ¤ñ¨Ò¤w¸g¥X¨Ó¤F¡A¦©°£¬üªÑ¨ºÃ䪺¨Ó»¡ «ùªÑªº¶qÁÙ¬O©úÅã¤W¤É¤F Ãø¹D¨º¨Ç¤jªÑªF¬O¶Ì¤l¡HÁÙn«ùÄò¶R¦^¨Ó¡H ¤@©w¬O¦³¤°»ò»¤¦]¤~·|¨Ï¥L̳o»ò°µ¡I ¥L̤]¥i¥H¸ò¤½¥qÁp¦X©Ô©ïªÑ»ù¶i¦æ¥X³f¤£¬O¶Ü¡H ¦A¨Ó¡A²H°¨¿ü¤½¥q³o¤G¦~¤S¤j¶q¶R¶i¨È·à±dªºADR¡A¥§¡¦¨¥»¤j¬ù8-9¬üª÷ ´«ºâ¦¨¥xÆWªÑ²¼¤]¤j¬ù¦b50¥ª¥k¡A²ö«D¥L̬O¶Ì¤l¡H ·s¥[©Y¬F©²¿ú¦h¨S¦a¤èªá¶Ü¡H §Ú¦³¥h¬d¹L²H°¨¿ü«ùªÑªº®É¶¡¡A³£¬Oªø´Áªº¡A«ù¦³¤j¬ù³£ºû«ù¦b¤Q¦~ ¤G¤T¦~³£¬Oºâµu´Á¾Þ§@¡I ²{¦bªºªÑ»ù¹ï¥L̨ӻ¡¤]¬OºG½ß~ ¤@©w¦³¤H¦n©_¬°¦ó¥L̦ۤv¤£¥Xªù°µ©Ô©ïªº°Ê§@ §ÚÓ¤H¬Ýªk¬O³o¼Ë ¤@¶¡¤½¥q¦pªG¨S¦³°µ¥X¦¨ÁZ¥h©Ô©ï¡A¥u·|²_¬°§ë¾÷«Èªºª£§@¹ï¶H ¦ý¦pªG¦³¦¨ÁZ¥X¨Ó¤~¥h©Ô©ï¡A¤Ï¦Ó¯à§l¤Þ§ó¦h§ë¸ê«Èªº°Ñ»P ²{¦b¨È·à±dÁÙ¨S¦³¥X¦âªºªF¦è¥X¨Ó¡A©Ò¥H¥LÌ¿ï¾ÜÀRÀq ²¦³º²_¬°§ë¾÷«Èªºª£§@¹ï¶H¡A¤½¥qªÑ»ùªø¤[¨Ó¬Ý¡A¯uªº·|§¹³J¡I Ó¤H²L¨£¡A¤£ª¾¨ä¥L¤H«ç»ò¬Ý«Ý¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2019/12/14 ¤U¤È 01:18:36
²Ä 1988 ½g¦^À³
|
to ·à¤l ¨È·à±dÄê¨ìªÑ»ù¶^¨ì7¶ô¿ú¬O¨Æ¹ê ! ¦³¦h¤Ö§ë¸êªÌ¦b50 40 30 ¶Rªº³£«¶Ë¤F(¥»¤H§¡»ù32¶ô¤W¤U 26¥X²M ºâ¹B®ð¦n) ... ¥B¤£n¸ò§Ú»¡¨S½æ´N¬O¨S½ß nªø©ê¤§Ãþªº¸Ü...³£¬O§¾¸Ü§a !! §A°Ý§Ú¬O§_n§C»ù¶R¶i ? ³o°ÝÃD¤Ó¥i¯º¤F ¤w¸g¤C¶ô¿ú¤F§AÁÙ¶û¤£§C ? ¦pªG«e´º¤@¤ù¥ú©ú¬°¦óÁÙ¦b7¶ô¿ú¥´Âà ? ª¾¹D«e´º¦nªº¤H¦¸Ó±½³fÅý§O¤H¶R¤£¨ì¤F ... §ë¸êªÑ²¼¤£¬O¦Û¤v¤Û·Q´N·|º¦ªº....
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/14 ¤U¤È 01:07:14
²Ä 1987 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/12/14 ¤U¤È 12:31:54
²Ä 1986 ½g¦^À³
|
¦U¦ì·à¤Í
èè¿ýµÀɳsµ²¦³°ÝÃD¡A§Ú«·s¤W¶Ç¤@¦¸¡C drive.google.com/open?id=1H2O99MNu0z_pU5Z4LGNfy1IdQTpuIDje
Thanks |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/12/14 ¤U¤È 12:07:17
²Ä 1985 ½g¦^À³
|
¦]¬°¤W¦¸BTC¥þ²y¸ÕÅçp¹º®É´N¤w¸g´£¥XÂX¥R¸ÕÅçp¹º¡A¥h¾é¸ÑHER±Ú¸s舆Àø®ÄªºÃö«Y¡A©Ò¥H¨È·à±d´`¤W¦¸p¹º¡A¤Î¥»¦¸±Ú¸sªº¥i¯à¦³®Äªº¸ê®Æ¡An©MFDA½Í30~40¤Hªº¼Ï¾÷¸ÕÅçÁ{§É¡]¥i¯àµL¹ï·Ó²Õ) .
¦pªGFDA¤£µªÀ³¤~·|°µ¤jªº¤T´ÁÁx¹DÀù¤G缐Á{§É¡C¡]¬O§_°µ¡H¡A©Î±ÂÅv§O¤H°µ¤£ª¾?)
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/12/14 ¤W¤È11:27:04²Ä 1981 ½g¦^À³ ¨È·à±dªk»¡·|´£°Ý :¿ýµÀɤ½¥q¦^µª aslan001 «GÂI
ASLAN001 ,¤½¥q¦^µª:¥¼¨Ó2-3Ӥ리¶°¸ê®Æ¡]¤¤°ê¤Î¥þ²y¤G缐Áx¹DÀùÁ{§É¹êÅç¸ê®Æ)«á¡A±N¦VFDA¥Ó½Ð30~40¤H¤p«¬¼Ï¶sÁ{§É¸ÕÅç¡A¥H½T»{¦¸²Õ¸sÀø®Ä¡C¡]«áª½±µ¥i¥Ó½ÐÃĵý¡^¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/12/14 ¤U¤È 12:06:30
²Ä 1984 ½g¦^À³
|
ÁÂÁ¸¤H¤j «Ü°ª¿³¤½¥q¸êª÷¥i¥H¥Î¨ì2021¦~ ·|·Q¿ìªkÀ°¥xÆW§ë¸ê¤HÄË¥XADR¥i¥HÂà´«ªºÃB«× ¤½¥q·|¦VFDA¥Ó½Ð¤G½uÁx¹DÀù¾A¥Î©ó¤p³¡¤À±Ú¸sªº¸ÕÅç¡Aµ¥¦b¹L2-3Ó¤ë«á¡A¸ê°T¦¬¶°§¹¾ã«á¡A¤½¥q¦³«H¤ß¥i¥H¥Î¦¹¼Æ¾Ú¡A¥Ó½Ð«°µ¼Ï¯Ã¸ÕÅçÀ³¥Î¯S©w±Ú¸sªº¤G½uÁx¹DÀù
§Ú¯à²z¸Ñ¤½¥q¸êª÷¦³¥²»Ý§â¿ú¥Î¦b«ÂI²£«~¬ãµo¤W, ASLAN004 ¤¤««×²§¦ì©Ê¥Ö½§ª¢ ¤H¤f¼Æ²³¦h¥«³õ¤j, ÁöµM¥¼¨ÓÁÙ·|¦³2ÁûÃĤW¥«·m¹150-200»õ¬ü¤¸¤W¤U¤j»æ, ¦ý§Ú¬Û«H ASLAN004 Âê©w¨üÅ餧®ÄªG¸ûÂê©w°tÅé¨Î,¬Û¹ï©ó¨ä¹ïÀ³¤§°tÅé¡AASLAN004 »P¨üÅ餧µ²¦Xµ{«×»·°ª©ódupilumab, ASLAN004 ¹ïIL-13Ra1¤§¿Ë©M¤O¬O¹ïIL-13¤§60¿ ¡ÄDupilumab ¹ïIL-4Ra¤§¿Ë©M¤O¶È¬O¹ïIL-4¤§3¿
±q tralokinumab ªº¥¿¦V¼Æ¾Ú±À½×ASLAN004 ªº¼ç¤OµL½a( ªvÀø¯e¯f¾÷¨îÃþ¦ü), ´Nºâ5¤À¤Ñ¤U¨C®a¥Í§Þ¤½¥q±j¹ 20-60»õ¬ü¤¸¤]¬O«D±`Åå¤Hªº¥«³õ.
¬Ý°_¨Ó¤½¥q2020²Ä¤@©u004´Á¤¤¼Æ¾Ú¥XÄl«áÁÙ¦³¶Ò¸ê³Wµe
ASLAN004¥Ö¤Uª`®g¤è«K©Ê¨Î, ³o»P41X7 ¤£¦P, ¥Î¦b²Ä¤½u¯f±w®Ú¾Ú³ø¾É¥u½æ´X¦Ê¤H( ¥´ÀR¯ß) , §Ú¬Û«H¥¼¨Ó¥Î¦b¥´¥Ö¤Uªº·R´þ¯f¨Ï¥Î¤H¤f¼Æ¤~·|¦h, ¯à®³¨ì·R´þ¯fÃÄÃÒ¤]¬Û·í¤£®e©ö §ó¬O¥xÆW¤§¥ú §ÚÌn«ä¦Òªº°ÝÃD¬O¤@Ӫѻù¬O3¦ì¼Æ, ¤@Ӫѻù¬OÓ¦ì¼Æ
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 4601 ~ 4700 «h¦^ÂÐ >> |
|